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Adenoviruses have evolved to inactivate host cell responses to DNA damage through 
interaction with host cell proteins and by targeting some of these proteins for 
ubiquitin-mediated proteolysis. Indeed, previous studies have suggested that early 
region proteins dysregulate ATR signalling pathways during infection by sequestering 
the MRE11-RAD50-NBS1 complex and promoting the proteasomal degradation of 
TopBP1. Moreover, the cellular E1B-55K-interacting protein, E1B-AP5 modulates 
ATR kinase activity during infection. Work presented here has established that 
adenovirus targets the cellular replication, and DNA damage response protein, 
SMARCAL1 for degradation in an E1B-55K/E4orf6 and Cullin Ring ligase-
dependent manner. As such, we determined that the phosphorylation of SMARCAL1 
residues, S123, S129 and S173 by ATR and CDK kinases promoted SMARCAL1 
degradation during infection. We also determined that SMARCAL1 recruitment to 
viral replication centres during infection was partially dependent upon SMARCAL1 
phosphorylation but was mainly dependent upon its ability to interact with the RPA 
complex. We also determined that E1B-55K interacted directly with SMARCAL1 in 
adenovirus E1-transformed cells and could modulate cellular DNA replication. 
Indeed, E1B-55K expression initially enhanced DNA replication fork speed but 
ultimately, promoted replication fork stalling. We propose that SMARCAL1 is 
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1.1. Viruses and Cancer. 
 
The World Health Organisation (WHO) International Agency for Research on Cancer 
(IARC) reported recently that estimates suggested that the global cancer burden had 
risen to 9.6 million deaths and 18.1 million new cases in 2018 (WHO, 2018). In this 
regard, it is extremely interesting to note that an earlier report suggested that 15-20 % 
of all cancers worldwide in 2012 were due to infection (WHO, 2012). Indeed, it was 
suggested that 2.1 million cases of new cancers in 2012 were attributable to infection 
and that up to one-quarter of all cancers in low- and middle- income countries were due 
to infections with human papilloma virus, hepatitis B and C viruses and other infectious 
agents, such as Helicobacter pylori (Plummer, de Martel et al. 2016).  
1.2. Tumour viruses. 
 
Human tumour viruses can be categorised into two groups, human DNA tumour viruses 
and human RNA viruses as listed in Table 1.1. The oncogenic protein products for these 
viruses have mostly been identified (Zheng 2010). 
 
 Table 1.1. List of viruses and oncogenes                          Taken from: (Zheng 2010). 
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1.2.1. Historical background 
 
Although it is now known that viral infection plays a major role in tumourigenesis with 
approximately 15 to 20 % of all human cancers being caused by infection, the role of 
infectious agents as tumour-promoting factors has only been appreciated in the last 50-
100 years. Indeed, early studies in animal models of cancer, then later cell and molecular 
biological studies identified the causative agents of cancer. It was in 1907 when, 
Guiseppe Ciuffo, an Italian physician determined the relationship between human warts 
and transmissible agents (i.e. viruses) such that this proliferative disease could be passed 
from an individual with the disease to a healthy individual through the small 
transmissible agent, now known as HPV (Bergonzini, Salata et al. 2010). Not long after 
this Francis Peyton Rous, working at the Rockefeller Institute, identified that a sarcoma 
from breast tissue of a chicken could be transplanted into other chickens to promote 
tumour growth and moreover, determined that a cell-free preparation from the tumour 
could similarly induce tumorigenesis in other chickens. As such, Rous suggested that ‘a 
minute parasitic organism’ was responsible for causing the disease (Rous 1910, Rous 
1911).  This transmissible agent was later renamed Rous sarcoma virus (RSV) which is 
an RNA virus. In 1933, Richard Edwin Shope, also working at the Rockefeller, 
discovered the first mammalian DNA tumour virus, cottontail rabbit papilloma virus, 
also known as the Shope virus which caused a ‘wart-like disease’ on the skin of infected 
rabbits; histology showed that this virus infected the cutaneous epithelium of rabbits 
(Shope and Hurst 1933). This discovery was closely followed by the identification of 
another RNA virus, mouse mammary tumour virus (MMTV) by John J Bitner who 
showed for the first time that the extrachromosomal factor that caused breast tumours 
in mice could be transmitted through breast feeding in experimental mice (Bitner 1936). 
4 
 
Interest in tumour viruses was enhanced in 1950s with the identification of murine 
polyoma virus that causes salivary gland tumours in mice (Gross 1953). In 1962, Eddy 
discovered that another polyoma virus, SV40 was oncogenic in rhesus monkey kidney 
cells (Eddy, Borman et al. 1962). As SV40 is found in both monkeys and humans there 
has been much controversy as to whether SV40 causes tumours in humans, but it is now 
generally accepted, based on numerous studies that SV40 is unlikely to be a causative 
agent of cancer in humans (Engels, Katki et al. 2003, Engels, Chen et al. 2005). 
 
The first tumour viruses in humans were discovered in 1960s and 1970s and initiated 
great interest in human tumour virology. In 1962, John Trentin identified human 
adenovirus as the first human oncogenic virus, when he determined that intrapulmonary 
injection of adenovirus 12, but not other adenovirus types, had the ability to induce 
tumours (sarcomas) in baby hamsters particularly on the ‘mediastinum, the internal 
chest wall, or on the diaphragm’ (Trentin, Yabe et al. 1962).  Quite soon after Epstein 
Barr virus (EBV), also known as human herpes virus 4, was identified in cultured 
lymphoblasts from Burkitt’s lymphoma by electron microscopy (Epstein, Achong et al. 
1964). Hepatitis B virus (HBV) surface antigen was isolated in 1967 by Blumberg from 
blood from an Australian Aboriginal, and was later, deemed to be found in the serum of 
Hepatitis B-infected individuals (Blumberg, Gerstley et al. 1967) (Prince 1968). The 
HBV particle, a causative agent of hepatocellular carcinoma, was then found in the 
serum of patients suffering from Hepatitis B (Dane, Cameron et al. 1970). 
 
Although early studies identified a role for papilloma viruses in the aetiology of tumours 
in rabbits (Shope and Hurst 1933), it was not until the 1970 and ‘80s when Harald Zur 
Hausen and colleagues established that multiple human papilloma virus (HPV) strains, 
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such as HPV11, 16 and 18, and not HSV-1 as previously thought, were causative agents 
for cervical cancer (Zur Hausen 1976, Dürst, Gissmann et al. 1983, Gissmann, Wolnik 
et al. 1983, Boshart, Gissmann et al. 1984). The first known human retrovirus to cause 
human cancer, human T-cell leukemia virus type 1 (HTLV-1) was identified from 
cultured lymphocytes from a patient with a T-cell lymphoma by Robert Gallo’s group 
(Poiesz, Ruscetti et al. 1980). Human herpes virus 8 (HHV-8) was found to be associated 
with the majority of Kaposi’s sarcomas in AIDS patients and was considered to be a 
causative agent (Chang, Cesarman et al. 1994). In this regard, the retrovirus HIV-1, was 
shown to facilitate KSHV (human herpes virus 8 (HHV-8)) induction of Kaposi 
sarcomas in AIDS patients, through immunosuppression (Cesarman, Damania et al. 
2019). More recently, Merkel cell polyoma virus (MCV) was shown to be clonally 
integrated in skin cancers known as Merkel Cell Carcinoma by Chang and Moore in 
2008 suggesting that the virus might contribute towards the pathogenesis of the disease 
(Feng, Shuda et al. 2008). 
 
1.2.2. Viral oncogenes and carcinogenesis. 
 
The next step in tumour virology was to determine the molecular basis of virus-induced 
tumourigenesis. More recently it has been recognized that viruses, or any infectious 
agent causes cancer either directly through the expression of viral oncogenes, or 
indirectly by the induction of chronic inflammation, induction of immunosuppression, 
inhibition of cellular apoptosis, or the induction of chromosomal instability and 




The study of retroviruses has taught us much about the molecular basis of cancer. The 
first viral oncogene to be identified was v-src from RSV, which was found to correspond 
to a cellular gene, c-src that had been acquired by the virus and incorporated into the 
RSV genome (Stehelin, Varmus et al. 1976). It was later established that v-src and c-src 
gene products were tyrosine kinases and that the v-src gene product was a constitutively 
activated version of c-src that lacked a regulatory C-terminal domain, such that v-src 
was oncogenic and c-src was not (Coussens, Cooper et al. 1985).  It has been suggested 
that the enhanced mitogenic activities of v-src promote uncontrolled cellular 
proliferation and cancer. Other retroviral oncogenes have subsequently been identified 
that similarly have a cellular origin and are often de-regulated in human cancer. For 
instance the transcription factor, v-Myc is the transforming protein of Avian 
myelocytomatosis virus MC29 (Vennstrom, Sheiness et al. 1982) and c-myc is often 
overexpresed in human cancers, such as Burkitt’s lymphoma and neuroblastoma (Meyer 
and Penn 2008). Other examples include the v-ras oncogenes of Harvey, and Kirsten 
Sarcoma viruses, whose cellular equivalents are often constitutively activated in human 
cancers such as colon carcinoma (Simanshu, Nissley et al. 2017). In this regard the Ras 
protein functions as a molecular switch in the mitogenic Ras-Raf-MAPK pathway which 
is constitutively activated in cancers (Simanshu, Nissley et al. 2017). 
 
Transforming DNA viruses also express their own distinct gene products that induce 
cancer. Whilst this will be discussed in detail later for adenoviruses, most DNA virus 
oncogene products inactivate the p53 and pRB cellular tumour suppressor proteins and 
other proteins involved in genomic stability to induce tumourigenesis. Although 
adenovirus is the main model for cellular transformation by DNA viruses, other viruses 
such as HPV and SV40 also target these pathways specifically. Indeed it is well known 
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that HPV E6 proteins inactivate p53, whilst HPV E7 proteins inactivate pRB and SV40 
large T antigen targets both p53 and pRB (Ali and DeCaprio 2001, Viarisio, Gissmann 
et al. 2017). As viruses typically target the key cellular proteins to promote its 
replication, it is perhaps no surprise that inactivation of p53 and/or pRB proteins occurs 
in most human cancers. 
1.3. Adenoviruses. 
 
Adenoviruses are small, linear, non-enveloped, double-stranded (ds) DNA viruses with 
icosahedral, nucleocapsid symmetry ranging in size from size 26 to 45 kilobases (kb), 
with human adenoviruses around 35 kb. It was originally discovered in 1953 by Rowe 
and his colleagues and, independently in 1954 by Hillman and Werner, whilst working 
with viruses of the common cold. Rowe isolated viral particles from the adenoids and, 
as such adenovirus was originally named ‘adenoid degenerating agent’ (Rowe, Huebner 
et al. 1953). Hillman and Werner were studying a flu-like virus in army recruits and, 
independently, successfully isolated adenovirus form tracheal cells (Hillman and 
Werner, 1954). Interest in the molecular biology of adenoviruses grew enormously 
when Trentin determined that human Ad12 induced tumours in hamsters (Trentin et al., 
1962). Indeed, adenovirus was the model system in which messenger RNA splicing was 
first discovered by Sharp and Roberts (Berk and Sharp 1977, Chow, Roberts et al. 1977). 
More generally however, adenoviruses are the causative agents of upper respiratory tract 
infections, conjunctivitis and gastroenteritis with lasting duration of infections mainly 
in immunocompromised patients (Turnell 2008). As adenoviruses are characterised as 
‘low risk’ viruses, which can induce tumours in experimental animals, they can be used 
as tools to study in detail the molecular and cellular biology of the normal cell, and 
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cancer cell. More recently, adenoviruses have been used as vectors for gene delivery 
and therapy, and have been modified substantially to generate conditionally-replicating 




David Baltimore classified adenoviruses as group one double-stranded (ds) DNA 
viruses in his Baltimore system of virus classification. Later in the 1960’s the ICTV 
(International committee on taxonomy of viruses) placed adenoviruses in the family 
Adenoviridae and divided them into five genera depending on its ancestral types: 
Mastadenoviridae (infecting Mammals), Aviadenoviridae (infecting birds), 
Atadenoviridae (infecting reptiles), Siadenoviridae (infecting frogs, turkeys and raptors) 
and IchtaAdenoviridae (infecting Fish) (Norrby, Bartha et al. 1976). The 
Mastadenoviridae (human Adenoviruses Ad) are further divided in to seven species (A, 
B1, B2, C, D, E, F and G) depending on their haem agglutination and neutralization 




Table 1.2. Classification of Adenoviruses.           Taken Adapted from,(Turnell 2008),          
(Dhingra A 2019), (http://hadvwg.gmu.edu/).  
                                                                             
 
Human adenovirus serotypes can cause a wide range of infections in humans being 
dependent on the host immune response (Echavarria 2008).  Although in recent years 
adenovirologists have begun to study the biology of different adenovirus types in more 
detail, most experimental studies have focussed on the closely related group C viruses, 
Ad2 and Ad5. Although Ad5 is non-tumourigenic it can transform human embryonic 
kidney cells, such that Ad5E1-transformed HEK293 cells are a widely utilised cell line 
for studying cellular functions (Graham, Smiley et al. 1977). The tumour-promoting 
Ad12, from group A, is also widely studied and can similarly transform human 
Group Types Oncogenicity in rodents
Transformation
in vitro
A 12, 18, 31 High Yes 
A (new) 61 Unknown Unknown
B(new) 66, 68, 76, 77, 78, 79 Unknown Unknown
B1 3, 7, 16, 21, 50 Moderate Yes
B2 11, 14, 34, 35, 55 Moderate Yes
C 1, 2, 5, 6, 89 Low or none Yes
D 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 
33, 36-39, 42-49, 51, 53, 54
Low or none Yes
D (new)
56, 58, 59, 60, 62, 63, 64, 65, 67, 69, 
70, 71, 72, 73, 74, 75, 80, 81, 82, 83, 
84, 85, 86, 87, 88, 90, 91, 92, 93, 94, 
95, 96, 97, 98, 99, 100, 101, 102, 103
Unknown Unknown
E 4 Low or none Yes
F 40, 41 None reported Yes
G 52 None reported Unknown
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embryonic retinoblast (HER) cells in tissue culture (Byrd, Brown et al. 1982). Although 
Ad12 induces undifferentiated tumours in new born hamsters, Ad12 is known to 
undergo fully productive replication cycle in human cell cultures, the probable 
explanation for the potential of Ad12 in crossing the barrier from humans to hamsters 
in its oncogenesis is, Ad12 when infects human cells, it kills all the infected cells with 
the productive interaction resulting in cells not transformed in to tumour cells, hence 
Ad12 is not identified as oncogenic in humans, however with the hit and run mechanism, 
Ad12 could be  involved in human tumorigenesis (Doerfler W. 2007) 
 
1.3.2. Adenovirus Structure and Genome. 
 
Adenoviruses are amongst the largest non-enveloped viruses studied by electron 
microscopy and X-ray diffraction at a resolution of 3.5 Å, with a size of 150 MDa. The 
capsid, approximately 70 to 100 nm in size, is comprised of 252 capsomeres of which 
240 are homotrimeric hexons forming the faces of the capsid, and the other 12 are penton 
bases that form the vertices of the capsid; small fibres with terminal knobs protrude from 
each penton base (Brenner and Horne 1959, Valentine and Pereira 1965)(Figure 1.1). 
Proteins IIIa, VI, VIII and IX also associate with the capsid and are thought to provide 
extra structural integrity to the capsid (Saban, Silvestry et al. 2006). The linear 
adenovirus dsDNA genome is 26 to 45 kb in size which is surrounded by capsid. The 
highly characterised adenovirus serotype 5 genome size is 36 kb and it encodes 40 
proteins (Saha, Wong et al. 2014) and the adenovirus serotype 12 genome size is 
34125bp and it encodes 27 proteins (Mariana Hosel 2001). In the well characterised 
Ad5 genome, depending on their expression patterns relative to viral DNA replication, 
the major transcription coding regions of adenoviruses are named as early genes: E1, 
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E2, E3 and E4, which are expressed before viral DNA replication, and late genes (L1 to 
L5) which are expressed after viral DNA replication. The intermediate genes (IVa2 and 
IX) and small VA RNAs are expressed before the late genes (Figure 1.2) (Russell 2000). 
Ad genomes are characterized by inverted repeated sequences (ITRs) that are located at 
both ends of the genome, which are 100-140 bp in size. Terminal protein (TP) associates 
covalently with the 5’ terminus of each ITR and serves as a primer for adenovirus 
replication (see section 1.3). The origin of viral replication from which adenovirus DNA 






















          
         Figure 1.1. Schematic depiction of the Adenovirus virion. The image shows the 
arrangement of the proteins that comprise the viral capsid and also illustrates the linear 
dsDNA adenovirus genome and the viral proteins associated with the genome. 






Figure 1.2. Schematic illustration showing Ad5 genomic transcription map. The 
panel outlines the gene expression profile form the Ad genome following viral infection. 
Black arrows represent E1A, E1B, E2A, E2B, E3 and E4 Ad early proteins, blue arrows 
indicate IX and IV2 intermediate proteins and green arrows highlights L1 – L5 late 
proteins. Taken from: (Hall, Blair Zajdel et al. 2010) 
 
1.3.3. Adenovirus replication. 
 
The successful propagation of adenovirus in the host cell depends on its ability to enter 
the host cell, replicate its genome and package itself into new virions for dissemination. 
Adenovirus DNA replication occurs approximately 6 to 8 hours post infection and 
within 40 hours of infection, Ad produces new virions in the infected cell. Different Ad 
proteins are involved in promoting viral DNA replication from virus entry into the cell 
to carry out successful viral DNA replication. Adenovirus cellular tropism is mainly 
defined by its fibre proteins which facilitate cell entry by attaching to the CAR receptor 
(Coxsackie virus and Adenovirus receptor)(Wu and Nemerow 2004). CAR is a 46 KDa 
Ig (immunoglobulin) super-family protein that act as a primary receptor for most of the 
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adenoviruses (Hartlerode, Morgan et al. 2015). The other important receptors are the 
membrane cofactor protein (MCP) also called as CD46, Desmoglein 2 (DSG2), Sialic 
acid and avb3/5 (Baker, Aguirre-Hernández et al. 2018). Some of the Ad proteins 
required to interact with distinct cellular receptors, and the residues implicated in 
binding are shown in the below Table 1.3 (Baker, Aguirre-Hernández et al. 2018).  
 
Along with the CAR, adhesion of the penton base proteins to avb3/5 integrin receptors 
through clathrin-coated pits triggers the internalisation of the virus (Imelli, Meier et al. 
2004). Endocytosis results in capsid dissociation and structural rearrangement of the 
viral particles. Viral particles utilise hexon association with cytoplasmic Dynein 
networks to transport to the nucleus whereupon they enter the host cell nucleus through 
nuclear pores to initiate viral DNA replication (Imelli, Meier et al. 2004, Wu and 





Table 1.3. Host cell receptors targeted by adenovirus capsid proteins. Table taken 
from (Baker, Aguirre-Hernández et al. 2018).  
 
There are three main replication proteins involved in adenovirus genome replication, 
the TP precursor protein (pTP), the Ad DNA polymerase protein (Ad pol) and the Ad 
DNA binding protein (Ad DBP) which are all transcribed from the E2 region (Holm, 
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Bergmann et al. 2002). pTP is an 80 kDa protein that acts as a primer for replication 
initiation and binds to both ssDNA and dsDNA, whilst Ad pol is a 140 kDa protein and 
belongs to the distant group of a-like DNA polymerases that utilises the pTP primer for 
replication initiation (Field, Gronostajski et al. 1984). Ad DBP is a multifunctional 
phospho-protein of approximately 55 kDa and is known to be involved in multiple 
activities during viral replication and is located in the nucleus of infected cell (Chang 
and Shenk 1990). For the initiation of Ad DNA replication, Ad Pol covalently links the 
b-OH group of a Ser residue in pTP to the a-phosphoryl group of dCMP (deoxycytidine 
monophosphate) to form the pTP/dCMP complex that functions as a primer for DNA 
synthesis (Liu, Naismith et al. 2003). Ad DBP binds to both ssDNA and dsDNA and 
stimulates the Ad pol by promoting the binding of cellular protein NFI to Ad pol (de 
Jong, van der Vliet et al. 2003, Hoeben and Uil 2013) (Rob C Hoeben 2013), and the 
cellular Oct-1 protein to pTP. Both cellular NFI and Oct-1 form the replication 
preinitiation complex with Ad pTP, pol and DBP, which in concert bind viral DNA and 
stimulate replication (Hoeben and Uil 2013). DBP also promotes DNA elongation in an 
ATP-dependent manner because of its helix destabilising activity and its ability to 
unwind DNA. The ability of the major replication proteins pTP, Ad pol and Ad DBP to 
form stable complexes with NFI and Oct-1 increases viral DNA replication up to 200 
fold (de Jong, van der Vliet et al. 2003). 
 
1.3.4. Ad early region gene E1A. 
 
Adenoviral E1A gene products are the first to be transcribed, within an hour of viral 
infection (Yousef, Brandl et al. 2009). The mRNAs transcribed from E1A 
transcriptional units are 13S, 12S, 11S, 10S and 9S that produce, respectively, proteins 
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of 289, 243, 217, 171 and 55 amino acids in size. The 13S and 12S gene products are 
produced during early stages of infection, whilst the 9S, 10S and 11S gene products are 
produced during the late stages of infection, although their function is poorly 
understood. The 13S and 12S gene products differ in size by 46 amino acids (Conserved 
Region 3- CR3) in Ad5 and are produced by differential splicing of mRNA. 12S and 
13S E1A gene products are highly modular with functional conserved regions CR1, CR2 
and CR4 that are conserved between different Ad types and a less well conserved N-
terminal region (NTR; Figure 2) that bind cellular protein targets (Boulanger and Blair 
1991). The molecular weight of E1A 12S and 13S gene products is highly variable when 
analysed by SDS-PAGE, ranging from 35 to 48.0 and 40 -52 kDa respectively, due to 
the highly phosphorylated nature of E1A.  The adenovirus E1A proteins are not DNA 
binding proteins (Yousef, Brandl et al. 2009), but they interact with cellular proteins 
that do interact directly with chromatin to regulate transcription (Figure 1.3) (Gallimore 
and Turnell 2001, Berk 2005). 
 
Adenovirus E1A proteins play a major role in transcriptional activation and repression 
and function as cooperating oncoproteins in cellular transformation. This ability of E1A 
resides in its capacity to initiate DNA synthesis and cell cycle entry in quiescent cells 
through interaction with cellular proteins that regulate cell cycle progression, mitosis 
and apoptosis (Gallimore and Turnell 2001). E1A promotes transformation through its 
association with host cellular proteins like the Retinoblastoma family (pRB, p107 and 
p130) of transcriptional repressors, the CBP/p300 transcriptional co-activators, the 
transcriptional co-repressor CtBP proteins, TRAPP/p400 chromatin modifiers, and 
DYRK1 and DCAF7 cell growth regulators (Fuchs, Gerber et al. 2001, Gallimore and 
Turnell 2001, Cohen, Yousef et al. 2013). E1A can however, can also act as a 
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transformation suppressor and function as anti-oncogene in the absence of cooperating 
oncogenes (Frisch and Mymryk 2002). 
 
1.3.5. Ad E1A 13S and 12S proteins. 
 
The adenovirus CR3 domain in the 13S E1A gene product plays a vital role in gene 
regulation by acting as transcriptional activator for all early region promoters during 
infection and has served as a vital tool to study basic transcriptional processes (Pelka, 
Ablack et al. 2009). The CR3 region is composed of two regions: a zinc-finger region 
(amino-acids 147-177; Ad5) and a carboxyl-terminal region (amino acids 183-188; 
Ad5). The zinc finger region is responsible for binding to the general transcriptional 
machinery such as TBP. It has been established that the transactivation capacity of zinc-
finger region of CR3 resides in its ability to bind to TBP, Mediator subunit, 
MED23/Sur2, and 19S, 20S and 26S proteasomes (Lee, Kao et al. 1991, Stevens, Cantin 
et al. 2002, Rasti, Grand et al. 2006). The carboxyl-terminal region of CR3 possesses a 
promoter-targeting region, which facilitates E1A interaction with several specific 
transcription factors like ATF1-3, SP1, USF and CBF/NF-Y and TBP-associated factors 
(TAFs).  Co-activator proteins, like CBP/p300, also bind to the CR3 domain to regulate 
transcription. In oncogenic Ad serotypes of adenoviruses, there is a alanine-rich region 
in between the CR2 and CR3 domain, which plays a significant role in tumour induction 
(Figure 1.3) (Gallimore and Turnell 2001). 
 
Unlike the 13S CR3 domain, which mainly functions as transcriptional activator, the 
smaller 12S E1A species, lacking CR3, has the capacity to function as both a 
transcriptional repressor and a transcriptional activator, in order to promote cell growth, 
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or apoptosis, and suppress differentiation (Gallimore and Turnell 2001). Specific 
binding regions present in CR1 and CR2 (LxCxE motif; Figure 1.3) are capable of 
binding the pocket domains of the cellular tumour suppressor proteins pRB, p107 and 
p130. The same pocket domains in the pRB family of proteins are required for binding 
E2F transcription factors and as a result, E1A expression blocks the E2F-interaction 
with pRB resulting in dissociation of E2F from the pRB complex resulting in E2F-
driven S-phase induction, cell cycle progression and cellular transformation 
(Raychaudhuri, Bagchi et al. 1991, Berk 2005). The adenovirus E1A N-terminal region 
and CR1 domain binds to several other cellular protein complexes involved in chromatin 
remodelling, like histone-directed acetyltransferase (HATs), histone–directed 
deacetylases (HDACs) proteins, nucleosomal remodelling factors like SWI/SNF and 
nucleosomal associated proteins (Gallimore and Turnell 2001, Berk 2005). The HAT 
protein p300 was the first identified through its interaction with the NTR and CR1 
regions of E1A; the closely related CREB-binding protein (CBP) was also found to 
associate with E1A through these regions. The p300/CBP HATs are approximately 300 
kDa in size and activate transcription by acetylating core histone proteins (Berk 2005). 
E1A has the capacity to associate with functional CBP/p300 HAT activity and can also 
redistribute CBP/p300 to specific genomic loci during infection (Ferrari, Pellegrini et 
al. 2008, Horwitz, Zhang et al. 2008, Ferrari, Gou et al. 2014). Mutational studies have 
shown that the interaction of CR1 and CR2 with either pRB proteins or CBP/p300 
proteins is required for E1A’s ability to induce S-phase in quiescent cells, whereas CR1 
domain interactions with both pRB and CBP/p300 proteins is required for cells to 




The C-terminal domain known as CR4 is encoded by Exon 2 of E1A (Figure 1.3). CR4 
extends from amino acid residues 240 to 288 of E1A (Yousef, Brandl et al. 2009). CR4 
interacts with cellular proteins CtBP-1, 2 and 3 (C-terminal binding proteins), which are 
named such as they were first identified through their interaction with the C-terminal 
region of E1A, in particular the PxDLS motif located in this region. CtBP are also 
known to interact with HDACs to repress transcription. Interestingly E1A acetylation 
by p300/CBP at amino acid K-239 adjacent to the CtBP-binding site inhibits CtBP 
association with E1A (Zhang, Yao et al. 2000). Apart from CtBP, CR4 also binds to the 
dual specific Tyrosine-regulated kinase proteins (DYRK 1A AND DYRK 1B) and 
DYRK 1A–co factor HAN 11 and these interactions aid virus infection and oncogenic 






Figure 1.3. Schematic illustration showing the conserved regions of E1A, E1A-
binding proteins and functional domains: The figure illustrates the conserved regions 
of Ad E1A species, and the key cellular proteins known to bind to the N-terminal region, 
CR1, CR2, CR3 and CR4 domains. The role of each E1A region in biological processes 
is also below each region. Taken from (Gallimore and Turnell 2001). 
 
 
                                              
1.3.6. Ad early region gene E1B. 
 
Adenovirus early region E1B gene products are involved in promoting viral DNA 
replication during infection and promoting cellular transformation. There are five 
different gene products encoded through alternative splicing of E1B mRNAs, of which 
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infection and transformation, where they co-operate with E1A in the transformation of 
rodent cells although they lack the ability to transform the cells individually. Research 
shows that both E1B-55K and E1B-19K together function to inhibit growth arrest and 
apoptosis (Sieber and Dobner 2007, Blackford and Grand 2009). Ad E1B-19K is a 
functional homologue of the BCL2 anti-apoptosis factor and binds to pro-apoptotic 
BAX, activated by tBID, and prevents the formation of BAK/BAX oligomers at 
mitochondrial membranes and thus inhibits apoptosis (Sundararajan, Cuconati et al. 
2001, White 2001). A major role of the E1B-55K protein is to inhibit p53-dependnet 
apoptosis. Ad5 E1B-55K directly binds to p53 and protects cells from p53 dependent 
apoptosis through its ability to inhibit the activation of p53-dependent transcription 
programmes (Sarnow, Hearing et al. 1984, Yew and Berk 1992). E1B-55K and p53 have 
been shown to associate in cytoplasmic compartments known as aggresomes (Zantema, 
Schrier et al. 1985, Yew and Berk 1992). Ad5 E1B-55K is post-translationally modified 
by phosphorylation and SUMOylation whereas Ad12 E1B-55K is not known to be post-
translationally modified by either phosphorylation or SUMOylation (Blackford and 
Grand 2009). Indeed, Ad5 E1B-55K is a SUMO-ligase and can self-SUMOylate as well 
as SUMOylate p53, which also serves to inhibit of p53 activity (Muller and Dobner 
2008). Ad E1B-55K does not function in isolation and is known to cooperate with 
E4orf3 and E4orf6 during infection particularly to regulate host-cell shut-off of protein 
synthesis, and cooperate with these proteins and E1A in cellular transformation (Nevels, 
Rubenwolf et al. 1997, Nevels, Täuber et al. 1999, Nevels, Täuber et al. 2001). 
 
Apart from E1B-55K and E1B-19K, the other three E1B proteins are E1B-84R, E1B-
156R and E1B-93R named depending on their number of amino acids; their functional 
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role is not known however (Sieber and Dobner 2007). A Schematic representation of 




                                                                        
Figure 1.4.A. linear representation of E1B-55K and depiction of its functional 
roles. Full length (289R) E1A protein structure, conserved regions (CR1 to CR4), 




Figure 1.4.B. linear representation of E1B mRNA species. Alternative spliced 
species of E1B mRNA showing bidirectional splicing enhancer in green as exon 2 and 
the arrows indicating splicing factors and regulators that control splice site selection and 





1.3.7. Adenovirus E3 region. 
 
The E3 transcription region of adenoviruses is mainly involved in encoding different 
immunomodulatory proteins and serves to promote immune evasion. E3 is conserved in 
different Ad serotypes and also plays vital roles in releasing progeny virus during 
infection, through expression of the ADP (Adenovirus death protein) gene product that 
is expressed late during infection. The E3 region is known to encode nine different 
mRNA splice variants from two RNA precursors, E3A and E3B. E3 promoters involved 
in generating E3 transcripts are activated by transcription factors such as ATF, NF-1, 
AP-1 and NFkB and a TATA box (Brady and Wold 1988, Wold, Tollefson et al. 1995, 
Zhao, Chen et al. 2014). Among the proteins encoded by the E3 region, gp-19K is an 
abundantly synthesised viral early protein and integral transmembrane glycoprotein 
which serves to down-regulate major histocompatibility complex class I antigens during 
infection (Brady and Wold 1988, Wold, Tollefson et al. 1995). Additionally, E3 14.7K 
and 10.4K proteins are involved in inhibiting TNF (tumour necrosis factor)-dependent 
cytolysis, which is known to be an anti-viral factor (Krajcsi, Dimitrov et al. 1996).  
 
1.3.8. Ad early region gene E4. 
 
The transcription unit of the E4 region is located at the right-hand side of the Ad genome 
and is transcribed from the bottom strand, generating a primary transcript of 2800 
nucleotides in length (Täuber and Dobner 2001). Alternative splicing of this transcript 
generates at least 18 E4 mRNAs that encode at least 7 different open reading frames 
(orf) orf1, orf2, orf3, orf3/4, orf4, orf6 AND orf6/7. Among these E4orf’s, orf3, orf4 
and orf6 have all been studied in detail (Halbert, Cutt et al. 1985, Thomas, Schaack et 
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al. 2001, Zhao, Chen et al. 2014). E4 proteins interact with multiple other cellular 
proteins involved in cell cycle survival and genome stability and play vital roles in viral 
DNA replication, virus assembly, transcription, translation and host cell shut off, as well 
as cooperating in Ad-mediated transformation (Nevels, Täuber et al. 2001, Täuber and 
Dobner 2001, Weitzman and Ornelles 2005, Ou, Kwiatkowski et al. 2012). Very little 
is known about the function of E4orf1 and E4orf2 during infection, although Ad9 E4orf1 
is highly oncogenic and can induce mammary tumours in rodents (Thomas, Schaack et 
al. 2001). E4orf4 is known to associate with the regulatory B subunits of protein 
phosphatase 2A to induce p53-independent apoptosis and, as such, is a potential cancer 
therapeutic agent (Kleinberger and Shenk 1993, Shtrichman, Sharf et al. 2000).  E4orf4 
is also known to inhibit the E1A-dependent transactivation of viral promoters E2 and 
E4 (Kleinberger 2015). E4orf6/7 are involved in regulating E2F-dependent transcription 
in a similar way to E1A and induces apoptosis (Helin and Harlow 1994). 
 
E4orf3 and E4orf6 are known to have overlapping, and significant roles, in both viral 
infection and cellular transformation and have been the source of intensive study 
(Täuber and Dobner 2001). Mutational analysis has shown that viral mutants lacking 
either E4orf3 or E4orf6 has little or no effect on the viral lytic life-cycle but mutants 
lacking both E4orf3 and E4orf6 have severe defects in viral replication, the 
accumulation of viral mRNA transcripts in the cytoplasm and host cell shut-off of 
protein synthesis (Halbert, Cutt et al. 1985). Furthermore, E4orf3 and E4orf6 associate 
with each other, and can similarly bind to E1B-55K and target E1B-55K to viral 
replication centres in the nucleus and prevent viral DNA concatemer formation (Halbert, 
Cutt et al. 1985, Huang and Hearing 1989, Weiden and Ginsberg 1994, Täuber and 
Dobner 2001, Stracker, Carson et al. 2002).  
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E4orf3 encodes a 11 kDa protein, which is highly conserved amongst different Ad types 
is and the first gene product of E4 region known to be found in infected cells. E4orf3 
associates with the nuclear matrix to reorganise components of PML (promyelocytic 
leukemia)-containing bodies to nuclear tracks surrounding viral replication centres 
(Sarnow, Sullivan et al. 1982, Downey, Rowe et al. 1983, Carvalho, Seeler et al. 1995, 
König, Roth et al. 1999). Structural analyses revealed that E4orf3 exists in cells as a 
dimer subunit, which are able to assemble with other E3orf3 dimers through interactions 
in the C-terminal regions of the protein, to form linear and branched oligomer chains 
throughout the cell. The consequence of E4orf3 polymerisation is to create high affinity 
multivalent binding sites for cellular interacting proteins (Soria et al 2010). E4orf3 is 
known to inactivate the functions of known tumour suppressor proteins p53, TIF1a 
(TRIM24), TIF1b (TRIM28), TIF1g (TRIM33) and PML through either direct 
interaction, or through modulation of epigenetic signalling pathways (Soria, Estermann 
et al. 2010, Forrester, Patel et al. 2012, Ou, Kwiatkowski et al. 2012). As such, E4orf3 
inhibits the transcription activity of p53 through the epigenetic silencing of transcription 
activated by p53-responsive promoters by acting as scaffolds to direct heterochromatin 
assembly to silence transcription activated by p53 by targeting p53 target promoters 
(Soria, Estermann et al. 2010). A schematic representation of E4 region is shown in 
Figure 1.5 (Zhao, Chen et al. 2014). Interestingly, E4orf3, akin to E1B-55K, has been 
shown to be a SUMO E3 ligase and targets TIF1g and TFII-I for SUMO-Targeted 
ubiquitin ligase-mediated degradation (Forrester, Patel et al. 2012, Bridges, Sohn et al. 
2016, Sohn and Hearing 2016). 
 
The E4orf6 mRNA encodes a highly conserved 34 kDa protein which contains an N-
terminal NES (nuclear export sequence) and C-terminal NLS (nuclear localization 
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signal) along with an a-helical, arginine-rich, NRS (nuclear retention signal) that helps 
recruit the E1B-55K and E4orf6 complex to the nucleus (Orlando and Ornelles 1999). 
In isolation, E4orf6 binds directly to p53 through its C-terminal regulatory domain and 
inhibits the interaction of the N-terminal transactivation domain of p53 with a 
component of transcription factor (TFIID), TAFII31, thus, serving to inactivate p53-
mediated transcription (Dobner, Horikoshi et al. 1996). Although many studies have 
studied these proteins in isolation, most of the functions of the E4orf6 are in cooperation 
with the E1B-55K protein. A consideration of their joint functions will be considered in 
detail later when discussing the relationship between adenovirus and host cell DNA 











1.3.9. Biological importance of studying adenoviruses. 
 
Since the discovery of adenovirus nearly 70 years ago by Rowe, Hillman and their 
colleagues and its discovery as a human oncogenic virus by John Trentin and colleagues, 
adenovirus has been widely used a model system in research to study the molecular and 
cellular biological processes of cellular transformation and tumourigenesis (Weitzman 
and Ornelles 2005). In this regard, a number of cellular proteins were first identified as 
interacting proteins for adenovirus proteins such as: p300, p400/TRRAP, CtBP, p107 
and ATF, whilst although not originally identified using adenovirus, studies with 
adenovirus have taught us much about the function of the pRB and p53 tumour 
suppressors (Berk 2005). More recently E1 and E3 -deleted adenoviruses have been 
used as a gene-delivery vectors for gene therapy applications, and the development of 
conditionally-replicating/oncolytic adenoviruses have been used to selectively infect, 
and kill cancer cells (McCormick 2001, Lyle and McCormick 2010). Whilst adenovirus 
still has much to teach us about the individual functions of cellular proteins, and how 
viruses utilise, or inhibit, these proteins during viral infection or cellular transformation, 
developments in genomic and proteomic technologies have allowed us to study how 
viruses, or individual viral proteins function globally to modulate signalling pathways 
important in cell growth, death and survival pathways (Weitzman and Fradet-Turcotte 
2018). Our laboratory, amongst many others, is particularly interested in utilising 
proteomic methods to understand how viruses and virus proteins regulate the cellular 
response to DNA damage in order to facilitate viral replication, such that we can also 
identify, and determine, the function of cellular proteins that participate in DNA damage 




1.4. The cellular response to DNA damage. 
 
The DNA damage response (DDR) is a cellular surveillance pathway that detects DNA 
damage and initiates cellular signalling pathways to halt the cell cycle and repair the 
DNA damage faithfully, or if the damage is deemed too extensive, to induce senescence 
or cellular apoptosis (Jackson and Bartek 2009). As such, DNA is constantly exposed 
to genotoxic stress-causing agents like ultra-violet (UV) light, ionizing radiation (I.R.) 
and toxic chemicals that can cause ssDNA and dsDNA breaks that need to be detected 
and repaired (Ciccia and Elledge 2010).  Similarly, the natural process of cellular DNA 
replication can lead to replication stalling can lead to DNA damage that also activates 
cellular DDR pathways (Cimprich and Cortez 2008). Heritable defects in the DDR 
pathway can cause autoimmune diseases, neurodegenerative disorders, growth 
retardation, and cardiovascular disorders and enhanced cancer susceptibility. 
Individuals with genetic mutations in DDR genes are commonly predisposed to tumour 
formation due to their sensitivity to DDR agents (Gorgoulis, Vassiliou et al. 2005). 
Examples of heritable syndromes that have defects in DDR genes include hereditary 
breast cancer caused by mutations in BRCA1 and BRCA2; Ataxia telangiectasia (A-T) 
caused by mutations in ATM; A-T mutated like disorder (ATLD) caused by mutations 
in MRE11; Li-Fraumeni syndrome (LFS) caused by mutations in p53; Fanconi Anaemia 
(FA) caused by mutations in FANC genes; Seckel syndrome caused by mutations in 
ATR; and Schimke immunoosseous dysplasia (SIOD) caused by mutations in 
SMARCAL1 (Jackson and Bartek 2009). 
 
DDR signalling pathways are controlled principally by the three members of the 
phosphoinositide 3-kinase (PI3K)-related kinases – termed PIKKs which have kinase 
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domains located within their C-terminal regions and have a preference for 
phosphorylating serine or threonine residues followed by a glutamine (Abraham 2004). 
These dual serine/threonine protein kinases are known as AT mutated (ATM), ATM 
and Rad3-related (ATR) and DNA-dependant protein kinase (DNA-PK) which act as 
apical sensor protein kinases in regulating cell cycle checkpoint control, DDR, DNA 
replication and apoptosis in response to DNA damage (Abraham 2001, Turnell and 
Grand 2012). 
 
1.4.1. DNA-dependent protein kinase (DNA-PK). 
 
DNA-PK is the prototypic member of the PIKK family of kinases and is involved 
exclusively in the non-homologous end-joining pathway. It is comprised of a 450 kDa 
catalytic subunit (DNA-PKcs), and has two regulatory subunits, Ku70 and Ku86 
(Sancar, Lindsey-Boltz et al. 2004). DNA-PK is activated when it is recruited to double-
strand breaks (DSBs) through engagement of the Ku 70/86 subunits with broken DNA 
ends. Two DNA-PK molecules at broken DNA ends serve to secure the broken ends to 
be ligated and moreover, recruit DNA ligase IV – XRCC4 complexes which mend the 
broken ends of DNA in the absence of a DNA template (Turnell and Grand 2012).  
 
1.4.2. ATM kinase. 
 
Ataxia telangiectasia mutated (ATM) is a 350-kDa protein that participates in 
homologous recombination repair pathways. Germ cell mutation, and inactivation of 
ATM causes the autosomal recessive syndrome known as Ataxia-Telangiectesia (A-T), 
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which is characterised by immunodeficiency, cerebellar degeneration, radiosensitivity, 
genome instability and cancer predisposition (Sancar, Lindsey-Boltz et al. 2004). ATM 
normally exists as an inactive homodimer and its activity is stimulated in vivo by DSB’s 
caused by agents such as ionizing radiation and activated, autophosphorylated, ATM 
binds to DSB’s in monomeric form through its regulatory partner, the MRN (Mre11- 
Rad50-NBS1) complex. ATM subsequently phosphorylates a number of substrates 
including the Chk2 effector kinase, p53, H2AX, TIF1b/KAP1, BRCA1 and NBS1 
which participate in the repair of damaged DNA (Sancar, Lindsey-Boltz et al. 2004, 
Turnell and Grand 2012). It also activates effector proteins through phosphorylation, 
such as p53 and CHK2,  to regulate the signalling cascades that initiate cell cycle 
checkpoint control (Hirao, Kong et al. 2000).  
 
1.4.3. ATR kinase. 
 
The ATR gene encodes a protein of size 303 kDa. Heritable, hypomorphic mutations in 
the ATR gene gives rise to the human autosomal recessive disorder, Seckel syndrome, 
which is characterised by microcephaly and mental, and growth, retardation (Sancar, 
Lindsey-Boltz et al. 2004, Byun, Pacek et al. 2005). ATR is an essential gene in 
proliferating cells and recent data suggests that ATR participates in regulating fidelity 
of chromosome segregation during mitosis (Brown and Baltimore 2000, Kabeche, 
Nguyen et al. 2018). ATR in association with its regulator, ATRIP (ATR-interacting 
protein) forms an ATR-ATRIP complex that responds to genotoxic stress such as UV 
light and agents that inhibit cellular DNA replication (Cimprich and Cortez 2008). ATR 
senses ssDNA breaks generated either during the processing of DSBs or ssDNAs 
generated during DNA replication fork stalling. ATR serves as both a sensor and 
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transducer in the DDR and initiates G2/M checkpoint control through the 
phosphorylation and activation of the CHK1 kinase (Byun, Pacek et al. 2005, Matsuoka, 
Ballif et al. 2007). ssDNA breaks are initially sensed by the ssDNA binding protein 
RPA (Replication protein A) complex. RPA is a heterotrimeric protein complex 
composed of three subunits: RPA70, RPA32 and RPA14. RPA32 is 
hyperphosphorylated by PIKK family kinases in response to DNA damage and 
modulates the downstream regulation of DNA replication. RPA is also involved in 
recombination and repair pathways. The RPA-DNA complex plays a vital role in the 
DDR by recruiting ATR-ATRIP complex to RPA-coated ssDNA at DNA breaks (Binz, 
Sheehan et al. 2004, Chen and Wold 2014). Recruitment of ATR activator proteins such 
as TopBP1 is required for full activation of ATR (Kumagai, Lee et al. 2006), as is 
TopBP1’s association with the RAD9-RAD1-HUS1 complex (Delacroix, Wagner et al. 
2007). In response to genotoxic stress ATR, in addition to activating cell cycle 
checkpoints, also serves to prevent replication fork collapse and promote the repair of 






Figure 1.6. Role of ATM, ATR and DNA-PK in DDR signalling pathways. Image 
taken from (Turnell and Grand 2012). 
 
 
1.5. The role of SMARCAL1 in cellular DNA replication 
and the DDR. 
 
SMARCAL1 (SWI/SNF related matrix associated, actin-dependent, regulator of 
chromatin, sub family A like 1) is a distant subfamily member of the SNF2 chromatin-
remodelling family of proteins (Figure 1.9A) (Flaus, Martin et al. 2006, Bansbach, 
Boerkoel et al. 2010). SMARCAL1 is mutated in SIOD (Schimke immunoosseous 
dysplasia), which is characterized by T-cell immunodeficiency, renal failure, skeletal 
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dysplasia, and, in approximately 50% of cases, microcephaly (Boerkoel, Takashima et 
al. 2002). SMARCAL1 is also known as HARP (Hep A-related protein) and functions 
as an ATP-dependent annealing helicase whose activity is stimulated by both ds and ss 
DNA, but is stimulated even more by DNA stem-loop and forked DNA structures 
(Muthuswami, Truman et al. 2000). It is a 954 residue protein and consists of an N-
terminal RPA-binding domain, two tandem HARP domains, HARP1 and HARP2, 
which are essential for SMARCAL1 annealing activity, and two C-terminal 
SNF2/ATPase domains which couples ATP hydrolysis to DNA annealing of the 
complementary strands (Figure 1.9B; (Ghosal, Yuan et al. 2011). The ability of the N-
terminal region of SMARCAL1 to bind RPA is important for SMARCAL1 recruitment 
to sites of DSBs and stalled or collapsed replication forks which serves to maintain 
genome integrity through its annealing helicase activity (Bansbach, Bétous et al. 2009, 





     
 
Figure 1.7. SWI/SNF2 family evolutionary relationship Figure taken from (Flaus, 
Martin et al. 2006) and SMARCAL1 protein domain structure taken from 
(Robbins 2012).  
 
RNA interference studies determined that loss of the SMARCAL1 protein results in 
increased sensitivity to agents that cause DSBs or replication fork collapse leading to 
increased cell death (Bansbach, Bétous et al. 2009, Ciccia, Bredemeyer et al. 2009). 
Overexpression of SMARCAL1 similarly leads to replication-associated DNA damage 
(Bansbach, Bétous et al. 2009). Given that alterations in SMARCAL1 levels results in 
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the activation of the DDR and enhanced apoptosis SMARCAL1 could be a potential 
drug target for cancer therapy (Zhang, Fan et al. 2012).  
 
1.5.1. Regulation of SMARCAL1 activities by the ATR kinase. 
 
As SMARCAL1 is involved in cellular DNA replication and the cellular DDR it is not 
surprising that its activity is tightly regulated by the PIKK kinases, ATM, ATR and 
DNA-PK during unperturbed S-phase and in response to DNA damage and genotoxic 
stress (Bansbach, Bétous et al. 2009, Ciccia, Bredemeyer et al. 2009). As ATR is the 
principal PIKK kinase that monitors DNA replication through its ability to 
phosphorylate substrate proteins and prevent the accumulation of aberrant fork 
structures, limit fork collapse and promote fork stability, SMARCAL1 activity is tightly 
regulated by ATR (Ciccia, Bredemeyer et al. 2009, Bhat, Bétous et al. 2015). In response 
to stalled replication SMARCAL1 associates with stalled replication forks. In these 
circumstances ATR phosphorylates SMARCAL1 on S652 to limit its fork regression 
properties in order to prevent aberrant fork processing and fork collapse (Couch, 
Bansbach et al. 2013). Indeed, when ATR is inhibited specifically by small molecule 
inhibitors dysregulated SMARCAL1 activity can lead to fork collapse (Couch, 
Bansbach et al. 2013). In other circumstances, ATR can stimulate SMARCAL1 ATPase 
activity in order to promote SMARCAL1-catalysed fork regression activities through 
phosphorylation of SMARCAL1 on S889 (Carroll, Bansbach et al. 2013). S889 lies 
within a C-terminal auto-inhibitory domain of SMARCAL1 that phosphorylation by 
ATR relieves (Carroll, Bansbach et al. 2013). SMARCAL1 is known to be 
phosphorylated on multiple sites including S112, S123, S129, S172, S173, S198, S652 
and S889 (Carroll, Bansbach et al. 2013). Despite the identification of these sites, the 
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biological role of most of these phosphorylation events is unknown. S112, S123, S129, 
S172, S173 and S198 lie close to the RPA-binding domain which are known to regulate 
cell cycle specific activities (Carroll, Bansbach et al. 2013). Of these sites S112, S123 
and S129 are all SP motif, which could be targeted by CDKs, whereas S173 is a PIKK 
motif and S172 does not conform to any known motif. It will be interesting in the future 
to establish how phosphorylation at these sites modulates SMARCAL1 activity. 
 
1.5.2. SMARCAL1 and telomere maintenance. 
 
Telomeres, which protect chromosome ends and act as a cellular ageing monitor, are 
maintained by two independent pathways. The enzyme telomerase is a 
ribonucleoprotein that utilises an RNA template to add telomere sequence to the 3’ end 
of telomeres, whilst the Alternative Lengthening of Telomere (ALT) pathway relies on 
homologous recombination. Telomerase is activated in approximately 90% of human 
cancers to maintain telomere length and the ALT pathways maintains telomere length 
in the remaining 10% of cancers (Shay and Wright 2019). SMARCAL1 has recently 
been shown to play an important regulatory role in the ALT pathway (Poole, Zhao et al. 
2015, Cox, Maréchal et al. 2016). SMARCAL1 associates with telomeric DNA and 
localises at ALT telomeres in response to replication stress and promotes telomere 
stability by preventing replication fork collapse. Indeed, in the absence of SMARCAL1 
stalled replication forks are processed to DSBs which promotes chromosome fusions 
(Figure 1.10) and the production of extrachromosomal telomere DNA, termed C-circles 
(Poole, Zhao et al. 2015, Cox, Maréchal et al. 2016). Interestingly, SMARCAL1 activity 
at telomeres is not dependent upon its interaction with the RPA complex and 
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SMARCAL1 does not increase the rate of telomere recombination through ALT (Poole, 
Zhao et al. 2015). 
 
 
 Figure 1.8. Role of SMARCAL1 in ALT telomere maintenance. Figure taken from 
(Cox,  Maréchal et al. 2016).  
 
 
1.6. Adenovirus and the DNA damage response. 
 
Viruses are like other genotoxic agents that are known to initiate DDR repair pathways. 
Upon adenovirus infection, the linear Ad dsDNA genome mimics a host cell DSB, 
whilst DNA replication generates ssDNA intermediates. The host cell DDR machinery 
recognises these species as DNA breaks and initiates DDR signalling pathways that 
would ordinarily induce cell cycle arrest or apoptosis (Weitzman, Carson et al. 2004). 
Activation of DDR pathways following adenovirus infection would limit severely viral 
replication and are therefore considered anti-viral responses. Adenoviruses, like other 
viruses, have evolved antiviral defence strategies through the expression of their early 
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gene products to regulate host cell DDR pathways to support viral replication. It is 
perhaps, therefore no surprise that adenovirus has a greater ability to replicate to higher 
titres in cancer cells rather than primary cells, as key DDR proteins are often inactivated 
in cancer cells (e.g.(Turnell, Grand et al. 1999); (Bischoff, Kirn et al. 1996, Heise, 
Sampson-Johannes et al. 1997, Johnson, Shen et al. 2002, O'Shea, Johnson et al. 2004)). 
Given this relationship, and the fact that conditionally-replicating adenoviruses are 
potential agents for cancer therapy, understanding the relationship between adenovirus 
and cellular DDR pathways is important towards understanding the molecular basis of 
host cell-virus interactions and generating the most efficient oncolytic viruses 
(Weitzman and Ornelles 2005, Turnell and Grand 2012).  
 
1.6.1. Regulation of p53 during infection. 
 
Forty years ago David Lane, William Old, Arnold Levine and Michel Kress initially 
identified a 53 kDa cellular protein that associated with SV40 large T antigen and named 
it p53 (DeLeo, Jay et al. 1979, Kress, May et al. 1979, Lane and Crawford 1979, Linzer 
and Levine 1979). Initially, p53 was identified as oncogene as the species originally 
cloned was mutant, but later functional studies determined that the w.t. p53 protein acted 
as a tumour suppressor gene product (Vogelstein, Lane et al. 2000). As such, p53 has 
the ability to induce cell cycle arrest, senescence and apoptosis in response to cellular 
stresses such as ionizing radiation, U.V. light, changes in intracellular oxygen levels etc 
(Vogelstein, Lane et al. 2000, Surget, Khoury et al. 2014). To ensure that adenoviruses 
replicate in the presence of such a potent tumour suppressor, the virus has evolved 
numerous mechanisms to inactivate p53 during viral infection. In addition to the known 
roles of E1B-55K and E4orf6 to inhibit p53 transcriptional activity in isolation (see 
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sections 1.3.6. and 1.3.8.) it was later established by Johannes Bos’s group that E1B-
55K and E4orf6 cooperated to reduce p53 levels in the infected cell by reducing the 
half-life of the p53 protein (Steegenga, Riteco et al. 1998).  In this regard they also 
demonstrated that E1B-55K and E4orf6 would similarly reduce the levels of mutant p53 
in infected cells (Steegenga, Riteco et al. 1998). It was later established that E1B-55K 
and E4orf6 cooperate to target p53 for degradation through the ubiquitin-proteasome 
system (Querido, Blanchette et al. 2001). As such, E1B-55K was shown to serve as a 
receptor for the p53 substrate whereas E4orf6 through its ability to bind E1B-55K 
recruited a cellular ubiquitin ligase, CRL5 (Cullin-Ring Ligase 5), to E1B-55K-p53 
complexes in order to promote the ubiquitin and 26S proteasome-mediated proteolysis 
of p53 (Figure 1.7; (Querido, Blanchette et al. 2001). Research from our laboratory later 
indicated that Ad12 E1B-55K and E4orf6 similarly targeted p53 for degradation by 
utilising CRL2, rather than CRL5 (Blackford, Patel et al. 2010). 
 
1.6.2. Regulation of cellular protein degradation by E1B-55K and 
E4orf6. 
 
Mass spectrometric identification of both cellular Ad5 E4orf6 and E1B-55K –
interacting proteins identified CRLs as major targets for E1B-55K/E4orf6 complexes 
during infection (Querido, Blanchette et al. 2001, Harada, Shevchenko et al. 2002). 
Indeed, all components of CRLs were identified in these screens including the Cullin 5 
and Elongin B and C proteins, and the Rbx1 ubiquitin ligase (Querido, Blanchette et al. 
2001, Harada, Shevchenko et al. 2002). It was later established that whilst the zinc-
finger binding region of E4orf6 was required for binding to E1B-55K, E4orf6 also 
possessed three BC boxes which promote E4orf6 association with Elongin B and C 
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components of CRLs to recruit the CRL to E1B-55K and associated cellular substrate 
for ubiquitin-mediated proteolysis (Blanchette, Cheng et al. 2004). It is known that the 
NEDD8-activating enzyme specifically enhances CRL activity through its ability to 
NEDDylate the associated Cullin subunit, which allows for a conformational change in 
the CRL complex and the dissociation of CAND1, a negative regulator of CRL activity 
(Duda, Borg et al. 2008). In this regard, our laboratory determined that during Ad5 
infection Cullin 5 became NEDDylated, whilst during Ad12 infection Cullin 2 became 
NEDDylated, consistent with the roles of CRL5 in Ad5 infection and CRL2 in Ad12 
infection (Blackford, Patel et al. 2010). 
 
Adenovirus early region oncoproteins E1B-55K and E4orf6 are now known to target 
numerous host cellular proteins for degradation via the ubiquitin-proteasome system by 
utilising cellular CRLs. In this regard, adenovirus utilises the cellular ubiquitylation 
machinery, more often than not, to inhibit DDR signalling pathways and to negate the 
activation of the DDR during adenovirus infection that would prove detrimental to viral 
replication. These will be discussed in detail in the following sections. Other studies 
suggest that adenovirus does not just utilise cellular CRLs to inhibit the DDR. Indeed, 
the Branton laboratory determined that integrin a3 was degraded in an E1B-55K and 
E4orf6 dependent manner during infection (Dallaire, Blanchette et al. 2009). It was 
proposed that integrin a3 degradation during infection might affect cell-cell interactions 
which would promote the release and spread of progeny virus (Dallaire, Blanchette et 
al. 2009). 
 Other collaborative studies from our laboratory and David Matthews laboratory showed 
using quantitative mass spectrometric proteomics, and infection with adenovirus 
mutants, that ALCAM, EPHA2, PTPRF were major targets for E1B-55K/E4orf6 (and 
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E1B-55K/E4orf3) degradation in Ad5-infected cells (Fu, Turnell et al. 2017). As these 
proteins are, like integrin a3, critical regulators of cell signalling and cellular adhesion 
the degradation of these proteins might similarly facilitate virus release and spread. It 
has also been determined, through the expression of a dominant-negative Cullin 5 
protein that CRL5 is important in the ability of E1B-55K/E4orf6 to promote the nuclear 
export of late viral mRNAs into the cytoplasm, though the cellular protein that is 
targeted for CRL5-mediated degradation is not known (Woo and Berk 2007). Other 
studies have suggested that E1B-55K can engage with CRL5, independently of E4orf6, 
to target the pro-apoptotic, Daxx (death-domain-associated protein), for degradation 
during Ad5 infection (Schreiner, Wimmer et al. 2010). How E1B-55K achieves this 
mechanistically however, is not known. 
 
 








1.6.3. Regulation of DNA-PK by adenovirus. 
 
Early studies indicated that both E4orf3 and E4orf6 could inhibit DNA-PK-dependent 
V(D)J recombination through NHEJ by interacting directly with DNA-PKcs (Boyer, 
Rohleder et al. 1999). Moreover, E4orf3 and E4orf6 were also shown to inhibit 
adenovirus genome concatemerization (i.e. the ligation of multiple adenovirus genomes 
together) which would produce a viral genome that would not be able to be packaged 
inside the capsid, suggestive of the notion that these viral proteins inhibited the ability 
of DNA-PK to catalyse DSB repair (DSBR).  Further work by the same group indicated 
that E1B-55K and E4orf6, but not E4orf3, could inhibit NHEJ directly during Ad5 
infection by promoting the CRL5-dependent degradation of DNA ligase IV (Baker, 
Rohleder et al. 2007). It was determined that the α2 helix in the DNA ligase IV BRCT-
1 domain was required for targeted degradation by adenovirus 5 during infection 
(Gilson, Greer et al. 2012), though it was not determined whether E1B-55K, or E4orf6 
interacted with this BRCT-1 domain during infection, or whether it was a phospho-
dependent interaction. It has recently been shown that the E4orf4 protein also interacts 
with DNA-PKcs during Ad5 infection where they co-localize at VRCs (Nebenzahl-
Sharon, Shalata et al. 2019). It has been suggested that early during infection E4orf4 
utilises DNA-PKcs to inhibit both the ATM and ATR pathways, through its ability to 
reduce ATM autophosphorylation and Chk1 activation whilst at later times post-
infection E4orf4 inhibits DNA-PK activity to enhance virus replication (Nebenzahl-





1.6.4. Regulation of the ATM pathway by adenovirus. 
 
As mentioned earlier and shown in Figure 1.6, DSBs are sensed by the MRN complex 
which then activates the ATM signalling pathway to promote cell cycle checkpoint 
control and DNA damage repair through HR, or induces apoptosis if the DNA damage 
is too great (Uziel, Lerenthal et al. 2003). The MRN complex and ATM are also 
components of the TRF2 telomere-binding complex and regulates telomere integrity (de 
Lange 2018). Adenoviruses are known to inactivate the ATM signalling pathway by 
targeting the MRN complex for degradation via the ubiquitin-proteasome system 
(Stracker, Carson et al. 2002). In studies similar to those of Boyer who looked at the 
role of DNA-PK in adenovirus genome concatemerization (Boyer, Rohleder et al. 
1999), the studies by the Weitzman laboratory showed that the Ad5 E1B-55K-E4ORF6 
mediated degradation of the MRN complex thorough the ubiquitin-proteasome system 
prevented adenovirus genome concatemerisation (Stracker, Carson et al. 2002). Further 
studies by the same group indicated that E4orf3 re-localized MRN components to PML-
containing nuclear tracks and to cytoplasmic aggresomes to inhibit MRN function 
(Araujo, Stracker et al. 2005). Additionally, the Weitzman group also established that 
the RecQ helicase family member, BLM, which participates in the resection of DNA 
breaks is also targeted for proteasome-mediated degradation by E1B-55K and E4orf6 
during Ad5 infection (Orazio, Naeger et al. 2011). It was also determined that E1B-55K 
could bind to BLM, independently of MRE11 and that BLM was detected close to sites 
of viral DNA synthesis in Ad5-infected cells, though whether BLM facilitated viral 





1.6.5. Regulation of the ATR pathway by adenovirus. 
 
ATR is an apical stress response kinase involved in regulating cellular DNA replication, 
DNA damage repair, cell cycle arrest and apoptosis (see section 1.4.3; (Cortez 2015)). 
Some of what we know about the relationship between adenoviruses and ATR comes 
from work performed in our laboratory, which has shown that Ad5 and Ad12 
differentially regulate the ATR signalling pathway during infection (Blackford, Bruton 
et al. 2008). As such, it was established that the E1B-55K-interacting protein, E1B-AP5 
participated in the ATR-mediated phosphorylation of RPA32 during both Ad5 and Ad12 
infection and that E1B-AP5, ATRIP, RAD9 and RAD17 were all recruited to VRCs 
during infection with these viruses (Blackford, Bruton et al. 2008).  Work from the 
Weitzman laboratory showed that Ad5 inhibited the ATR-dependent activation of Chk1 
by promoting the E4orf3-dependent relocalization of MRN to PML-containing nuclear 
tracks, although they determined that many virus types, including Ad12 did not possess 
this ability as the key E4orf3 residue responsible in the Ad5 form was not conserved in 
Ad12 E4orf3 (Carson, Orazio et al. 2009). Our laboratory determined that Ad12 inhibits 
the ATR-dependent activation of Chk1, by promoting the ATR activator, TopBP1 for 
E4orf6-CRL2 dependent degradation (Blackford, Patel et al. 2010). As such, E4orf6 
associated with both TopBP1 and CRL2 in order to promote TopBP1 degradation 
(Blackford, Bruton et al. 2008). It has also been demonstrated that a mutant adenovirus 
lacking E1B-19K, which sensitizes pancreatic cancer cells to cell death with the 
cytotoxic drugs gemcitabine and irinotecan, promotes the down-regulation of the 
cellular replication protein and ATR activator, Claspin during the infection, by both 
transcriptional and proteolysis in order to inhibit Chk1 activation which has the 
consequence of enhancing cell killing (Pantelidou, Cherubini et al. 2016). The down-
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regulation of MRE11 also contributed to the attenuation of Chk1 activation (Pantelidou, 
Cherubini et al. 2016).  Interestingly, it has been shown that Claspin and another 
replication protein and ATR activator, Timeless, are both excluded from newly 
replicated adenovirus dsDNA, suggesting both of these proteins attenuate adenovirus 
genome replication (Reyes, Kulej et al. 2017). Given these findings it is clear that 





Figure 1.10. Regulation of ATM and ATR signalling pathways by different 
adenovirus serotypes. Schematic illustration of ATM and ATR pathways showing how 
different Ad early region proteins E1B-55k, E4orf3 and E4orf6 modulate the signalling 
pathways. Ad5 E4orf4 target ATM pathway, Ad5, Ad12 E4orf6-E1b-55K and E4orf3 
target MRN complex, p53 and NHEJ pathway, whilst Ad5 E4orf3 and E4orf4 target 
ATR pathway, Ad12 E4orf6 target ATR activator TOPBP1 and Ad5 and Ad12 E4orf6-
E1B-55K target RPA interacting protein and ATR substrate SMARCAL1 for 











1.7. Project aims.  
 
The current literature indicates that adenoviruses have evolved specifically to engage 
with the host cell ubiquitin-proteasome system to evade DDR signalling pathways that 
would, otherwise be detrimental to adenovirus replication. Our laboratory has long been 
interested in how adenoviruses regulate the ATR signalling pathway, and have shown 
previously that adenoviruses target E1B-AP5 and TopBP1 in order to modulate ATR 
kinase function during infection. As adenovirus typically targets multiple components 
of the same pathway, we were interested to study the relationship between adenovirus 
and ATR in more detail. Indeed, previous work by a PhD student in our laboratory 
suggested that adenovirus targeted SMARCAL1 for degradation during infection in an 
E1B-55K/E4orf6- dependent manner. The main aim of this study was, therefore, to 
establish the molecular basis of SMARCAL1 degradation in Ad-infected cells, 
particularly the requirement for CRLs and other cellular proteins. As E1B-55K is known 
to affect p53 transcriptional activity we also wished to determine whether E1B-55K 
similarly, affected SMARCAL1 function in cellular DNA replication. The results of 
















Materials and methods  
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2.1. CELL CULTURE TECHNIQUES: 
 
2.1.1. Cell lines. 
 
Cell line Type Origin Source Culture media 

























A549 epithelial small cell lung 
carcinoma cells 
human DMEM 
RPE-1 epithelial Retinal pigment 
cells 
human DMEM 
  Table 2.1. List of cell lines used in this study 
 
 
2.1.2. Maintenance of cell lines. 
 
Adenovirus 5 E1-transfromed human embryo kidney cells (HEK293; (Graham, Smiley 
et al. 1977)), adenovirus 12 E1-transformed human embryonic retinal cells (HER2; 
(Byrd, Grand et al. 1988)), GP2-293 retroviral packaging cells (Clontech), A549 lung 
carcinoma cells (ATCC CCL-185), U2OS FRT cells (Thermofisher), and TERT-
immortalized RPE-1 cells (ATCC CRL-4000) were all maintained and cultured in 
HEPES-buffered DMEM medium supplemented with 8% (v/v) foetal bovine serum 
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(FBS; Sigma-Aldrich) and L-glutamine (2 mM; Sigma-Aldrich).  Cells were maintained 
at 37°C and kept at constant humidity and 5% (v/v) CO2 in a Mars Safety class 2 safety 
cabinet (Scanlaf). Confluent cells were washed with warmed PBS and trypsinized with 
1 ml of Trypsin (Gibco). Detached cells were resuspended in 9 ml of DMEM and seeded 
on to new dishes under sterile conditions in the laminar flow hood.  
2.1.3. Cryopreservation of cells. 
 
For long time storage of cells, cells were first trypsinised and then resuspended with 
DMEM containing 10% (v/v) DMSO (dimethyl sulphoxide), typically at a density of 
5x106 cells/ml, and placed in cryo-tubes (Thermo-Scientific). Cells were then cooled to 
-80°C at a controlled rate of 1°C/min with isopropanol using a Mr. FrostyTM freezing 
container. Frozen cells were transferred the following day to liquid nitrogen tanks at -
180°C for long time storage. 
2.1.4. Recovery of cells from liquid nitrogen. 
 
Cells were resurrected from liquid nitrogen by rapidly thawing in a water bath at 37°C. 
Cells were immediately transferred in to centrifuge tube with 10 ml of DMEM and then 
pelleted at 1400 rpm for 5 min. Cells were then washed in fresh DMEM, subjected to 
re-centrifugation and resuspended in fresh DMEM, whereupon they were plated on to 





2.2. CELL BIOLOGY TECHNIQUES: 
2.2.1. Adenoviruses. 
 
Wild type (w.t.) Ad5 and Ad12 (Huie) types were obtained from ATCC (American type 
culture collection), whilst Ad E1B-55K deletion viruses, Ad5 dl1520 and Ad12 dl620 
were generated over 30 years ago and have been characterized and used extensively 
over this time (Barker and Berk 1987, Byrd, Grand et al. 1988, Turnell, Grand et al. 
1999, Forrester, Patel et al. 2012). w.t. Ad5 and Ad5 dl1520 viruses were propagated on 
permissive Ad5E1 HEK293 cells, and w.t. Ad12 and Ad12 dl620 were propagated on 
HER3 cells. Titres of the viruses were determined by colony plaque assays on HER911 
cells for Ad5 and HER3 cells for Ad12, respectively (Turnell, Grand et al. 1999). 
2.2.2. Adenovirus infection. 
 
Cells were infected with either w.t. Ad5 or w.t. Ad12 (Huie) in serum-free DMEM at 
an infectivity of 10 plaque forming units (p.f.u.) per cell for 2 h. Infected plates were 
incubated at 37°C and cells were agitated every 10 min intervals to ensure an even spread 
of the virus. Following infection, excess virus was removed, and the medium was 
replaced with 10 ml of fresh DMEM + 8% (v/v) FBS and incubated at 37°C in the 
incubator until required.   
2.2.3. Transient DNA transfection.  
 
Transfections were performed on retroviral packaging GP2-293 cells, which are 
HEK293 cells that express the essential viral packaging, gag (Group antigens 
polyprotein), and pol (reverse transcriptase) genes.  GP2-293 cells were plated the day 
before transfection on 75 cm2 flasks such that they were 70-80% confluent at the time 
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of transfection. For transfection, 10 µg of the appropriate pEGFP-C1-SMARCAL1 
construct and 10 µg of pCMV-VSV-G was added to 200 µl of Opti-MEM (Invitrogen) 
in a sterile eppendorf tube and incubated for 5 min at room temperature. Similarly, 20 
µl of Lipofectamine 2000 was added to a separate eppendorf tube containing 200 µl of 
Opti-MEM and incubated for 5 min. After this time, the DNA opti-MEM mixture and 
the transfection reagent mixture were combined, mixed gently and incubated at room 
temperature for 30 min to allow for the formation of DNA-liposome complexes. In the 
meantime, cells to be transfected were washed twice with Opti-MEM and then incubated 
in 4.6 ml of Opti-MEM. After 30 min incubation, the DNA-liposome complexes were 
added to the GP2-293 cells and incubated for 6 h at 37°C. After the incubation time, 
Opti-MEM was replaced with 10 ml of fresh DMEM-HEPES supplemented with 8% 
(v/v) FBS and 2 mM glutamine. Plasmid constructs used in this study are listed below. 
 
Insert Vector 
w.t. SMARCAL1 pLEGFP-C1 (Clonetech) 
SMARCAL1 S123A; SMARCAL1 S129A; 
SMARCAL1 S173A 
pLEGFP-C1 (Clonetech) 
SMARCAL1 S123A/S129A; SMARCAL1 
S123A/S173A; SMARCAL1 S129A/S173A 
pLEGFP-C1 (Clonetech) 
SMARCAL1 S123A/S129A/S173A pLEGFP-C1 (Clonetech) 
G glycoprotein of the vesicular stomatitis 
virus 
 pCMV-VSV-G (Addgene) 




2.2.4. Retroviral transduction. 
 
At 72 h post-transfection supernatant containing retrovirus particles was collected from 
the GP2-293 cell cultures and filtered using a 0.45 µM filter (Sartorious). As these cells 
produce high titre viruses and the A549 and RPE-1 cells transduce well, we typically 
did not need to concentrate the virus by centrifugation, or use cationic transfection 
agents such as Polybrene to facilitate transduction. Thus, RPE-1 and A549 cells seeded 
at very low density (10%) on 75 cm2 flasks on the day of transduction and infected 
overnight with 5 ml of the appropriate retrovirus. Cells were then incubated in DMEM-
HEPES for an additional 48 h, whereupon cells were trypsinized and seeded at 500 
cells/10 cm dish. After a further 24 h incubation individual clones were ‘picked’ with a 
sterile 1ml pipette using a microscope placed in the tissue culture hood and positive 
clones were selected for using G418 (500 µg/ml; Gibco). Positive clones, identified 
using an EVOS fluorescent digital microscope were expanded on 24-well and then 6-
well plates in order to generate enough cells for freezing and experimentation. 
2.2.5. Drug treatments. 
 
As and when required, cells were treated with drugs such as: caffeine (Sigma-Aldrich), 
the ATM inhibitor, KU-55933 (Sigma-Aldrich), the ATR inhibitor, AZD6738 (Cayman 
chemicals) and the CDK inhibitor, RO-3306 (Merk Millipore) to inhibit cellular kinases. 
Drugs that inhibit the ubiquitin-proteasome system such as: Nedd8-activating enzyme 
(NAE) inhibitor, MLN-4924 (Cayman chemicals), and proteasome inhibitors MG132 
and salinosporamide A (SAL A; Sigma-Aldrich) were also used in this study. 
Ganciclovir (Sigma-Aldrich) was also used to inhibit adenoviral DNA replication. The 
concentrations of drugs used are detailed in the appropriate Figure legends. 
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2.3. PROTEIN BIOCHEMISTRY AND IMMUNOLOGICAL 
TECHNIQUES. 
2.3.1. Cell lysis. 
 
Cells were washed twice in ice-cold PBS and then lysed in either NETN lysis buffer 
(250 mM NaCl, 0.5 mM EDTA (pH 8.0), 50 mM (pH 7.5) Tris- HCL, 1% (v/v) NP-40), 
HiLo salt lysis buffer (50 mM Tris (pH 7.4). 0.825 M NaCl, 1% (v/v) NP-40), or UTB 
buffer (9 M urea, 50 mM Tris (pH7.4), 150 mM β-mercaptothanol). The cells lysed in 
UTB or HiLo salt buffer were sonicated for 15 sec at power setting, 5, using a Microson 
ultrasonic cell disruptor. Cells lysed in NETN buffer were Dounce-homogenized, on 
ice, using a tight pestle for 20 strokes with a 5 min break on ice after 10 strokes. The 
samples were then centrifuged at 13,000 rpm for 30 min at 4⁰C and the clarified lysates 
collected for further analyses. 
2.3.2. Bradford assay quantification of protein concentrations. 
 
Bradford reagent (BIO-RAD) was diluted 1 in 5 with deionised H20. 1 ml of the 
Bradford reagent was added, typically, to 4 µl of clarified cell lysates of unknown 
protein concentration. A standard curve of protein concentration was generated by 
adding 1ml of Bradford reagent to 0–30 µg of bovine serum albumin (BSA). 
Absorbance at 595 nm was then measured using a Cecil CE9200 spectrophotometer and 






2.3.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
 
Protein samples were mixed one-to-one with sample buffer (1 volume SDS (10% w/v): 
2 volumes 9 M urea, 50 mM Tris (pH 7.4), 150 mM b-mercaptoethanol) and boiled at 
95°C for 5 min prior to separation by SDS-PAGE. 50 µg of cell lysates and 
immunoprecipitated samples that had been prepared in sample buffer were separated 
according to molecular weight upon a 10% acrylamide (w/v) (acrylamide/bisacrylamide 
(37.5:1); Severn Biotech Ltd) gel containing 0.1 M Tris-Bicine (pH 8.3), 0.1% (w/v) 
SDS, 0.3% (v/v), TEMED and 0.06 % (w/v) ammonium persulphate. For the analysis 
of larger proteins 6 to 8 % acrylamide gels were used and for smaller proteins 12 to 14 
% acrylamide gels were used. The vertical gel electrophoresis apparatus was assembled 
as per the manufacturer’s guidelines (Hoefer). The gel mixture was then poured into the 
apparatus and a 15-well comb was inserted to create wells. Once the gel had polymerised 
the comb was removed, wells washed with deionized water and samples were loaded in 
to the wells that contained running buffer (100 mM Tris-bicine, 0.1% (w/v) SDS). Gels 
were run between 10 to 20 mA overnight in running buffer depending on the molecular 
weight of the proteins to be analysed.  
2.3.4. Coomassie staining of gels. 
 
Acrylamide gels were stained overnight in a colloidal coomassie solution that was 
comprised of coomassie brilliant blue G250 (0.1% (w/v); Fisher scientific), 
orthophosphoric acid (1.6% (v/v); Fisher scientific), ammonium sulphate (8% (w/v); 
Sigma-Aldrich) and methanol (20% (v/v)). Gels were washed extensively in distilled 




2.3.5. Western blotting. 
 
After separating proteins by SDS-PAGE, proteins were transferred on to nitrocellulose 
membrane in transfer buffer [(24 mM) Tris, (193 mM) Glycine, 20% (v/v) methanol] at 
280 mA for 6h. The membrane was then blocked in 5% (w/v) Milk powder in TBST 
(Tris buffered saline-Tween 20) [20 mM Tris HCL (pH 7.5), 0.1% (v/v) Tween-20, 150 
mM NaCl] for at least 1 h. The membrane was then cut according to the sizes of the 
proteins under investigation and washed once in TBST. Primary antibodies were diluted 
to the desired concentration in 5% (w/v) milk powder in TBST and incubated with the 
membrane overnight on a rocker at 4⁰C. Blots were then washed three times in TBST 
(15 min each time) followed by incubation in the appropriate secondary conjugated HRP 
antibodies in 5% (w/v) milk powder in TBST for 3 h on a rocker at room temperature. 
The blots were then washed three times (15 min each time) in TBST and incubated in 
Immobilon chemiluminescent HRP reagent (Millipore) and exposed to blue X-ray film 
(Wolf laboratories) for the desired time. Protein bands were visualized after developing 











Antigen Clone/code Species Usage Supplier 
SMARCAL1 sc-376377 mouse WB, IP Santa Cruz 
Ad5 E1B-55K 2A6 mouse WB, IP In-house 
Ad5 E1B-55K pAb rabbit WB, IP  Eurogentec 
Ad12 E1B-55K XPH9 mouse WB, IP In-house 
Ad5 E1B-55K pAb rabbit WB, IP Eurogentec 
Ad12 E1A M13 mouse WB In-house 
Ad5 E4orf3 6A11 rat WB Thomas 
Dobner 
Ad12 E4orf6 RSA3 mouse WB Thomas 
Dobner 
p53 DO-1 mouse WB, IP David Lane 
MRE11 12D7 mouse WB GeneTex 
β-actin AC-74 mouse WB Sigma-
Aldrich 
GFP B-2 mouse WB Santa Cruz 
Normal Mouse IgG 12-371 mouse IP Sigma-
Aldrich 
Normal Rabbit IgG 12-370 rabbit IP Millipore 
bromodeoxyuridine BU1/75 rat  IF Abcam 
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bromodeoxyuridine B44 mouse IF Becton 
Dickinson 
Anti-mouse HRP  P044701-2 Goat WB Dako 
Anti-rabbit HRP  PO39901-2 Swine WB Dako 
Anti-mouse  
Alexa Fluoro 488 
A32723 Goat IF Thermo 
Fisher 
Anti-Rabbit  
Alexa Fluoro 594 
A32731 Goat IF Thermo 
Fisher 
         Table 2.3. List of antibodies used in this study.  




Cells were lysed in NETN or HiLo buffers for immunoprecipitation. 10 µg of 
immunoprecipitating antibody, or normal IgG control antibody, was added to the lysates 
and incubated at 4°C overnight on a rotator. The next morning 20 µl of packed Protein 
G agarose beads (KPL) were added to the antibody-containing lysates and incubated at 
4°C for 2 h on a rotator. The immunoprecipitates were then washed 3 times with the 
lysis buffer and repeated rounds of centrifugation at 13,000 rpm and 4°C. After 
sufficient washing, sample buffer was added to the beads and incubated at 95⁰C for 5 
min, and the samples prepared for SDS-PAGE. 
2.3.8. Treatment of immunoprecipitates with l-phosphatase. 
 
l-phosphatase is a broad-range Mn2+-dependent protein phosphatase that cleaves 
phosphate groups from phospho-serine, phospho-threonine and phospho-tyrosine 
residues. To assess whether SMARCAL1 was phosphorylated following Ad5 and Ad12 
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infection, SMARCAL1 was immunoprecipitated from mock, and Ad5 and Ad12 -
infected cell lysates using a SMARCAL1-specific antibody (see section 2.3.7). 
Immunoprecipitates were collected on protein G- sepharose beads and washed with 25 
mM Tris (pH 7.4) prior to incubation in 1X l-phosphatase buffer (NEBuffer), 1 mM 
MnCl2 and 100 U of l-phosphatase (NEB). Samples were then incubated for 1 hour in 
water bath at 30°C, after which they were resuspended in SDS-PAGE sample buffer and 
subjected to SDS-PAGE and Western blot analysis. 
2.3.9. Mass Spectrometry. 
 
To identify SMARCAL1 residues that were phosphorylated during Ad5 and Ad12 
infection SMARCAL1 was immunoprecipitated from mock, and Ad -infected A549 
cells (section 2.3.7). Immunoprecipitates were isolated on protein G Sepharose beads, 
re-suspended in SDS-PAGE sample buffer and separated on pre-cast Novex NuPageTM 
4-12% bis- tris gels (Life technologies). The gel was then stained in coomassie Brilliant 
Blue as described in section 2.3.4. Multiple bands around the corresponding molecular 
weight of SMARCAL1 were excised with a sterile scalpel in a laminar flow cabinet and 
washed at room temperature, on a shaker, three times for a total time of 45 min, in  a 
solution containing 50 mM Ammonium bicarbonate (ABC; Sigma-Aldrich) and 50% 
(v/v) Acetonitrile (ACN; Millipore). Note that all solutions were made using HPLC 
(High-Performance Liquid Chromatography)-grade H2O (Chromanorm, VWR). Protein 
bands were then reduced with 50 mM dithiothreitol in a 10% (v/v) solution of ACN and 
50 mM ABC at 56⁰C for 1 h. The reducing solution was then removed and proteins were 
carboxymethylated, by incubation in the dark for 30 min, in a solution of 200 mM 
iodoacetamide in 10% (v/v) ACN and 50 mM ABC. The gel slices containing the protein 
bands were then washed three times for a total time of 45 min in 10% (v/v) ACN and 
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40mM ABC on a shaker at room temperature. The gel slices were then dehydrated by 
incubation with pure ACN for 1 h, on a shaker at room temperature. The dehydrated 
samples were then resuspended in sequence-grade modified trypsin (Promega) in a 
solution of 40mM ABC and 10% (v/v) ACN for rehydration and incubated overnight at 
37⁰C to generate tryptic peptides that could be analysed by mass spectrometry. The 
tryptic peptides were washed-out of the gel slices by washing with 3% (v/v) formic acid 
(Fisher scientific) and then dried in a DNA-mini-vacuum centrifuge for 3-4 h. The dried 
sample was then either stored at -20°C until required or resuspended in a solution of 1% 
(v/v) formic acid and 1% (v/v) ACN prior to analysis on a Q exactive HF hybrid 
quadrupole-Orbitrap mass spectrometer (ThermoFisher Scientific).  
2.3.10. DNA fibre analysis. 
 
Cells were labelled successively with 25µ M of CldU and 250 µM of IdU (both Sigma-
Aldrich) for 20 min at 37°C. Cells were then washed twice with PBS, trypsinised and 
resuspended in PBS at 4°C and diluted to a density of 5x105 cells/ml. Cell extracts 
containing DNA fibres were then prepared in spreading buffer (200 mM Tris-HCl (pH 
7.4), 50 mM EDTA, 0.5% (v/v) SDS). For DNA spreading 2µl of cell extract was added 
to a microscope slide, dried for 5-7 min until fibres looked sticky but not dry, after which 
time 7 µl of spreading buffer was added and mixed gently with a pipette tip. Cell extracts 
were then incubated for approximately 2 min and the slides tilted slightly to let the drops 
containing the cell extracts run down the slides slowly (3-5 min). Microscope slides 
were then air dried the DNA fibres fixed in methanol/acetic acid (3:1) for 10 min. Slides 
could be stored at -20°C at this stage prior to immunostaining if required. 
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For immunostaining the slides were washed twice with distilled H2O (5 min each time) 
and rinsed once with 2.5 M HCl; DNA was then denatured in 2.5 M HCl for 80 min. 
Slides were then rinsed twice with PBS, twice with blocking solution (PBS + 1% (w/v) 
BSA + 0.1% (v/v) Tween 20) and incubated in blocking solution for up to 1 h. DNA 
fibres were then co-stained with rat anti-bromodeoxyuridine (Abcam) and mouse anti-
bromodeoxyuridine (Becton Dickinson) in blocking buffer for 1h. Fibres were then 
fixed with 4% (w/v) paraformaldehyde, washed twice with PBS and incubated further 
with anti-rat Alexa Fluor 555 and anti-mouse Alexa Fluor 488 for 1.5h. Finally, slides 
were mounted in mounting medium (vectashield antifade mounting medium, vector 
laboratories) and fibres analysed on a Nikon E600 microscope using a Nikon Plan Apo 
60x (1.3-numeric-aperture) oil lens and Hamamatsu digital camera (C4742-95) and the 
Velocity acquisition software (Perkin Elmer). DNA fibre images were prepared using 
Image J software. 
2.4. MOLECULAR BIOLOGY TECHNIQUES. 
2.4.1. Media Preparation. 
 
Luria Broth (LB) comprised of 1% (w/v) bactotryptone (Melford chemicals), 0.5% 
(w/v) yeast extract (Melford chemicals) and 1% (w/v) NaCl (Sigma-Aldrich). The pH 
was adjusted to 7.2 and the LB sterilized by autoclaving. To make 1.5% (w/v) LB-agar, 
15 g of Agar was added to one litre of LB and sterilised by autoclaving. LB-agar was 
melted when needed and ampicillin (100µg/ml) was added. Plates were poured in a 
sterile laminar flow hood. Once the plates had cooled down, the plates were stacked and 
saved at 4°C for bacterial transformations. 
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2.4.2. Bacterial transformation. 
 
Transformations were performed using one of the competent E.coli strains listed in 
Table 2.4. 100 ng of plasmid DNA was typically added to 20 µl of bacteria and incubated 
on ice for 30 min and then heat-shocked at 42⁰C for 1 min to allow for plasmid entry. 
The bacteria were then rested on ice for 5 min, after which time 300 µl of Super Optimal 
broth with Catabolite repression (SOC) medium (2% (w/v) bactotryptone, 0.5% (w/v) 
yeast extract, 10 mM NaCl, 10 mM MgCl2, 20 mM glucose; ThermoFisher Scientific) 
was added to the bacteria which were then incubated for 1 h in a shaker at 220 rpm. 
Cells were then plated on LB-agar plates in the presence of 100mg/ml ampicillin, air 
dried and incubated overnight at 37 ⁰C. 
Bacterial Strain Provider 
Library efficiency DH5a Invitrogen 
Subcloning efficiency DH5a Invitrogen 
XL1-Blue supercompetent Agilent technologies 
XL1-Gold supercompetent Agilent technologies 
MAX Efficiency Stbl2 competent Invitrogen 
    Table 2.4. List of bacterial strains used during this study. 
2.4.3. Plasmid DNA Mini Preparation. 
 
A single bacterial colony was picked from an agar plate and added to 5 ml of LB 
containing 100 μg/ml ampicillin, and incubated in a shaker overnight at 37 ⁰C. The next 
morning the tubes were centrifuged at 5,000 rpm for 5 min to pellet the bacteria. DNA 
was purified using a Sigma-Aldrich GenElute plasmid miniprep kit as outlined below. 
The pellet was resuspended in 250 µl of resuspension buffer containing RNase A and 
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transferred to a sterile eppendorf. 250 µl of lysis buffer was then added and the solution 
mixed by inversion. To precipitate cellular debris, 350 µl of neutralisation solution was 
added to the solution and inverted 4 to 6 times to mix.  The tubes were then centrifuged 
at 13,000 rpm for 10 min to obtain the plasmid-containing supernatant. The plasmid-
binding columns were prepared by washing with 500 µl of column preparation solution 
and centrifugation for 2 min. The waste eluate from the tubes was then discarded and 
supernatants containing plasmid DNA were added to the columns and centrifuged for 2 
min at 13,000 rpm to allow for plasmid DNA association with the column matrix. The 
waste eluate from the columns was discarded and columns containing bound plasmid 
were washed sequentially with 500 µl of optional wash solution and 750 µl of wash 
solution by centrifugation. Waste eluates were discarded, and the empty columns were 
dried by centrifugation at 13,000 rpm for an additional 1 min. To elute the DNA, the 
columns were transferred to new sterile eppendorfs and 100 µl of nuclease-free distilled 
water (Ambion) was added. After 5 min incubation the columns were centrifuged for 2 
min at 13,000 rpm to elute the plasmid DNA. The columns were discarded, and the 
eluted DNA was stored at -20⁰C prior to use. 
2.4.4. Plasmid DNA Maxi Preparation. 
 
For larger scale plasmid DNA production, a single bacterial colony was picked from a 
an agar plate and inoculated in 5 ml of LB with 100 μg/ml ampicillin and incubated for 
6 h in an orbital shaker at 37⁰C. After the incubation period, the culture was transferred 
to 250 ml of LB containing 100 μg/ml ampicillin and grown overnight in an orbital-
shaking incubator at 37⁰C. The next morning the culture was centrifuged for 10 min at 
5000 rpm at 4°C and plasmid DNA purified using the NucleoBond Xtra Maxi kit 
(Macherey-Nagel) as described below. The bacterial pellet was resuspended in 12 ml 
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resuspension buffer supplemented with RNase. Cells were then lysed by the addition of 
12 ml of lysis buffer after which the plasmid-containing solution was mixed by inversion 
and incubated at room temperature for 5 min. Cellular debris was precipitated by the 
addition of 12 ml of neutralisation buffer which was then pelleted by centrifugation to 
generate a clarified supernatant that contained plasmid DNA. Plasmid purification 
columns were prepared by adding 25 ml of EQU solution, to the columns after which 
the supernatant containing plasmid DNA was gravity-fed onto the column to allow for 
binding of the plasmid DNA to the column. After binding the column was washed twice 
with 25 ml of Wash buffer, and once with 70% (v/v) ethanol. The DNA was then eluted 
into a clean tube by adding 15 ml of elution buffer. Following elution, plasmid DNA 
was precipitated upon the addition of 10.5 ml of isopropanol; plasmid-containing 
solutions were then centrifuged for 30 min at 15000 rpm and 4°C to pellet the DNA. In 
a sterile laminar flow cabinet, the pelleted DNA was washed twice with 70% (v/v) 
ethanol and then air-dried for 15 to 20 minutes until the DNA pellet became translucent. 
The DNA was then hydrated in an appropriate amount of nuclease free-water. The 
concentration and quality of the DNA was measured by a NanoDrop spectrophotpmeter 
ND-1000 (ThermoFisher Scientific) using ND-1000 spectrophotometer v3.2 software 
(ThermoFisher Scientific). 
2.4.5. PCR-based site-directed mutagenesis. 
 
Given the size of the SMARCAL1 cDNA and the corresponding p-CMV-EGFP-C1 
vector, site-directed mutagenesis was performed using the QuikChange II XL site-
directed mutagenesis kit (Agilent Technologies) by PCR using the oligonucleotides 
listed in Table 2.5. The PCR reaction was performed in a final volume of 50 µl and 
comprised (10X reaction buffer (5 µl), DNA template (10 ng), Forward and Reverse 
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mutagenic primers (500 nM), dNTPs (200 µM), Pfu Ultra DNA polymerase (2.5 U/µl) 
and nuclease-free distilled water to make up to the required volume. The PCR reaction 
was performed using a Thermal-cycler 2720 PCR machine (Applied Biosystems) with 
the following parameters: 95°C for 1 min followed by 18 cycles of 95°C for 50 sec, 
60°C for 50 sec, 68°C at 1min/kb for 10 min. The PCR product was then subjected to 
digestion with the Dpn1 (10 U/µl) restriction enzyme at 37°C for 1 h in a water-bath. 
After digestion of the parental plasmid, 4 µl of DNA was added to 25 µl of 
supercompetent XL1-gold bacterial cells (Agilent Technologies) and the bacterial 
transformation performed as described in section 2.4.2. Individual colonies were then 
selected for mini-prep plasmid DNA preparation as discussed in the section 2.4.3. 
Sequencing was then performed using Sanger sequencing as outlined below to validate 


























2.4.6. Sanger sequencing. 
 
Sequencing reactions were performed by PCR. In each 20 µl reaction there was 5 µl of 
mini-prep plasmid DNA (typically 100-200 ng), forward or reverse sequencing primers 
(10 ng/µl; listed in Table 2.6), 4 µl of 5X sequencing buffer, 1 µl of Big Dye (Applied 
Biosystems) and nuclease-free distilled water made up to 20 µl. The PCR reaction was 
carried out using the Thermal-cycler 2720 PCR machine using the following method: 
25 cycles of 96°C for 10 sec, 55°C for 5 sec, 60°C for 4 min. After PCR, to each PCR 
reaction tube was added 62.5 µl of absolute ethanol, 3 µl of 3 M sodium acetate and 
14.5 µl of nuclease-free distilled water. Samples were incubated at room temperature 
for 30 min to precipitate amplified DNA and then centrifuged at 13,000 rpm for 20 min 
to pellet the DNA. The supernatant was removed, and the pellet washed twice with 100 
µl of 70% (v/v) ethanol followed by successive rounds of centrifugation at 13,000 rpm 
for 15 min. The supernatant was removed, and tubes were air dried, resuspended in 11 
µl of Hi-Di, vortexed briefly and heated at 100⁰C for 5 min before being cooled on ice 
for 5 min. Samples were then loaded into the wells of a plate for sequencing. Sequencing 
was carried out using a 3500xl Genetic Analyzer (Applied Biosystems) and analysed 
using Chromas Lite (Technelysium Pty Ltd.). Results were compared to the reference 








Oligo name Sequence 
EGFP 5'-CATGGTCCTGCTGGAGTTCGTG-3' 
pLNCX 5'-ACCTACAGGTGGGGTCTTTCATTCCC-3' 
SMARCAL1 Seq1 5'- CACAGTCCACGTAGTCAAATGGCT-3' 
SMARCAL1 Seq2 5'- TTGATTGGGTACAATGCGGAACTC-3' 
SMARCAL1 Seq3 5'-CAAGTTCAGCTGGACCCTCTGCCC -3' 
SMARCAL1 Seq4 5'- CTTCTTAGCAAGTTGGAAAAACAG-3' 
SMARCAL1 Seq5 5'- ATAGTGGTGATTGCCCCAGGACGG-3' 
SMARCAL1 Seq6 5'-CTGATCCAGGCTGAGGACCGCGTG -3' 
SMARCAL1 Seq Rev1 5'-GCTGTGGGCATTTCTTCTGGCTTT -3' 
















































Statement: Some of the Figures and Figure legends presented in this thesis have been 
published in J.Virol 2019 Jun 14;93(13); doi: 10.1128/JVI.00402-19 and will be 
highlighted as such. All of the Figures presented are my own work. The text from the 
J.Virol publication has not been used ‘directly’ in this thesis although there might be 







Accurate replication, and segregation, of the genome is essential for cell survival and 
genome maintenance; these cellular processes are controlled by the coordinated 
activities of cell cycle, DNA replication, and DNA response/repair and pro/anti-
apoptotic proteins. Defects in the activities of any of these proteins can cause replication 
stress and DNA damage, which can lead ultimately to genome instability, cellular 
transformation and cancer (Kastan and Bartek 2004). The cellular response to DNA 
replication stress and DNA damage is controlled mainly by the phosphatidylinositol 3-
kinase-related kinase (PIKK) family of kinases, comprising ATM, ATR and DNA-PK 
that function specifically as Ser/Thr-directed protein kinases (Abraham 2004). ATM 
functions specifically to regulate the cellular response to DNA double-strand (ds) 
breaks, whilst ATR functions to coordinate the response to single-stranded (ss)DNA 
that result during DNA replication and double-strand break repair (Blackford and 
Jackson 2017, Shibata and Jeggo 2018); DNA-PK functions to activate NHEJ repair and 
inhibit HR-mediated repair pathways (Blackford and Jackson 2017). 
 
As adenovirus genome replication results in the production of large amounts of ssDNA 
and linear dsDNA that would otherwise activate the PIKK family of protein kinases, the 
virus has evolved to disable the anti-viral activities of the ATM, ATR and DNA-PK 
pathways in order to promote viral replication (Brestovitsky, Nebenzahl-Sharon et al. 
2016). As such, adenoviruses have evolved to inhibit ATM, ATR and DNA-PK 
pathways through the targeted sequestration and/or degradation of number of cellular 
proteins such as the MRN complex, p53, TopBP1, DNA-PKCS and Ku70/Ku80 (Turnell 
and Grand 2012, Weitzman and Fradet-Turcotte 2018). Adenoviruses have also evolved 
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to utilize aspects of DNA response/repair pathways that possess inherent pro-viral 
activities. Indeed, previous work from our laboratory has revealed that the ATR kinase 
substrate and E1B-55K binding protein, E1B-AP5 participates in ATR-dependent 
phosphorylation events during infection (Blackford, Bruton et al. 2008).  
 
As detailed above, the relationship between adenovirus and the ATR pathway is 
complex. ATR function is inhibited, to an extent, by the Ad-mediated degradation of 
MRN and TopBP1 (Carson, Orazio et al. 2009, Blackford, Patel et al. 2010), though 
ATR does retain the ability to phosphorylate RPA and H2AX during infection 
(Forrester, Sedgwick et al. 2011). Given this complexity, our laboratory has focused 
upon delineating the relationship between Ad infection and ATR kinase function in full. 
To these ends recent preliminary studies from our laboratory established that the protein 
levels of, the ATR substrate and DNA replication/damage response protein, 
SMARCAL1 are reduced following both Ad5 and Ad12 infection (F.S.I Qashqari, PhD 
thesis, The University of Birmingham, 2017). These studies determined that 
SMARCAL 1 is recruited to VRCs during infection and, suggested that the loss of 
SMARCAL1 was dependent upon E1B-55K and E4orf6 expression (F.S.I Qashqari, 
PhD thesis, The University of Birmingham, 2017). Despite these observations, a number 
of questions remain unanswered, particularly relating to the mechanism responsible for 
promoting SMARCAL1 loss. In particular, although a role for E1B-55K and E4orf6 in 
the regulation of SMARCAL1 expression has been determined, a role for Cullin-
containing RING E3 ligases and the proteasome has yet to be investigated. Moreover, it 
has yet to be established whether SMARCAL1 is a substrate for ATM/ATR or DNA-
PK kinases during infection, or whether these kinases contribute towards the loss of 
SMARCAL1 during infection. The principal aim of this chapter therefore was to 
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determine the mechanism that promoted the loss of SMARCAL1 protein during 
infection. The results of these studies are presented herein. 
 
3.2. Results 
3.2.1. SMARCAL1 protein levels are reduced following Ad5 and 
Ad12 infection. 
As previous work in our laboratory has suggested that SMARCAL1 protein levels are 
reduced following Ad infection we first wished to confirm these findings. To do this we 
infected A549 cells with either w.t Ad5 or w.t. Ad12 and examined by Western blot 
(WB) the protein levels of SMARCAL1 at different time-points post infection [Figures 
3.1A and 3.1B]. Consistent with earlier results, following the infection of A549 cells 
with w.t. Ad5 the levels of SMARCAL1 were reduced in a similar timeframe to p53, 
which has previously been shown to be targeted for degradation following Ad infection 
[cf lanes 7 and 8 with lanes 3 and 4, panels i and ii; Figure 3.1A]. Similarly, the levels 
of SMARCAL1 were also reduced following the infection of A549 cells with w.t. Ad12 
[cf lanes 7 and 8 with lanes 3 and 4, panel I; Figure 3.1B]. Consistent with published 
observations the levels of p53 increased initially following Ad12 infection, before being 
degraded [Figure 3.1B, panel 2]. Interestingly, we also observed that the mobility of 
SMARCAL1 was retarded upon SDS-PAGE following the infection of A549 cells with 
either w.t. Ad5 or w.t. Ad12, which had not been acknowledged previously [cf lanes 5 
and 6 with lanes 1 and 2, panel i; Figures 3.1A and 3.1B]. Taken together, these data 



































Figure 3.1: SMARCAL1 protein levels are reduced following Ad infection. A549 cells were 
mock treated (uninfected) or infected with w.t Ad5 (A) or w.t Ad12 (B) at 10 p.f.u./cell. Whole 
cell lysates were prepared at the appropriate times post-infection. 50μg protein samples were 
separated by SDS-PAGE and subjected to WB analysis using the appropriate antibodies. This 








3.2.2. SMARCAL1 is phosphorylated following both Ad5 and Ad12 
infection. 
In light of the observation that SMARCAL1 mobility was retarded upon SDS-PAGE 
during the early stages of Ad infection we hypothesised that SMARCAL1 might be 
phosphorylated following Ad infection, as protein phosphorylation often decreases 
protein mobility on SDS-PAGE (Hunter 1995, Cohen 2002). To test this hypothesis, we 
subjected SMARCAL1, isolated from mock and Ad -infected cells to an in vitro 
phosphatase assay. To do this we immunoprecipitated SMARCAL1 from mock-infected 
and Ad5- or Ad12- infected A549 cells, using an anti-SMARCAL1 antibody, and 
incubated the immunoprecipitates that had been collected on Protein G Sepharose beads, 
in the absence or presence of λ-phosphatase, and analysed the results following SDS-
PAGE by WB for SMARCAL1. The results presented in Figure 3.2 show clearly that 
the mobility of SMARCAL1 isolated from Ad5 and Ad12 -infected A549 cells was 
retarded in the absence of λ-phosphatase relative to mock-infected cells [cf lanes 5 and 
7 with lane 1; Figure 3.2]. These analyses also revealed that SMARCAL1 levels on 
SDS-PAGE was comparable to the protein levels observed for mock-infected cells, 
following λ-phosphatase treatment, suggesting that SMARCAL1 retardation on SDS-
PAGE following Ad infection is due to phosphorylation [cf lanes 6 and 8 with lanes 1 
and 2; Figure 3.2]. Treatment of mock-infected samples, and MLN4924-treated samples 
with λ-phosphatase increased modestly SMARCAL1 motility on SDS-PAGE 
suggesting that SMARCAL1 also exists as a phosphorylated species in non-infected 
A549 cells [cf lanes 2 and 4 with lanes 1 and 3; Figure 3.2]. Taken together, these data 
suggest that SMARCAL1 is subject to both Ad5 and Ad12 -induced phosphorylation 
during infection. These data also suggest that SMARCAL1 might be phosphorylated, 
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Figure 3.2: SMARCAL1 is phosphorylated following Ad5 and Ad12 infection. A549 
cells were mock treated (uninfected) or infected with w.t. Ad5 or w.t. Ad12 at 10 p.f.u/cell, 
or treated with the NAE inhibitor, MLN4924. At 18h post-infection whole cell lysates 
were prepared in IP buffer and SMARCAL1 was immunoprecipitated using an anti-
SMARCAL1 antibody on to protein G-Sepharose beads. IP’s were then treated in the 
absence or presence of λ-phosphatase and subjected to SDS-PAGE and WB analysis. This 
figure is representative of three independent experiments. (Published in J.Virol 2019 by 





3.2.3. SMARCAL1 is phosphorylated on S123, S129 and S173 following 
Ad5 and Ad12 infection.  
As we established that SMARCAL1 was phosphorylated following both w.t. Ad5 and 
w.t. Ad12 infection we wished to identify the residues that were phosphorylated in 
response to Ad infection. To do this we harvested mock-, Ad5-, and Ad12- infected 
A549 cells at 18h post-infection, when we should observe significant phosphorylation 
[Figure 3.1] and subjected cell lysates to immunoprecipitation for SMARCAL1 with an 
anti-SMARCAL1 antibody. Following SDS-PAGE and the gel excision of 
SMARCAL1-containing bands, samples were processed accordingly for mass 
spectrometric analyses (see section 2.3.9, Materials and Methods), prior to analysis of 
tryptic peptides upon a Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer 
(ThermoFisher Scientific). Mass spectrometric analyses revealed that SMARCAL1 was 
phosphorylated on three residues following both Ad5 and Ad12 infection, S123, S129 
and S173 [Figure 3.3A]; Table showing associated modifications is presented [Figure 
3.3B]. We were, however unable to detect any SMARCAL1 phospho-residues in mock-
infected cells despite the suggestive results from the λ-phosphatase experiment [data not 
shown]. S123 and S129 form part of SP motifs, which are known consensus sites for 
CDKs, and other cellular kinases such as MAPKs/ERKs. S173, forms part of an SQE 
motif, which is a known consensus site for ATM, ATR and DNA-PK. Sequence 
alignment revealed that all three residues were conserved amongst primates, whilst in 
other mammals these residues were less well conserved. For instance, S123 and S129 
are conserved in dog, whilst S173 is not, and only S129 is conserved in mice [Figure 
3.2C]. These data indicate that SMARCAL1 is phosphorylated during the early stages 












Figure 3.3: SMARCAL1 is phosphorylated following Ad5 and Ad12 infection. 
A549 cells were mock (uninfected) or infected with w.t Ad5 or w.t Ad12 (10 p.f.u/cell). 
At 18h post-infection whole cell lysates were prepared and SMARCAL1 was 
immunoprecipitated using an anti-SMARCAL1 antibody. IP’s were subjected to SDS-
PAGE whereupon SMARCAL1containing bands were isolated and subject to mass 
spectrometry. (A) phospho-residues identified following MS analyses; (B) other 
modifications identified on SMARCAL1 peptides identified by MS; (D) CLUSTAL 
Omega alignment of SMARCAL1 sequences from primates and other mammals. 
Shaded areas indicate phosphorylation motifs conserved between species. The MS 
studies are representative of two independent experiments. (Published in J.Virol 2019 





Peptides identified by MS 
Ad5, Ad12 S123, S129 SQmALTGISPPLAQSPPEVPK 







3.2.4. Investigating a role for phosphorylation in the reduction of 
SMARCAL1 protein levels following Ad infection. 
As we have determined that SMARCAL1 is phosphorylated during the early stages of 
Ad infection we wished to establish whether SMARCAL1 phosphorylation was an 
important pre-requisite for the Ad-induced reduction in SMARCAL1 protein levels. We 
therefore decide to use selective protein kinase inhibitors to determine whether they 
could attenuate the ability of Ad to target SMARCAL1 protein loss during infection. 
 
3.2.4.1 The PIKK inhibitor, caffeine reduces the ability of Ad5 and 
Ad12 to promote the loss of SMARCAL1 protein. 
As we determined that S173 of SMARCAL1 is phosphorylated during both Ad5 and 
Ad12 infection, and it forms part of an SQE motif- a known target for PIKK cellular 
kinases we decided to investigate whether caffeine, a broad-range PIKK family 
(Sarkaria, Busby et al. 1999, Block, Merkle et al. 2004), affected the ability of Ad to 
promote the reduction in SMARCAL1 protein levels. To do this we subjected A549 
cells to mock infection, or infection with w.t Ad5 and w.t Ad12 and two hours post-
infection we incubated cells in the absence or presence of caffeine (5 mM optimised 
dose) (Blackford, Bruton et al. 2008).  At 24h and 48h post-infection we then harvested 
cell lysates and subjected them to SDS-PAGE and WB analysis [Figure 3.4]. WB 
analyses revealed that SMARCAL1 protein levels were stabilised to some extent in Ad5 
infected A549 cells in the presence of caffeine, relative to Ad-infected cells that were 
not treated with caffeine [cf lanes 7 and 8 with lanes 5 and 6, panel I; Figure 3.4A]. WB 
analyses also revealed, however, that caffeine restricted significantly the ability of Ad12 
to induce SMARCAL1 loss following infection [cf lanes 7 and 8 with lanes 5 and 6, 
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panel I; Figure 3.4B]. Caffeine did not, however, affect the ability of either w.t Ad5 or 
w.t Ad12 to promote the loss of the p53 protein [cf lanes 7 and 8 with lanes 5 and 6, 
panel ii; Figure 3.4A and and 3.4B]. Given that caffeine suppresses the Ad-induced loss 
of the SMARCAL1 protein these data suggest that the caffeine-sensitive PIKK family 
of kinases might be involved in the phosphorylation, and loss, of the SMARCAL1 














































Figure 3.4: Effect of PIKK inhibitor, caffeine on SMARCAL1 and p53 levels during 
Ad12 infection: A549 cells were mock treated (uninfected) or infected with either w.t. 
Ad5 (A) or w.t. Ad12 (B) at 10 p.f.u./cell and treated with PIKK inhibitor Caffeine (5mM) 
following infection for the times indicated. Whole cell lysates were then prepared and 
50μg protein samples were separated by SDS-PAGE and subjected to Western blot 







3.2.4.2 The ATM inhibitor, KU-55933, does not affect the ability of Ad5 
or Ad12 to promote the loss of the SMARCAL1 protein during 
infection. 
Given that we have shown that caffeine-sensitive kinases are involved in the 
phosphorylation of SMARCAL1 following Ad infection, we next wanted to identify the 
caffeine-sensitive kinase responsible for SMARCAL1 phosphorylation. To do this we 
used more selective kinase inhibitors. First, we investigated the ability of the ATM 
kinase inhibitor, KU-55933 (Hickson, Zhao et al. 2004), to modulate the Ad-induced 
phosphorylation, and loss, of SMARCAL1 [Figure 3.5]. We therefore infected A549 
cells with w.t. Ad5 or w.t. Ad12 then subsequently incubated infected cells in the 
absence or presence of the ATM kinase inhibitor prior to WB determination of 
SMARCAL1 protein levels [Figure 3.5]. WB analyses revealed that the ATM inhibitor 
did not affect the ability of w.t. Ad5 or w.t. Ad12 to promote the loss of the SMARCAL1 
protein [cf lanes 7 and 8 with lanes 5 and 6, panel I; Figure 3.5A and 3.5B]. Similarly, 
WB analyses also revealed that the ATM inhibitor did not affect the ability of w.t. Ad5 
or w.t. Ad12 to promote the loss of p53 [cf lanes 7 and 8 with lanes 5 and 6, panel ii; 
Figure 3.5A and 3.5B]. Taken together these data indicated that ATM does not induce 
the loss of the SMARCAL1 protein during infection, and by extension suggests that 
































Figure 3.5: Effect of ATM kinase inhibition on SMARCAL1 degradation during 
Ad5 and Ad12 infection: A549 cells were either mock (uninfected) or infected with 
w.t Ad5 (A) or w.t. Ad12 (B) at 10 p.f.u./cell and treated with ATM kinase inhibitor 
(10µM) 2 hours post infection. Whole cell lysates were prepared at 24h and 48h post-
infection. 50μg protein samples were separated by SDS-PAGE and subjected to 
Western blot analysis using the appropriate antibodies. This figure is representative 






3.2.4.3. The ATR inhibitor, AZD-6738, reduces the ability of w.t. Ad5 
and w.t. Ad12 to promote the loss of the SMARCAL1 protein during 
infection. 
We next investigated whether ATR modulated the Ad-induced phosphorylation, and 
loss, of SMARCAL1 [Figure 3.6]. To do this we used the ATR-specific inhibitor, AZD-
6738, which has been used previously to inhibit ATR function in vivo with IC50 value 
less than 1 µM (Vendetti, Lau et al. 2015, Min, Im et al. 2017) (Carrassa and Damia 
2017).  We therefore, infected A549 cells with w.t. Ad5 or w.t. Ad12 then subsequently 
incubated infected cells in the absence, or presence, of AZD-6738. Cell lysates were 
harvested at 24h and 48h post-infection, then subjected to SDS-PAGE and WB analysis 
to check the SMARCAL1 protein levels [Figure 3.6]. Interestingly, treatment of A549 
cells with AZD-6738, limited, the loss of SMARCAL1 protein levels, albeit to a modest 
extent, in Ad5-infected A549 cells, relative to Ad5-infected cells not treated with the 
inhibitor [cf lanes 7 and 8 with lanes 5 and 6, panel I; Figure 3.6A]. More dramatically 
however, the treatment of A549 cells with AZD-6738 almost completely ablated the 
ability of w.t. Ad12 to promote the loss of the SMARCAL1 protein in Ad12-infected 
A549 cells, relative to Ad12-infected cells not treated with the inhibitor [cf lanes 7 and 
8 with lanes 5 and 6, panel I; Figure 3.6B]. The ATR inhibitor did not however affect 
the ability of either w.t Ad5 or w.t Ad12 to promote the loss of the p53 protein [cf lanes 
7 and 8 with lanes 5 and 6, panel ii; Figure 3.6A and 3.6B]. Taken together, these data 
suggest strongly that the ATR kinase phosphorylates SMARCAL1 during Ad infection, 
which ultimately contributes towards the Ad-induced loss of the SMARCAL1 protein 




























Figure 3.6: The ATR kinase inhibitor (AZD-6738) reduces the ability of Ad5 
and Ad12 to promote SMARCAL1 degradation: A549 cells were mock 
(uninfected) or infected with w.t Ad5 (A) or w.t Ad12 (B) at 10 p.f.u/cell. 
Following infection cells were incubated in the absence or presence of the ATR 
inhibitor, AZD-6738 (1 µM). Samples were then harvested 24h and 48h post 
infection and 50μg protein samples subject to SDS-PAGE and WB analysis using 






3.2.4.4. The CDK inhibitor, RO-3306, reduces the ability of w.t. Ad5 
and w.t. Ad12 to promote the loss of the SMARCAL1 protein during 
infection. 
As we determined by mass spectrometry that SMARCAL1 residues S123 and S129 
were targeted for phosphorylation following both w.t. Ad5 and w.t. Ad12 infection we 
next sought to determine whether the kinase or kinases that target these residues, 
similarly promote the loss of SMARCAL1 protein in Ad-infected cells. As CDKs are 
known to be activated following Ad infection (Grand, Ibrahim et al. 1998) and S123 and 
S129 are part of SP motifs, known to be targeted by CDKs, we investigated whether the 
CDK inhibitor, RO-3306, affected the ability of Ad5 or Ad12 to promote the loss of 
SMARCAL1 in Ad-infected cells. RO-3306 is purportedly a CDK1-selective inhibitor 
but, at the concentrations used here will also inhibit CDK2, CDK4 and CDK6 (Vassilev, 
Tovar et al. 2006). We thus infected A549 cells with w.t Ad5 or w.t Ad12 then treated 
cells in the absence or presence of the CDK inhibitor, RO-3306 for the duration of the 
infectious life cycle [Figure 3.7]. We harvested the cells 24h and 48h post-infection and 
performed WB analyses for SMARCAL1. These analyses revealed that RO-3306, 
attenuated the ability of w.t. Ad5 to promote the loss of the SMARCAL1 protein, 
relative to Ad5-infected cells not treated with the CDK inhibitor [cf lanes 7 and 8 with 
lanes 5 and 6, panel i; Figure 3.7A]. In contrast, RO-3306, only modestly inhibited the 
ability of w.t. Ad12 to promote the loss of the SMARCAL1 protein, relative to Ad12-
infected cells not treated with the CDK inhibitor [cf lanes 7 and 8 with lanes 5 and 6, 
panel i; Figure 3.7B]. Akin to the ATR inhibitor studies the CDK inhibitor did not affect 
the ability of either w.t Ad5 or w.t Ad12 to promote the loss of the p53 protein [cf lanes 
7 and 8 with lanes 5 and 6, panel ii; Figure 3.7A and 3.7B]. These data suggest that a 
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CDK also phosphorylates SMARCAL1 during Ad infection and contributes towards the 

















































Figure 3.7: Effect of CDK inhibition on SMARCAL1 degradation during Ad5 and 
Ad12 infection: A549 cells were either mock infected (uninfected) or infected with w.t 
Ad5 (A) or w.t Ad12 (B) at 10 p.f.u/cell. Following infection cells were incubated in the 
absence, or presence, of the CDK kinase inhibitor, RO-3306 (9µM) for the duration of the 
experiment. Samples were then harvested 24h and 48h post infection and 50μg protein 
samples subject to SDS-PAGE and WB analysis using the appropriate antibodies. This 








3.2.4.5: ATR and CDK kinases cooperate to promote the loss of 
SMARCAL1 protein during w.t. Ad5 and w.t. Ad12 infection. 
Given that ATR and CDK inhibitors, in isolation, do not ablate completely the ability 
of w.t. Ad5 or w.t. Ad12 to promote the loss of the SMARCAL1 protein during infection 
we next investigated whether dual inhibition of ATR and CDKs would prevent 
SMARCAL1 loss following Ad infection. To do this we infected A549 cells with w.t 
Ad5 or w.t Ad12 and immediately post-infection incubated cells in the absence, or 
presence of both the ATR kinase inhibitor, AZD-6738 and the CDK inhibitor RO-3306. 
We then harvested cells at 24h and 48h post-infection and subjected whole cell lysates 
to SDS-PAGE and WB analysis. In agreement with the notion that ATR and CDKs 
cooperate to modulate SMARCAL1 protein levels following infection treatment of w.t. 
Ad5-infected cells with both ATR and CDK inhibitors ablated completely the ability of 
w.t. Ad5 to promote the reduction in SMARCAL1 protein levels during infection [cf 
lanes 7 and 8 with lanes 5 and 6, panel I; Figure 3.8A]. Likewise, treatment of w.t. Ad12-
infected cells with both ATR and CDK inhibitors ablated completely the ability of w.t. 
Ad12 to promote the reduction in SMARCAL1 protein levels during infection [cf lanes 
7 and 8 with lanes 5 and 6, panel I; Figure 3.8B]. Interestingly however, treatment of 
both w.t. Ad5 and w.t. Ad12 -infected A549 cells with both ATR and CDK inhibitors 
did not affect the ability of these viruses to target the loss of the p53 protein during 
infection [cf lanes 7 and 8 with lanes 5 and 6, panel ii; Figure 3.8 A and B]. These data 
indicate that ATR and CDKs cooperate during Ad infection to regulate the levels of the 




























Figure 3.8: The degradation of SMARCAL1 following Ad5 and Ad12 
infection is dependent on ATR and CDKs. A549 cells were either mock 
infected (uninfected), or infected with w.t Ad5 (A) or w.t Ad12 (B) at 10 p.f.u/cell. 
Following infection cells were incubated in the absence or presence of ATR and 
CDK inhibitors (AZD-6738 1µM and RO-3306 9µM). Samples were then 
harvested 24h and 48h post infection and 50μg protein samples subject to SDS-
PAGE and WB analysis using the appropriate antibodies. This figure is 
representative of three independent experiments. (Published in J.Virol 2019 by 









3.2.5. Investigating roles for Ad E1B-55K, the proteasome and Cullin 
Ring Ligases in the degradation of the SMARCAL1 protein following 
Ad infection. 
Previous studies have determined that adenoviruses engage with cellular ubiquitin 
ligases to promote the ubiquitin-proteasome dependent degradation of host cell proteins 
such as p53, MRE11, DNA-ligase IV, TopBP1, BLM, Daxx and TIF1γ for proteolysis 
during infection in a manner that is dependent on early region protein expression 
(Querido, Blanchette et al. 2001, Harada, Shevchenko et al. 2002, Stracker, Carson et 
al. 2002, Blackford, Patel et al. 2010, Orazio, Naeger et al. 2011, Schreiner, Wimmer et 
al. 2011, Forrester, Patel et al. 2012). Given that SMARCAL1 protein levels mirror 
those of p53 during Ad infection, we next decided to establish whether SMARCAL1 
was similarly, targeted by CRLs for proteasome-mediated degradation in an E1B-55K-
dependent manner. 
 
3.2.5.1. SMARCAL1 degradation during Ad infection is dependent 
upon E1B-55K expression. 
Previous studies from our laboratory suggested that SMARCAL1 degradation was 
dependent upon E1B-55K and E4orf6 expression (F.S.I Qashqari, PhD thesis, The 
University of Birmingham, 2017). To confirm that the Ad-mediated degradation of 
SMARCAL1 was dependent upon E1B-55K expression we infected A549 cells with 
w.t. Ad5 and w.t. Ad12 and the corresponding E1B-55K deletion viruses, Ad5 dl1520 
and Ad12 dl620 and analysed SMARCAL1 protein levels by WB analyses (Figure 3.9). 
Consistent with earlier observations our data suggested that, like p53, SMARCAL1 
degradation during both Ad5 and Ad12 infection was dependent upon E1B-55K 
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expression (cf panels i and ii; Figures 3.9A and 3.9B). Moreover, our data also suggested 
that loss of E1B-55K did not limit the abilities of ATR and CDKs to target SMARCAL1 
for phosphorylation during infection as there was an obvious retardation in SMARCAL1 
mobility on SDS-PAGE following infection with either Ad5 dl1520, or Ad12 dl620 (cf 












































Figure 3.9: SMARCAL1 is degraded in an Ad E1B-55K-dependent manner 
following Ad5 and Ad12 infection: A549 cells were mock infected (uninfected) 
infected with either w.t. Ad5 and Ad5 dl1520 (A) or w.t. Ad12 and Ad12 dl620 (B) 
at 10 p.f.u./cell. Whole cell lysates were prepared at appropriate times post-
infection and 50μg protein samples were separated by SDS-PAGE and subjected to 
Western blot analysis using the appropriate antibodies. This figure is 
representative of three independent experiments. 
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3.2.5.2. The proteasome inhibitor, MG132 reduces the ability of w.t. 
Ad5 and w.t. Ad12 to degrade SMARCAL1 in Ad-infected cells. 
To investigate whether the proteasome contributes towards the Ad-induced loss of the 
SMARCAL1 protein during infection we first investigated whether the peptide aldehyde 
and reversible proteasome inhibitor, MG132 (Lee and Goldberg 1996), could inhibit the 
ability of w.t. Ad5 and w.t. Ad12 to promote the loss of the SMARCAL1 protein. To do 
this, A549 cells were infected initially, with either w.t. Ad5 or w.t. Ad12, and 
immediately after infection incubated in the absence, or presence, of MG132. After the 
appropriate time post-infection cells were harvested and protein lysates subjected to 
SDS-PAGE and WB analyses [Figure 3.10 A and B]. Treatment of w.t. Ad5-infected 
A549 cells with MG132 appeared to reduce the rate of SMARCAL1 protein loss during 
infection relative to infected cells not treated with MG132, but did not prevent 
completely the loss of the SMARCAL1 protein [cf lanes 10-12 with lanes 7-9, panel I; 
Figure 3.10A]. Similarly, treatment of w.t. Ad12-infected A549 cells with MG132 also 
reduced the rate of SMARCAL1 protein loss during infection relative to infected cells 
not treated with MG132, but SMARCAL1 protein was still reduced significantly in the 
presence of MG132 [cf lanes 10-12 with lanes 7-9, panel I; Figure 3.10A]. MG132 did 
not affect the ability of w.t. Ad5 or w.t. Ad12 to promote the degradation of p53 [cf 
lanes 10-12 with lanes 7-9, panel ii; Figure 3.10 A and B]. Taken together, these data 
suggest that the proteasome might contribute towards the degradation of SMARCAL1 
during infection, but indicate that the proteasome inhibitor, MG132 is possibly not that 
effective in inhibiting proteasome activity fully as it was unable to prevent the 



























Figure 3.10: Investigating a role for the proteasome in the Ad-induced loss of 
SMARCAL1 during infection: A549 cells were either mock infected (uninfected) 
or infected with w.t Ad5 or w.t. Ad12 at 10 p.f.u./cell. Following infection cells 
were incubated in the absence, or presence of the proteasome inhibitor, 
MG132 (10 μM). Samples were then harvested 24h and 48h post infection and 
50μg protein samples subject to SDS-PAGE and WB analysis using the 




3.2.5.3. The proteasome inhibitor Sal A has some effect on the ability 
of w.t. Ad5 and w.t. Ad12 to degrade SMARCAL1 in Ad-infected cells. 
To establish further the role of the proteasome in the degradation of SMARCAL1 during 
infection, we decided to investigate the effects of the γ-lactam-β-lactone and irreversible 
proteasome inhibitor, Salinosporamide A (Sal A; also known as Marizomib) (Feling, 
Buchanan et al. 2003), upon the ability of w.t. Ad5 and w.t. Ad12 to promote 
SMARCAL1 loss during infection. As such, A549 cells were infected with either w.t. 
Ad5 or w.t. Ad12 then incubated in the absence or presence of Sal A, prior to harvesting 
cell lysates and subjecting them to SDS-PAGE and WB analyses. These analyses 
revealed that Sal A limited SMARCAL1 protein loss at 24h post-infection with w.t. 
Ad5, relative to infected cells not treated with Sal A, but clearly did not prevent the loss 
of the SMARCAL1 protein during infection [cf lanes 7 and 8 with lanes 5 and 6, panel 
I; Figure 3.11A]. Interestingly, however, Sal A had a more pronounced inhibitory effect 
on the ability of w.t. Ad12 to promote SMARCAL1 protein loss during infection relative 
to infected cells not treated with Sal A [cf lanes 7 and 8 with lanes 5 and 6, panel i; 
Figure 3.11B]. Sal A did not affect the ability of w.t. Ad12 to promote the degradation 
of p53 but appeared to limit p53 degradation following w.t. Ad5 infection [cf lanes 7 
and 8 with lanes 5 and 6, panel ii; Figure 3.11 A and B]. The major caveat with these 
experiments, however, is that Sal A treatment alone appeared to stabilize SMARCAL1 
and p53 protein levels in the absence of infection (e.g. cf lanes 3 and 4 with lanes 1 and 
2, panels i and ii; Figure 3.11 A and B), which makes the interpretation of the results 
less clear. These results do suggest however that the proteasome does contribute towards 
SMARCAL1 degradation during infection. These data also suggest either that other 
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mechanisms contribute towards SMARCAL1 protein loss during infection, or that the 























Figure 3.11: The proteasome inhibitor, Sal A, reduces SMARCAL1 degradation 
following Ad5 and Ad12 infection A549 cells were mock treated (uninfected) or 
infected with w.t Ad5 and w.t Ad12 at 10 p.f.u./cell and then treated with the 
proteasome inhibitor, Sal A (100nM). Samples were then harvested 24h and 48h 
post infection and 50μg protein samples subject to SDS-PAGE and WB analysis using 




3.2.5.4: SMARCAL1 is targeted for degradation in a Cullin Ring 
Ligase-dependent manner during Ad infection. 
Previous studies from our laboratory and data presented in this Chapter suggested that 
E1B-55K was required for the Ad5 and Ad12 -induced degradation of SMARCAL1 and 
that Ad5 E4orf6 was also required for the degradation of SMARCAL1 during Ad5 
infection (Figure 3.9; F.S.I Qashqari, PhD thesis, The University of Birmingham, 2017). 
We reasoned therefore, that given the known role of these proteins that they would 
similarly engage with cellular CRLs to promote SMARCAL1 degradation during Ad 
infection. To investigate this possibility we took advantage of the observation that the 
NEDD8-activating enzyme (NAE) inhibitor, MLN4924, inhibits the NEDDylation, and 
activation of the Cullin component of CRLs (Soucy, Smith et al. 2009) (Nawrocki, 
Griffin et al. 2012).  
 
We therefore infected A549 cells with either w.t Ad5 or w.t. Ad12 and subsequently 
treated the infected cells with NAE inhibitor, MLN4924 at different concentrations. We 
then harvested cell lysates at 24h and 48h post-infection and subjected them to SDS-
PAGE and WB analyses. At 100nM MLN4924, the ability of w.t. Ad5 to promote the 
loss of SMARCAL1 was reduced slightly at 24h post-infection, relative to w.t. Ad5-
infected cells not treated with MLN4924 [cf lane 7 with lane 3, panel i, Figure 3.12A]. 
At 500nM MLN4924, the ability of w.t. Ad5 to promote the loss of SMARCAL1 was 
ablated almost completely at 24h post-infection, relative to w.t. Ad5-infected cells not 
treated with MLN4924 [cf lane 10 with lane 3, panel i Figure 3.12A]. At 48h post-
infection however, MLN4924 was unable to inhibit the ability of w.t. Ad5 to promote 
the loss of the SMARCAL1 protein, relative to w.t. Ad5-infected cells not treated with 
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MLN4924 [cf lanes 8 and 12 with lane 4, panel i; Figure 3.12A].  
 
Similar results were seen following w.t. Ad12 infection. At 100nM MLN4924, the 
ability of w.t. Ad12 to promote SMARCAL1 loss was reduced slightly at both 24h and 
48h post-infection, relative to w.t. Ad12-infected cells not treated with MLN4924 [cf 
lanes 7 and 8, with lanes 3 and 4, panel i, Figure 3.12B]. At 500nM MLN4924, the 
ability of w.t. Ad12 to promote SMARCAL1 loss was almost completely ablated at 24h 
post-infection, relative to w.t. Ad12-infected cells not treated with MLN4924 [cf lane 
11 with lane 3, panel i, Figure 3.12A]. At 48h post-infection, MLN4924 still retained 
some capacity to inhibit the ability of w.t. Ad12 to promote the loss of SMARCAL1, 
relative to w.t. Ad12-infected cells not treated with MLN4924 [cf lane 12 with lane 4, 
panel i, Figure 3.12B]. 500nM MLN4924 appeared to have an inhibitory effect on the 
ability of both w.t. Ad5 and w.t. Ad12 to promote the degradation of p53 during 
infection [cf lanes 11 and 12 with lanes 3 and 4, panel ii, Figure 3.11 A and B] but these 
results were complicated by the observation that MLN-4924 treatment elevated p53 
protein levels in non-infected cells [cf lanes 5 and 6, and lanes 9 and 10 with lanes 1 and 
2, panel ii; Figure 3.11 A and B].  
 
Taken together, these data suggest that E1B-55K and E4orf6 do utilise cellular CRLs to 
promote the degradation of SMARCAL1 during both w.t. Ad5 and w.t. Ad12 infection, 
but akin to the proteasome studies described earlier, suggest that adenovirus might also 
utilise other mechanisms to promote the degradation of SMARCAL1, and other 


























Figure 3.12: SMARCAL1 is degraded in a CRL-dependent manner following Ad5 and 
Ad12 infection: A549 cells were mock treated (uninfected) or infected with either w.t. 
Ad5 (A) or w.t. Ad12 (B) at 10 p.f.u./cell and then treated with NAE inhibitor, MLN4924 
(at 100nM or 500nM) until harvested. Whole cell lysates were prepared at appropriate 
times post-infection and 50μg protein samples were separated by SDS-PAGE and 
subjected to Western blot analysis using the appropriate antibodies. This figure is 




3.2.6. Ad genome replication is not required to initiate SMARCAL1 
degradation. 
As an important function of SMARCAL1 is to regulate cellular DNA replication, we 
were interested to investigate whether the loss of SMARCAL1 protein during infection 
was dependent upon the initiation of viral DNA replication. To investigate this 
possibility we took advantage of previous observations that established that Ganciclovir 
200 to 500µM inhibited Ad genome replication (Faulds and Heel 1990, Ying, Tollefson 
et al. 2014). We therefore optimised the dose to 500 µM and infected A549 cells with 
either w.t Ad5 or w.t. Ad12 and then treated the infected cells with Ganciclovir. We 
subsequently harvested cell lysates at 24h and 48h post-infection and subjected them to 
SDS-PAGE and WB analyses and repeated the experiment thrice. These analyses 
revealed that treatment of both w.t. Ad5 and w.t. Ad12 -infected cells with Ganciclovir 
had no effect on the ability of these viruses, relative to cells not treated with Ganciclovir, 
to inhibit SMARCAL1 degradation during infection [cf lanes 7 and 8 with lanes 5 and 
6, panel i, Figure 3.13 A and B]. Interestingly however, it appeared that treatment of 
Ad-infected cells with Ganciclovir did limit the ability of both w.t. Ad5 and w.t. Ad12 
to target p53 for degradation [cf lanes 8 and 12 with lane 4, panel ii; Figure 3.13 A and 
B]. Taken together, these data suggest that adenoviral genome replication might not be 
required to induce SMARCAL1 degradation but does affect p53 degradation but might 


























Figure 3.13: Ad replication inhibitor Ganciclovir does not affect the Ad-induced 
degradation of SMARCAL1: A549 cells were mock treated (uninfected) or infected 
with w.t. Ad5 (A) and w.t. Ad12 (B) at 10 p.f.u./cell and then treated with 
Ganciclovir (500µM) until harvested. Whole cell lysates were prepared at 
appropriate times post-infection and 50μg protein samples were separated by 
SDS-PAGE and subjected to Western blot analysis using the appropriate 




As adenovirus genome replication results in the production of large amounts of ssDNA 
and linear dsDNA adenoviruses have developed numerous strategies to inhibit host cell 
DDR pathways and prevent cell cycle checkpoint activation and DNA repair; viral 
inhibition of DDR pathways prevents viral DNA concatenation and promotes viral DNA 
replication. One mechanism adenoviruses utilize to inhibit DDR pathways is to engage 
with the ubiquitin-proteasome system and target a number of host cell DDR proteins for 
ubiquitin-mediated degradation (Turnell and Grand 2012). In this regard, E1B-55K 
typically functions as an adaptor protein, binding to the cellular protein substrate to be 
degraded, and recruiting CRL2 or CRL5 to the substrate through its association with 
another viral protein, E4orf6 (Querido, Blanchette et al. 2001).  
 
In this chapter we have shown that adenoviruses utilize the ubiquitin-proteasome system 
to target the cellular DNA replication protein, SMARCAL1 for degradation during Ad 
infection.  As such, we first determined that the protein levels of SMARCAL1 were 
reduced significantly following infection of A549 cells with Ad5 and Ad12, in a manner 
similar to p53, a known target for the Ad ubiquitin ligase during infection (Figure 3.1). 
Interestingly, WB analyses also revealed that there was an obvious retardation of 
SMARCAL1 mobility on SDS-PAGE following Ad infection, suggesting that 
SMARCAL1 was post-translationally modified, prior to its degradation, in response to 
Ad infection (Figure 3.1). As mobility-shifts on SDS-PAGE are often due to changes in 
the phosphorylation status of the protein, and multiple cellular kinases are known to be 
activated in response to Ad infection (Turnell and Grand 2012) we next investigated 
whether SMARCAL1 was phosphorylated following Ad infection. To do this we treated 
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anti-SMARCAL1 immunoprecipitates from Ad5- and Ad12- infected cells with the 
broad range protein phosphatase, λ-phosphatase. Importantly, the λ-phosphatase assay 
revealed that SMARCAL1 was indeed, phosphorylated following both Ad5 and Ad12 
infection (Figure 3.2). Mass spectrometric analyses then revealed that SMARCAL1 was 
phosphorylated on three specific residues during Ad infection: S123, S129 and S173 
which are well conserved amongst higher mammals (Figure 3.3). S123 and S129 
constitute part of a minimal CDK consensus site, SP, whilst S173 forms part of a PIKK 
family kinase consensus site, SQE (Figure 3.3). 
 
As SMARCAL1 is subject to phosphorylation following Ad infection we next sought 
to investigate whether SMARCAL1 phosphorylation was required for SMARCAL1 
degradation. Firstly, as S173 is likely to be phosphorylated by ATM, ATR or DNA-PK 
we investigated a generic role for these kinases in SMARCAL1 degradation by 
investigating the effects of the common PIKK family inhibitor, caffeine upon Ad-
induced SMARCAL1 degradation. Consistent with a role for a caffeine-sensitive kinase 
in the Ad-mediated degradation of SMARCAL1, treatment of Ad-infected cells with 
caffeine reduced the ability of Ad5 and Ad12 to target SMARCAL1 for degradation 
(Figures 3.4). We next extended these studies to investigate specifically the role of ATM 
and ATR in SMARCAL1 phosphorylation following Ad infection. Studies with the 
ATM specific kinase inhibitor, KU-55933, established that ATM was not responsible 
for targeting SMARCAL1 for degradation during Ad5 and Ad12 infection (Figure 3.5). 
Given that the ATM activator, MRN, is targeted for degradation during Ad infection 
(Stracker, Carson et al. 2002) it is, perhaps, not surprising that ATM does not 
phosphorylate SMARCAL1 during infection. Interestingly however, previous studies 
from our laboratory suggested that H2AX phosphorylation during Ad infection was 
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dependent, to some extent, on ATM, whilst a more recent study suggested that the MRN 
complex was not absolutely required for ATM activation (Blackford, Bruton et al. 2008, 
Hartlerode, Morgan et al. 2015).  
 
As we have previously shown that ATR was required for the Ad-mediated 
phosphorylation of RPA32, Smc1 and H2AX during Ad infection (Blackford, Bruton et 
al. 2008), we next investigated the effects of the ATR kinase inhibitor, AZD-6738, on 
the Ad-targeted degradation of SMARCAL1 (Figure 3.6). Interestingly, these studies 
indicated that inhibition of ATR kinase reduced significantly the ability of Ad12 to 
target SMARCAL1 for degradation and limited, to a modest extent, the ability of Ad5 
to promote SMARCAL1 degradation (Figures 3.6). A possible explanation for these 
differences is that ATR is not activated to the same extent following Ad5 infection, as 
compared to an Ad12 infection and that Ad12 is more reliant on ATR during infection 
than Ad5 (Blackford, Bruton et al. 2008). In this regard the E1B-55K interacting protein, 
E1B-AP5 (hnRNPUL1) participates in the ATR-dependent phosphorylation of RPA32 
in Ad12-infected cells  (Blackford, Bruton et al. 2008). Given that Ad12 promotes the 
degradation of the ATR activator, TopBP1, in order to prevent Chk1 activation whilst 
Ad5 does not (Blackford, Patel et al. 2010), it would be interesting to re-evaluate 
whether ATR also participates in the degradation of TopBP1, or other known 
degradation targets, during Ad12 infection. In this regard, whilst early MS screens for 
ATM and ATR substrates by the Elledge group identified a number of SQ/TQ sites 
targeted for phosphorylation following treatment with ionizing radiation (Matsuoka, 




As SP motifs are substrates for CDKs which are known to be activated following Ad 
infection (Grand, Ibrahim et al. 1998), we next used a CDK inhibitor, RO-3306, to 
investigate whether CDKs were responsible for targeting SMARCAL1 for degradation 
following Ad infection (Figure 3.7). In contrast to the ATR inhibitor studies, we 
established that the CDK inhibitor, RO-3306, had a greater propensity to inhibit Ad5-
mediated degradation of SMARCAL1, compared to Ad12, which was only limited 
modestly in its ability to target SMARCAL1 for degradation (Figure 3.7). These 
findings might suggest that Ad5 is more reliant on CDK activity during infection than 
Ad12. Given these differences in requirements for ATR or CDKs in different Ad types 
it would be extremely interesting to see, if first SMARCAL1 degradation is conserved 
between different Ad groups, and the differential contribution of ATR and CDKs in 
these processes. Indeed, our group have reported previously that different Ad types have 
evolved different strategies to combat the cellular DDR (Forrester, Sedgwick et al. 
2011). 
 
We did establish that ATR and CDK kinases co-operate during Ad infection to promote 
SMARCAL1 (Figure 3.8). At this stage, however, we cannot determine which CDK is 
involved in the phosphorylation of SMARCAL1, as RO-3306 inhibits CDK1, CDK2, 
CDK4 and CDK6 kinases at the concentrations used in these experiments.  It will be 
important in the future to establish which CDK is responsible for SMARCAL1 
phosphorylation during infection. To do this we should use more specific inhibitors of 
CDK1, CDK2 and CDK4 and CDK6, or use siRNA/CRISPR to deplete these kinases 
prior to Ad infection. Given that Ad infection promotes cell entry into S-phase it is likely 




It is well established that the adenovirus oncoproteins E1B-55K and E4orf6 work in 
concert to promote the CRL-mediated degradation of host cell proteins, such as p53 and 
MRE11 for degradation via the ubiquitin-proteasome system during infection (Querido, 
Blanchette et al. 2001). As studies presented in this Chapter (Figure 3.9) and from others 
in our laboratory, indicated that SMARCAL1 is degraded in an E1B-55K and E4orf6 -
dependent manner (F.S.I Qashqari, PhD thesis, The University of Birmingham, 2017), 
we next sought to establish a requirement for the ubiquitin-proteasome system in 
SMARCAL1 degradation. The peptide aldehyde, reversible proteasome inhibitor, 
MG132 (Pehere, Nguyen et al. 2019) reduced the ability of Ad5 and Ad12 to promote 
SMARCAL1 degradation during infection, particularly at early time-points post-
infection though it did not ultimately prevent SMARCAL1 degradation; MG132 did not 
affect the ability of Ad5 or Ad12 to target p53 for degradation (Figure 3.10).  We also 
used the irreversible proteasomal inhibitor, Sal A (Gulder and Moore 2010), to establish 
the role of the proteasome in SMARCAL1 (and p53) degradation. Unfortunately, 
although treatment with Sal A limited SMARCAL1 and p53 degradation following 
infection, treatment of mock-infected cells with SalA clearly increased the basal levels 
of these proteins, which complicates the interpretation of the data (Figure 3.11). It is 
clear from published studies investigating the role of CRLs in adenovirus-mediated 
degradation of cellular proteins that the inhibitory effects of proteasome inhibitors upon 
the Ad-mediated degradation of cellular substrates are not fully restorative (e.g. MRE11 
(Stracker, Carson et al. 2002)). Moreover, some studies have not performed experiments 
showing the effects of proteasome inhibitors on Ad-mediated degradation, or have 
performed these experiments, but lack the appropriate controls (e.g. p53, (Steegenga, 
Riteco et al. 1998, Querido, Blanchette et al. 2001). Explanations for these observations 
are not immediately apparent. It could be that the Ad-induced targeting of large amounts 
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of substrates for proteasome degradation, ultimately out-compete reversible inhibitors 
such that degradation is delayed, but not inhibited. It is also possible that combinations 
of proteasome inhibitors should be used to ensure complete inhibition of 20S b1, b2 and 
b5 proteolytic activities. 
 
As CRLs are known to be utilized by adenovirus in the targeted degradation of host cell 
proteins we next investigated whether SMARCAL1 was similarly targeted for 
degradation via the action of cellular CRLs. As CRLs are activated by cullin 
NEDDylation we used an NEDD8 activating enzyme, inhibitor MLN 4924 to prevent 
CRL activation (Lan, Tang et al. 2016). Akin to the proteasome studies we determined 
that MLN 4924 reduced the rate of SMARCAL1 degradation in both Ad5 and Ad12 –
infected cells but did not inhibit fully SMARCAL1 degradation (Figure 3.12). These 
data are entirely consistent with a role for CRLs in the Ad-mediated degradation of 
SMARCAL1, but suggest also, that Ad might overcome CRL inhibition, or 
alternatively, use different viral oncoproteins, cellular ubiquitin ligases, or cellular or 
viral proteases to promote the degradation of SMARCAL1 during infection. Indeed, our 
laboratory has shown previously that E4orf3 does not use CRLs in the targeted 
degradation of TIF1g and HPV targets host cellular pRB protein for degradation utilising 
different cellular ubiquitin ligases (Bischof, Nacerddine et al. 2005, Forrester, Patel et 
al. 2012). Moreover, it would be interesting to determine the effects of cell permeable 
lysosomal/autophagic (e.g. chloroquinone) and apoptotic (Z-VAD-FMK) inhibitors on 
the ability of Ad to target SMARCAL1 (and other substrates) for degradation as the 




The ability of Ad oncoproteins to usurp the control of host cell pathways through the 
proteasomal-mediated degradation of cellular proteins that possess anti-viral activity to 
promote viral replication is well established. Given that SMARCAL1 is known to 
regulate cellular DNA replication, we also investigated whether the Ad DNA replication 
inhibitor, Ganciclovir, affected the ability of Ad to target SMARCAL1 for degradation, 
but it did not, suggesting that SMARCAL1 degradation occurs prior to the onset of Ad 
DNA replication (Figure 3.13). Interestingly, though p53 degradation did seem to be 
dependent to some extent on the initiation of Ad replication as Ganciclovir did limit p53 
degradation during infection (Figure 3.13). 
 
In conclusion, we have shown here that ATR kinase and, an unidentified, CDK 
phosphorylate SMARCAL1 directly upon residues S123, S129 and S173 following Ad 
infection, which results in the E1B-55K/E4orf6, and CRL-targeted degradation of 
SMARCAL1. The specific requirement for SMARCAL1 phosphorylation during 






















Role of the RPA complex and 
phosphorylation in the recruitment 














Adenoviruses are known to neutralise host cell DDR pathways and inhibit anti-viral 
signalling pathways in order to promote viral DNA replication (Weitzman, Carson et al. 
2004, Turnell and Grand 2012, Weitzman and Fradet-Turcotte 2018). In this regard, 
adenoviruses have been shown to inhibit ATM, ATR and DNA-PK pathways by 
targeting activators, or effectors, for CRL- and proteasome- dependent degradation (e.g. 
(Querido, Blanchette et al. 2001, Stracker, Carson et al. 2002, Baker, Rohleder et al. 
2007, Blackford, Patel et al. 2010)). In chapter 3 of this thesis we determined that the 
DDR protein, and ATR substrate, SMARCAL1, was phosphorylated and targeted for 
degradation following both Ad5 and Ad12 infection. In this regard, we found that 
SMARCAL1 degradation was dependent upon the ATR- and CDK- dependent 
phosphorylation of SMARCAL1 (Chapter 3). As such, we showed by mass 
spectrometry that SMARCAL1 was phosphorylated at residues 123, 129 and 173 by 
ATR and CDK kinases during Ad infection (Chapter 3). All of these SMARCAL1 
residues have previously been identified by David Cortez’s group as targets for 
phosphorylation in vivo (Carroll, Bansbach et al. 2013).  S173 lies within an 
ATM/ATR/DNA-PK SQE consensus site and is phosphorylated, in a DDR kinase-
dependent manner, in response to cellular replication stress following hydroxyurea 
treatment (Carroll, Bansbach et al. 2013). These studies also demonstrated that 
phosphorylation of S173 did not affect the intrinsic ATPase activity of SMARCAL1. 
Indeed, the biological significance of phosphorylation at this site remains to be 
determined. S123 and S129 lie within an N-terminal cluster of SP residues in 
SMARCAL1 that have been shown to be phosphorylated by CDKs in vivo (Carroll, 
Bansbach et al. 2013). It is presumed that these sites might be involved in regulating 
SMARCAL1 cell cycle-specific activities such as replication fork processing, though 
109 
 
such activities have yet to be ascribed to these residues (Bansbach, Bétous et al. 2009).  
SMARCAL1 is known to be recruited to sites of DNA damage through its ability to 
interact with the ssDNA-binding protein complex, RPA (Ciccia 2009, LA Poole 2017). 
It has been suggested that high affinity binding sites on RPA allow SMARCAL1 to 
associate with RPA-bound ssDNA, and that RPA orientates itself relative to replication 
fork junctions to allow SMARCAL1 access to DNA for remodelling of replication forks 
whilst bound to RPA (Bhat, Bétous et al. 2015).  
 
Given that SMARCAL1 is targeted for degradation in an ATR- and CDK- dependent 
manner during Ad infection (Chapter 3), and that SMARCAL1 residues S123, S129 and 
S173 are all phosphorylated during the early stages of Ad infection (Chapter 3) we 
wished to determine the functional significance of S123, S129 and S173 SMARCAL1 
phosphorylation upon SMARCAL1 degradation during Ad infection. Moreover, as 
SMARCAL1 has been shown to be recruited to Ad VRCs (Chapter 3), we also wished 
to establish whether SMARCAL1 phosphorylation at one or more of these sites 
promotes SMARCAL1 recruitment to VRCs during infection. Additionally, as 
SMARCAL1 is a known RPA-binding protein (Bansbach, Bétous et al. 2009, Ciccia, 
Bredemeyer et al. 2009) and co-localizes with RPA at VRCs during Ad infection 
(Chapter 3), we also wished to establish whether the RPA complex regulates 
SMARCAL1 localization, or promotes SMARCAL1 degradation, during Ad infection. 








4.2.1. Generation of inhibitory phosphorylation-defective SMARCAL1 
mutants 
To begin to investigate the effects of SMARCAL1 phosphorylation on SMARCAL1 
function during infection we utilised a retroviral plasmid that expressed w.t. 
SMARCAL1 as an N-terminally tagged GFP construct under the control of a CMV 
promoter (pLEGFP-SMARCAL1). In an attempt to ablate the responsiveness of 
SMARCAL1 to ATR- and CDK- dependent phosphorylation at residues S123, S129 
and S173, we performed site-directed mutagenesis on the pLEGFP-SMARCAL1 
construct to generate Serine to Alanine mutants for all three sites identified (S123A, 
S129A and S173A). We then employed Sanger sequencing, in the context of the entire 
open reading frame (2,865 base pairs), to verify the generation of the appropriate 
mutants [Figure 4.1A]. In the expectation that phosphorylation of S123, S129 and S173 
might cooperate to regulate SMARCAL1 function, we also generated the corresponding 
double (S123A/S129A, S123A/S173A and S129A/S173A) and triple 
(S123A/S129A/S173A) phosphorylation-defective SMARCAL1 mutants and validated 
their integrity by Sanger sequencing [Figures 4.1B and 4.1C, respectively].  
 
To generate clonal cell lines that express w.t., or mutant, GFP-SMARCAL1 fusion 
proteins we next transfected GP-293 cells with appropriate pLEGFP-SMARCAL1 and 
VSV-G constructs and, 96h post-transfection isolated replication-defective retroviral 
particles to transduce either A549, or RPE-1 cells that were seeded at low density (see 
materials and methods, section 2.2.4 for detailed description). Seventy-two hours 
following retroviral transduction of A549 and RPE-1 cells we seeded transduced cells 
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at 500/cells per 10cm dish and isolated clonal cell lines, under selection with G418 (500 
µg/ml), approximately two weeks later with a 1ml pipette tip, using a low power light 
microscope under aseptic conditions. Using this technique, we were able to isolate both 
A549 (Figure 4.2), and RPE-1 (data not shown), clonal cell lines that expressed 
constitutively w.t. GFP-SMARCAL1 and GFP-SMARCAL1 mutants that possessed 
residues that could no longer be phosphorylated on particular SMARCAL1 residues 
(Figure 4.2). In this regard, clonal cell lines expressed almost identical levels of w.t. 
SMARCAL1 and phosphorylation-defective SMARCAL1 mutants, consistent with the 











































Figure 4.1A to 4.1C. Generation of SMARCAL1 phosphorylation-defective mutants: 
Using the QuikChange XL site-directed mutagenesis Kit (see material and methods, 
section..), we mutated the phospho-acceptor serine residues to alanine for all the three 
phosphorylation sites identified S123, S129 and S173 (A) and also generated, S123-
S129, S123-S173 and S129-S173 double (B), and S123-S129-S173 triple (C) serine to 
alanine phosphorylation defective mutants. The images presented were generated with 











































































Figure 4.2. GFP-SMARCAL1 protein expression in A549 clonal cell lines. Individual 
w.t. GFP-SMARCAL1 and GFP-SMARCAL1 mutant clones were expanded and 
harvested; protein lysates were separated by SDS-PAGE, prior to Western blot 




4.2.2. Investigating the effects of phosphorylation upon SMARCAL1 
degradation in A549 cells. 
A primary objective of this study was to use the GFP-SMARCAL1 phosphorylation-
defective mutants to investigate further, whether phosphorylation upon these residues 
was an essential prerequisite for Ad-induced SMARCAL1 degradation given that ATR 
and CDK inhibitors limited SMARCAL1 degradation during infection (Figures 3.6-3.8, 
Chapter 3). To begin to address this possibility we infected two A549 clonal cell-lines 
that constitutively expressed w.t. GFP-SMARCAL1 with either w.t. Ad5, or w.t. Ad12 
and examined the levels of GFP-SMARCAL1 species by WB at appropriate times post-
infection (Figure 4.3). Consistent with Ad infection, E1B-55K was expressed following 
infection of these A549 cell derivatives with either w.t. Ad5, or w.t. Ad12 (panels iii 
and iv, Figure 4.3). Moreover, and as expected, p53 was targeted for degradation early 
during Ad5 infection, and later following Ad12 infection (panel ii, Figure 4.3). Despite 
these observations however, GFP-SMARCAL1 was at very low levels in mock-infected 
cells, relative to Ad5 and Ad12 infected cells where it was vastly overexpressed (panel 
i, Figure 4.3). In this regard, the exposure time for the WB was a few seconds for the 
GFP blot following Ad infection, whereas previously we required 5 minutes to visualise 
GFP in uninfected cells (Figure 4.2). Whilst there was modest decrease in the levels w.t. 
GFP-SMARCAL1 at late times post Ad5 and Ad12 infection the levels of GFP-
SMARCAL1 were elevated substantially following infection. These data indicate that, 
in contrast to endogenous SMARCAL1, the protein levels of GFP-SMARCAL1 are 
increased, not decreased, following Ad infection. To investigate this phenomenon 
further we infected constitutively expressing w.t. GFP-SMARCAL1 A549 cells with 
either w.t. Ad5, or w.t. Ad12 and determined GFP-SMARCAL1 protein levels in cells 
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by live-cell imaging of GFP fluorescence (panels i-iii, Figure 4.4). Consistent with the 
WB analyses, GFP-SMARCAL1 protein levels were low in mock-infected cells and 
high in both Ad5- and Ad12- infected A549 cells (cf panel i with panels ii and iii, Figure 
4.4). GFP-SMARCAL1 was pan-nuclear in mock-infected cells (panel i, Figure 4.4) 
whilst GFP alone was distributed evenly throughout the cell (data not shown) indicating 
that SMARCAL1 dictates the cellular localization of the fusion protein. Moreover, in 
support of previous observations in our laboratory (F.S.I Qashqari, PhD thesis, The 
University of Birmingham, 2017) GFP-SMARCAL1 was redistributed to nuclear 
structures, that resembled VRCs, during infection (panels ii and iii, Figure 4.4). These 
data indicate that GFP-SMARCAL1 behaves differently to the endogenous 
SMARCAL1 protein. These results will be considered fully in the discussion at the end 
of this chapter. However, given these results, we reasoned that w.t. and mutant GFP-
SMARCAL1 cell lines could not be used to investigate the role of site-specific 







































Figure 4.3. GFP-SMARCAL1 protein expression is increased following w.t. Ad5 and 
Ad12 infection. A549 clonal cell lines expressing WT GFP-SMARCAL1 were either 
mock infected or infected with WT Ad5 and WT Ad12 at 10 pfu/cell. Cells were 
harvested at the time indicated and protein lysates separated by SDS-PAGE, prior to 
Western blot analyses for GFP (SMARCAL1), Ad5 E1B-55K, Ad12 E1B-55K and b-actin. 























































Figure 4.4. Expression and distribution of GFP-SMARCAL1 in WT GFP-
SMARCAL1 expressing A549 clonal cell lines following Ad infection. WT GFP-
SMARCAL1 expressing A549 cell lines were either mock infected or infected with 
WT Ad5 and WT Ad12 at 10 pfu/cell. Cells were visualised by live cell imaging 




4.2.3. Investigating the requirement for SMARCAL1 phosphorylation 
in the recruitment of SMARCAL1 to viral replication centres. 
As we have established that w.t. GFP-SMARCAL1 is reorganised to VRCs in A549 
cells (Figure 4.4) during both w.t. Ad5 and w.t. Ad12 infection we next decided to 
establish whether GFP-SMARCAL1 was also reorganised to VRCs in Ad-infected 
RPE-1 cells. To do this we infected clonal GFP-SMARCAL1- expressing RPE-1 cells 
with either w.t. Ad5 or w.t. Ad12 and analysed the cellular distribution of GFP-
SMARCAL1 at 24h post-infection by immmunofluorescent live-cell imaging (Figure 
4.5). In mock-infected cells GFP-SMARCAL1 was distributed throughout the nucleus, 
though there were noticeable differences in the protein levels of GFP-SMARCAL1 
between individual cells (panel i, Figure 4.4). Following infection of RPE-1 cells with 
either Ad5 or Ad12, akin to the A549 studies, there was a noticeable increase in the level 
of GFP-SMARCAL1 protein expression, and GFP-SMARCAL1 was reorganized, 
typically to structures that resembled VRCs (cf panel i with panels ii and iii, Figure 4.5). 
 
It was apparent that upon infection with either w.t. Ad5 or Ad12 that GFP-SMARCAL1 
RPE-1 cells retained their, oval-shaped, nuclear integrity better than the Ad-infected 
GFP-SMARCAL1 A549 cells which often became crescent-shaped and distorted (RN 
and AST, unpublished observations). It was therefore easier using the GFP-
SMARCAL1 RPE-1 cells, to record in which cells GFP-SMARCAL1 was redistributed 
to VRCs during Ad infection. We therefore chose to use these cells to determine whether 
ablation of SMARCAL1 phosphorylation acceptor sites affected the recruitment of 




We first investigated whether phosphorylation-defective mutants in which one phospho-
acceptor site was mutated to alanine affected the ability of w.t. Ad5 or Ad12 to induce 
the reorganization of GFP-SMARCAL1 to VRCs. To check this, we infected the 
relevant GFP-SMARCAL1 RPE-1 cell lines with w.t. Ad5 or w.t. Ad12 and analysed 
GFP-SMARCAL1 distribution to VRCs at 24h post-infection (Figure 4.6). Pertinently, 
in the mock-treated RPE-1 cells, the distribution of w.t. GFP-SMARCAL1, GFP-
SMARCAL1 S123A, GFP-SMARCAL1 S129A and GFP-SMARCAL1 S173A were 
all observed to be pan-nuclear [panels i-iv, Figure 4.6A]. However, when GFP-
SMARCAL1 RPE-1 cells were infected with either w.t. Ad5 or w.t. Ad12, GFP-
SMARCAL1 levels increased, relative to mock-infected cells, though this was not as 
dramatic as observed for A549 cells [cf panels i-iv with panels v-xii, Figure 4.6A]. 
Interestingly, results of these analyses indicated that both w.t. and mutant GFP-
SMARCAL1 species were redistributed to VRCs following Ad infection [panels v-xii, 
Figure 4.6A]. To determine whether there was any significant difference in the 
recruitment of w.t. or mutant GFP-SMARCAL1 species to VRCs following Ad 
infection we decided to quantify the proportion of mutant GFP-cells, relative to w.t. 
GFP-SMARCAL1 cells, which were recruited to VRCs following either w.t. Ad5, or 
w.t Ad12 infection. Analyses revealed that although there was a modest reduction in the 
recruitment of GFP-SMARCAL1 S123A, GFP-SMARCAL1 S129A and GFP-
SMARCAL1 S173A, relative to w.t. GFP-SMARCAL1, following both w.t. Ad5 and 
w.t Ad12 infection, only the recruitment of GFP-SMARCAL1 S173A, relative to w.t. 
GFP-SMARCAL1, was reduced significantly following Ad5 infection [Figure 4.6B]. In 
all other instances, the recruitment of mutant GFP-SMARCAL1 species to VRCs did 
not differ significantly from the recruitment of w.t. GFP-SMARCAL1 species to VRCs, 
125 
 
although it appeared that the recruitment of S173A mutant to VRCs in Ad12-infected 
cells were reduced, relative to w.t. GFP-SMARCAL1 [Figure 4.6B]. 
 
Using an identical strategy, we next investigated whether the GFP-SMARCAL1 RPE-
1 double phosphorylation-defective mutants, S123A/S129A, S123A/S173A and 
S129A/S173A were recruited to VRCs following Ad infection [Figure 4.7]. Visual 
inspection of mutant GFP-SMARCAL1 species cellular distribution revealed that, akin 
to w.t. GFP-SMARCAL1 species, they were recruited to VRCs following either w.t. 
Ad5 or w.t. Ad12 infection [cf panels i-iv with panels v-xii, Figure 4.7A]. Again, 
although there was a modest decrease in the recruitment of phosphorylation-defective 
mutants to VRCs following Ad infection this was not statistically significant for the 
majority of mutants [Figure 4.7B]. Only the distribution of GFP-SMARCAL1 mutant 
S129A/S173A to VRCs, was reduced significantly following Ad5 infection, relative to 































































Figure 4.5. Expression and distribution of GFP-SMARCAL1 in WT GFP-SMARCAL1 
expressing RPE-1 clonal cell lines following Ad infection. WT GFP-SMARCAL1 
expressing A549 cell lines were either mock infected or infected with WT Ad5 and 
WT Ad12 at 10 pfu/cell. Cells were visualised by live cell imaging fluorescence 
























Figure 4.6. Quantification of SMARCAL1 recruitment to VRCs in GFP-Smarcal1 S123A, 
S129A and S173A expressing RPE-1 clonal cell lines. A] GFP-SMARCAL1 single mutants 
S123A, S129A and S173A expressing RPE-1 cell lines were either mock infected or 
infected with WT Ad5 and WT Ad12 at 10 pfu/cell. Cells were visualised by live cell 
imaging fluorescence microscopy at 24 h post-infection. B] The percentage of cells where 
GFP-SMARCAL1 was recruited to VRCs were recorded and analysed by (n=3, 200 cells per 


























Figure 4.7. Quantification of SMARCAL1 recruitment to VRCs in GFP-Smarcal1 
S123/S129A, S123/S173A and S129/S173A expressing RPE-1 clonal cell lines. A] GFP-
SMARCAL1 double mutants S123/S129A, S123/S173A and S129/S173A expressing RPE-1 
cell lines were either mock infected or infected with WT Ad5 and WT Ad12 at 10 pfu/cell. 
Cells were visualised by live cell imaging fluorescence microscopy at 24 h post-infection. 
B] The percentage of cells where GFP-SMARCAL1 was recruited to VRCs were recorded 
and analysed by (n=3, 200 cells per experiment). The data is expressed as mean +/- S.D. 
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4.2.4. GFP-SMARCAL1 recruitment to viral replication centres 
following Ad5 and Ad12 infection is dependent upon phosphorylation 
on S123, S129 and S173 and its association with the RPA complex. 
To investigate the combined effect of CDK and ATR -directed phosphorylation upon 
SMARCAL1 localization to VRCs following Ad infection we utilized the RPE-1 cells 
that constitutively express the GFP-SMARCAL1 triple phosphorylation-defective 
mutant (S123A/S129A/S173A (∆P) where S123, S129 and S173 are all mutated to A). 
Akin to w.t. GFP-SMARCAL1, GFP-SMARCAL1-∆P was distributed evenly 
throughout the nucleus in mock-infected cells [cf panels i and ii with panels iv and v, 
and vii and viii, Figure 4.8A]. Interestingly, although GFP-SMARCAL1-∆P was 
recruited to VRCs following both w.t. Ad5 and w.t. Ad12 infection, statistical analyses 
revealed that the recruitment of GFP-SMARCAL1-∆P to VRCs, was attenuated 
significantly, relative to w.t. GFP-SMARCAL1 [Figure 4.7B]. In Ad5-infected cells, 
GFP-SMARCAL1-∆P recruitment to VRCs was reduced by approximately 25% 
relative to w.t. GFP-SMARCAL1, whereas GFP-SMARCAL1-∆P recruitment to VRCs 
was reduced by approximately 40% relative to w.t. GFP-SMARCAL1, following Ad12 
infection [Figure 4.7B]. These data suggest that SMARCAL1 phosphorylation does 
contribute towards SMARCAL1 recruitment to VRCs following both Ad5 and Ad12 
infection. 
 
As the RPA complex has long been known to be recruited to VRCs, and SMARCAL1 
associates with RPA at VRCs we were interested to establish whether SMARCAL1 
recruitment to VRCs was dependent, or not, on its ability to bind RPA. We therefore 
took advantage of an N-terminal SMARCAL1 mutant that lacks the first 32 amino acids 
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that has previously been shown to define the binding site on SMARCAL1 for RPA 
(Bansbach, Bétous et al. 2009). As for other GFP-SMARCAL1 constructs we generated 
clonal RPE-1 cell lines that expresses constitutively, a GFP-SMARCAL1 species that 
does not bind RPA (data not shown; GFP-SMARCAL1-∆RPA). Like w.t. GFP-
SMARCAL1, GFP-SMARCAL1-∆RPA was distributed throughout the nucleus in 
mock-infected cells [cf panel i with panel iii, Figure 4.8A]. In contrast to w.t. GFP-
SMARCAL1 however, it was evident upon inspection of cells under the microscope that 
GFP-SMARCAL1-∆RPA was not re-organised to VRCs efficiently following either 
w.t. Ad5 or w.t. Ad12 infection [cf panels iv and vii with panels v, vi, viii and ix, Figure 
4.7A]. Analyses revealed that there was an approximately, two-thirds reduction in the 
recruitment of GFP-SMARCAL1-∆RPA to VRCs, when compared directly to w.t. GFP-
SMARCAL1 recruitment to VRCs [Figure 4.8B]. These data suggest that SMARCAL1 
recruitment to VRCs following both Ad5 and Ad12 infection is largely dependent upon 





















Figure 4.8. Quantification of SMARCAL1 recruitment to VRCs in WT GFP-Smarcal1, GFP-
SMARCAL1 phosphorylation-defective triple mutant and GFP-SMARCAL1-△RPA mutant 
expressing RPE-1 clonal cell lines. A] WT GFP-Smarcal1, GFP-SMARCAL1-△P triple mutant 
and GFP-SMARCAL1-△RPA mutant expressing RPE-1 cell lines were either mock infected 
or infected with WT Ad5 and WT Ad12 at 10 pfu/cell. Cells were visualised by live cell 
imaging fluorescence microscopy at 24 h post-infection. B] The percentage of cells where 
GFP-SMARCAL1 was recruited to VRCs were recorded and analysed by (n=3, 200 cells per 






In order to replicate successfully in the host cell, adenoviruses employ several strategies 
to neutralize host cell anti-viral proteins. In recent years, it has become evident that Ads 
target cellular proteins for degradation through the ubiquitin-proteasome system 
(Schreiner, Wimmer et al. 2012). It is also accepted that in this regard a number of anti-
viral proteins are recruited to: VRCs through interaction with the RPA complex or E1B-
55K; or nuclear tracks through interaction with E4orf3 prior to their degradation 
(Querido, Blanchette et al. 2001, Blackford, Bruton et al. 2008, Carson, Orazio et al. 
2009, Blackford, Patel et al. 2010, Schreiner, Wimmer et al. 2011, Forrester, Patel et al. 
2012, Bridges, Sohn et al. 2016). Alternatively, anti-viral host cell proteins have been 
suggested to be inactivated through sequestration, rather than undergo degradation, at 
these sites during infection (Nebenzahl-Sharon, Shalata et al. 2019). As we had shown 
in Chapter 3 that the combined actions of ATR and CDK inhibitors reduced substantially 
the ability of Ad to target SMARCAL1 for degradation (Figure 3.8), we wished to 
establish whether the phosphorylation of those specific SMARCAL1 residues targeted 
during Ad infection (S123, S129 and S173, Figure 3.3 , Chapter 3), contributed directly 
towards SMARCAL1 degradation during infection. This is an important question to 
resolve as phosphorylation has not been previously shown to modulate the degradation 
of host cell proteins during infection. To investigate this possibility we made A549 and 
RPE-1 cell lines that expressed constitutively w.t. GFP-SMARCAL1, and GFP-
SMARCAL1 mutants where phospho-acceptor sites were inactivated through mutation 




Once generated, we intended to use these cell lines to establish whether these GFP-
SMARCAL1 phosphorylation-defective mutants were degraded during Ad infection, or 
not. Unfortunately, our initial studies in A549 cells indicated that w.t. GFP-
SMARCAL1 species were elevated, not reduced, following both w.t. Ad5 and w.t. Ad12 
infection, suggesting that these cell lines were not a good model to investigate the role 
of phosphorylation in the degradation of SMARCAL1 (Figure 4.3). What is the 
explanation for our observations? It has long been known that the 13S E1A gene product 
serves to transactivate early region promoters during infection (e.g. (Berk, Lee et al. 
1979, Jones and Shenk 1979, Bernards, Schrier et al. 1983, Bos and ten Wolde‐
Kraamwinkel 1983). In this regard the Zn-finger region of CR3 associates with host cell 
factors such as TBP, Sur2 and the proteasome (Geisberg, Lee et al. 1994, Liu and Green 
1994, Boyer, Martin et al. 1999, Rasti, Grand et al. 2006), whilst the C-terminal region 
of CR3 targets E1A to promoter elements, through association with transcription factors 
such as ATF2, to stimulate transcription from viral early gene promoters (Liu and Green 
1990). Crucially, it has also been shown that the 13S E1A gene product can transactivate 
heterologous promoters such as the CMV immediate early promoter (Metcalf, Monick 
et al. 1994). Unfortunately, mammalian expression vectors utilise constitutively active 
promoters such as the CMV promoter to induce the expression of exogenous gene 
products. In this regard, the retroviral pLEGFP vector utilised in this study uses a CMV 
promoter to induce the expression of the GFP construct [Clontech]. It is our expectation 
therefore that E1A stimulates the overexpression of GFP-SMARCAL1 species through 
transactivation of the CMV promoter in the pLEGFP vector. To overcome this problem 
in the future it might be worthwhile to express E1B-55K and E4orf6 as plasmids, or 
recombinant Ads, in the absence of E1A, in GFP-SMARCAL1 expressing cell lines to 
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see if we can establish whether E1B-55K and E4orf6 can drive the degradation of GFP-
SMARCAL1 phospho-mutants. 
 
As we have shown previously that SMARCAL1 is recruited to VRCs during infection, 
we next investigated, using our GFP-SMARCAL1 phospho-mutants, whether ATR 
and/or CDKs promote the recruitment of SMARCAL1 to VRCs. Our data indicated that 
GFP-SMARCAL1 recruitment to VRCs was dependent upon both ATR and CDKs, as 
only the triple phosphorylation-defective GFP-SMARCAL1 mutant was significantly, 
defective in its recruitment to VRCs (Figure 4.8). In this regard, the ability of w.t. Ad5 
to promote the recruitment of the phosphorylation-defective GFP-SMARCAL1 mutant 
to VRCs was reduced by approximately 25%, relative to w.t. GFP-SMARCAL1 species, 
and the ability of w.t. Ad12 to promote recruitment of the phosphorylation-defective 
GFP-SMARCAL1 mutant to VRCs was reduced by approximately 40%, relative to w.t. 
GFP-SMARCAL1 species (Figure 4.8). 
 
It is well established that ATR substrates and regulators, such as the RPA complex 
(including RPA32), ATRIP, RPA32, E1B-AP5 (hnRPUL1) and TopBP1 are all 
recruited to VRCs during Ad infection (Blackford, Bruton et al. 2008, Carson, Orazio 
et al. 2009, Blackford, Patel et al. 2010). Of these, only the RPA subunit, RPA32 is 
known to be phosphorylated by in an ATR-dependent manner during infection but that 
protein, unlike SMARCAL1, is not targeted for degradation [Blackford et al, 2008]. 
Given our analyses it would be interesting to determine whether ATR, and CDK, 
inhibitors similarly restrict the recruitment of these host cell proteins to VRCs. More 
generally, it would be of interest to establish whether the recruitment of any other host 
cell proteins (e.g. p53, MRN complex), or viral proteins (e.g. E1B-55K or E4orf6) is 
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dependent upon ATR or CDK activities. As RPA32 is known to be recruited to VRCs 
and is also a SMARCAL1-interacting protein where they co-localize at sites of ssDNA 
during cellular DNA replication or DNA damage (Bansbach, Bétous et al. 2009, Ciccia, 
Bredemeyer et al. 2009, Yusufzai, Kong et al. 2009) we investigated whether 
SMARCAL1 interaction with the RPA complex was important in its recruitment to 
VRCs. To do this we utilised a GFP-tagged N-terminal SMARCAL1 deletion mutant 
that does not interact with the RPA complex (Bansbach, Bétous et al. 2009). 
Interestingly, our analyses revealed that SMARCAL1 recruitment to VRCs was largely 
dependent upon its interaction with the RPA complex [Figure 4.8]. In this regard it 
would be interesting to see if the interaction between the RPA complex and 
SMARCAL1 is phosphorylation-dependent, or whether these two pathways function 
independently to recruit SMARCAL1 to VRCs. 
 
Although the role of the RPA complex at VRCs is largely under-explored, our data 
suggest that it possesses pro-viral activities by promoting the recruitment, and 
subsequent degradation of SMARCAL1, at VRCs. Given these results, it would be 
interesting to establish whether other RPA complex-interacting proteins such as 
TopBP1 and E1B-AP5 are recruited to VRCs through their interaction with the RPA 
complex. Moreover, as both E1B-55K and E4orf6 are recruited to VRCs it would also 
be interesting to see if these proteins contribute towards the phosphorylation-dependent 
and/or RPA-dependent recruitment of SMARCAL1 to VRCs. As mentioned above the 
role of the RPA complex in Ad replication is not known. However, in some other viruses 
such as SV40, the large T-antigen (LT) -dependent replication of the viral genome is 
dependent upon the RPA complex (Wold, Li et al. 1987). It has been determined that 
LT functions as a replicative helicase and binds to the RPA complex through its origin 
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DNA-binding domain (Dornreiter, Erdile et al. 1992). It has been proposed that LT loads 
the RPA complex onto emerging ssDNA at the SV40 origin of DNA replication. In this 
regard, CDKs are implicated in the phosphorylation of the RPA32 subunit and the 
stimulation of DNA unwinding at origins of replication (Dutta and Stillman 1992). 
Given these data, it is highly likely that the RPA complex is pro-viral and associates 
with adenovirus ssDNA following unwinding at origins of replication within the 5’ and 
3’ ITRs, and following Ad DNA replication, though its role in Ad replication awaits 
experimental confirmation.  Given our findings it will also be interesting to determine 
whether SV40 similarly inhibits SMARCAL1 during infection, or whether it utilises 
SMARCAL1 for viral DNA replication. In this regard, SV40 is not known to engage 
with the ubiquitin-proteasome system to promote the degradation of DDR proteins, 
although LT has been shown to interact with CRL7 to inhibit the degradation of the 
insulin receptor substrate 1 (Hartmann, Xu et al. 2014).  
 
In conclusion, results presented in this Chapter have demonstrated that SMARCAL1 
recruitment to VRCs is complex, and relies upon both upon its phosphorylation by ATR 
and CDKs, and its association with the RPA complex. Further studies will be required 
to determine the molecular inter-relationship between these two pathways and 
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Adenovirus has evolved numerous strategies to counteract host cell defence 
mechanisms. For instance, the linear dsDNA genome of adenovirus, or adenovirus 
replication ssDNA intermediates, would ordinarily, be recognised as host cell DNA 
damage by the cellular DDR signalling cascades coordinated by ATM, ATR and DNA-
PK. Adenoviruses have evolved to overcome the cellular DDR by inhibiting the 
activities of key components of these pathways (Turnell and Grand 2012, Weitzman and 
Fradet-Turcotte 2018). In this regard, the early region proteins play a key role in 
disrupting host cellular DDR signalling pathways that lead to cell cycle checkpoint 
activation and DNA repair, or apoptosis. Specifically, E1B-55K, E4orf3 and E4orf6 all 
participate in targeting the key cellular proteins involved in the DDR for degradation 
through the ubiquitin-proteasome system to usurp cell cycle checkpoints and cellular 
apoptotic programmes. Hence, understanding the biological activities of adenovirus 
early region proteins is key in the identification, and molecular characterization, of 
important DDR proteins that function as anti-viral agents, and discerning how 
adenovirus dysregulates their cellular functions.  
 
The adenovirus early region protein, and oncoprotein, E1B-55K is a multifunctional 
protein that plays a major role in inhibiting the cellular DDR (see Introduction, section 
1.3.6 and 1.6.2). In this regard, it associates with E4orf6 and recruits an E3 ubiquitin 
ligase complex consisting of CRLs (Cullin Ring Ligases), Elongins B and C and Rbx1 
to target a number of cellular proteins involved in the DDR for degradation via the 
ubiquitin-proteasome system (Querido, Blanchette et al. 2001, Harada, Shevchenko et 
al. 2002, Stracker, Carson et al. 2002, Blackford, Patel et al. 2010, Orazio, Naeger et al. 
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2011). Apart from promoting viral replication, Ad E1B-55K is also involved in the 
transformation of mammalian cells with the co-operation of other E1, and E4 gene 
products, particularly E1A, E1B-19K, E4orf3 and E4orf6 (Yew and Berk 1992, Nevels, 
Täuber et al. 1999, Nevels, Täuber et al. 2001). Previous observations have shown that 
E1B-55K contributes to the transformation process through its ability to interact with 
the tumour suppressor protein, p53 and blocking the transcriptional activities of p53, to 
disable cell cycle checkpoint control and p53-dependent apoptosis (Yew and Berk 1992, 
Yew, Liu et al. 1994, Harada and Berk 1999).  
 
Previously, we have shown that the RPA-interacting protein and ATR substrate 
SMARCAL1 is recruited to VRCs during infection and then targeted for proteasomal 
degradation in an E1B-55K and E4orf6 dependent manner (Figure 3.9; F.S.I Qashqari, 
PhD thesis, The University of Birmingham, 2017). As E1B-55K typically functions as 
a substrate adaptor for the Ad ubiquitin ligase through interaction with substrates such 
as p53 and MRE11, in the absence of E4orf6, we hypothesized that E1B-55K would 
also serve the same purpose for SMARCAL1. We wished therefore to establish whether 
E1B-55K associates with SMARCAL1 in the absence of E4orf6. Given that E1B-55K 
neutralizes p53 function through interaction, in the absence of E4orf6 (Yew and Berk 
1992) we also hypothesized that E1B-55K could, in isolation, potentially modulate the 
cellular DNA replication functions of SMARCAL1. These hypotheses were tested 







5.2.1. Ad5 E1B-55K associates with SMARCAL1 in Ad5 transformed 
HEK 293 cells. 
As previous observations have shown that E1B-55K associates with cellular proteins 
like MRE11 and p53 in Ad-transformed cells we wished to establish whether E1B-55K 
also associates with SMARCAL1 in Ad-transformed cells. To investigate this 
possibility, we performed reciprocal co-immunoprecipitation assays, and 
immunoprecipitated SMARCAL1 and E1B-55K from Ad5 E1-transformed HEK 293 
cells using anti-E1B-55K and anti-SMARCAL1 antibodies [Figure 5.1]. Following 
incubation with anti-E1B-55K and anti-SMARCAL1 antibodies immunocomplexes 
were collected on protein G-sepharose beads, separated by SDS-PAGE and subjected to 
Western blot analyses. Co-immunoprecipitation studies revealed that the anti-Ad5 E1B-
55K antibody co-immunoprecipitated SMARCAL1 and that the anti-SMARCAL1 
antibody co-immunoprecipitated E1B-55K in Ad5 HEK 293 cells [Figure 5.1]. In this 
regard, it was evident that the anti-SMARCAL1 antibody was better at co-
immunoprecipitation of E1B-55K than, the anti-E1B-55K antibody was at co-
immunoprecipitating SMARCAL1 [Figure 3.1]. To validate the experimental approach 
taken we also showed by co-immunoprecipitation using anti-E1B-55K antibodies and 
























Figure 5.1: Ad5 E1B-55K associates with SMARCAL1 in Ad5 E1-transformed HEK 
293 cells. Ad5 E1B-55K and SMARCAL1 were immunoprecipitated from Ad5 E1-
transformed HEK 293 cells using the appropriate antibodies and subjected to 
Western blot analysis using anti-SMARCAL1 and anti- Ad5 E1B-55K antibodies. As 
p53 is a known Ad5 E1B-55K binding protein, reciprocal Ad5 E1B-55K and p53 IPs 
were performed as a positive control. Normal mouse IgG was used for control IPs 
to assess non-specific binding. Data presented is representative of three 
independent experiments. (Published in J.Virol 2019 by Nazeer et al). 
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5.2.2. Ad12 E1B-55K association with SMARCAL1 in Ad12 
transformed HER2 cells. 
After confirmation that Ad5 E1B-55K associates with SMARCAL1 in vivo, we wished 
to investigate whether Ad12 E1B-55K similarly interacts with SMARCAL1 in vivo in 
Ad12 E1-transformed HER2 cells. We therefore carried out reciprocal co-
immunoprecipitation assays in Ad12 E1 transformed HER2 cell lysates using anti-
SMARCAL1 and anti-E1B-55K antibodies. Consistent with the Ad5 studies, an anti- 
Ad12 E1B-55K antibody co-immunoprecipitated SMARCAL1, and moreover, an anti-
SMARCAL1 antibody co-immunoprecipitated Ad12 E1B-55K [Figure 5.2]. In this 
regard the Ad12 E1B-55K antibody was more efficient than the Ad5 E1B-55K antibody 
at co-immunoprecipitation of SMARCAL1 [cf Figures 5.1 and 5.2]. Again, we further 
validated our findings by demonstrating that E1B-55K associates with p53 in Ad12 E1-
















                           



















Figure 5.2: Ad5 E1B-55K associates with SMARCAL1 in Ad12 E1-transformed 
HER2 cells. Ad12 E1B-55K and SMARCAL1 were immunoprecipitated from Ad12 
E1-transformed HER2 cells using the appropriate antibodies and subjected to 
Western blot analysis using anti-SMARCAL1 and anti- Ad12 E1B-55K antibodies. 
As p53 is a known Ad12 E1B-55K binding protein, reciprocal Ad5 E1B-55K and p53 
IPs were performed as a positive control. Normal mouse IgG was used for control 
IPs to assess non-specific binding. Data presented is representative of three 
independent experiments. (Published in J.Virol 2019 by Nazeer et al). 
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5.2.3. Validation of TET-inducible Ad5 and Ad12 E1B-55K U2OS cell 
lines. 
After establishing that Ad5 and Ad12 E1B-55K interact with SMARCAL1 in Ad E1- 
transformed HEK-293 and HER2 cells, respectively [Figure 5.1 and 5.2], we next 
wished to investigate whether E1B-55K modulates the cellular activities of 
SMARCAL1. To do this we took advantage of TET-inducible Ad5 and Ad12 E1B-55K 
U2OS cell lines that had been generated in our laboratory specifically as an experimental 
tool to study E1B-55K function [A Albalawi and AS Turnell, unpublished data]. To 
validate the usefulness of these experimental systems we first, assessed the expression 
of Ad5 and Ad12 E1B-55K in these cell lines, before and after, doxycycline induction 
by Western blot analysis [panels iv and v, Figure 5.3]. Moreover, given that both Ad5 
and Ad12 E1B-55K are known to stabilise (increase the levels of) the p53 protein by 
inhibiting the Mdm2-mediated degradation of p53 (Querido, Blanchette et al. 2001), we 
also performed Western blot analyses for p53 in the absence and presence of 
doxycycline induction [panel ii, Figure 5.3]. Consistent with previous observations the 
levels of p53 were increased following the expression of Ad5 and Ad12 E1B-55K, 
suggesting that E1B-55K is functional in these cells [panel ii, Figure 5.3]. However, the 
levels of E1B-55K binding partners MRE11 and SMARCAL1 were not altered 
following Ad5 and Ad12 E1B-55K induction [panels i and iii, Figure 5.3]. Taken 
together, these data indicate that the TET-inducible Ad5 and Ad12 E1B-55K U2OS cell 
lines express functional E1B-55K that can be used to investigate the specific effects of 






















Figure 5.3: Validation of Ad5 and Ad12 E1B-55K TET-inducible U2OS FlpIn cells. 
Ad5 E1B-55K and Ad12 E1B-55K TET-inducible U2OS cell lines were induced to 
express in E1B-55K in the presence of 0.1µg/ml doxycycline. Cells were harvested 
24h post-induction and the lysates were subjected for SDS-PAGE analysis for Ad5 
and Ad12 E1B-55K, p53, MRE11 and 𝛽-actin using appropriate antibodies. Data 
presented is representative of two independent experiments. (Published in J.Virol 
2019 by Nazeer et al). 
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5.2.4. Investigating the effects of E1B-55K on cellular DNA replication. 
It is well established that SMARCAL1 is a DNA helicase that helps to prevent 
replication fork collapse in unperturbed S-phase and promotes replication restart after 
fork collapse during replication stress (Postow, Woo et al. 2009, Poole and Cortez 
2017). Akin to the ability of E1B-55K to inhibit p53 functions (Boyer, Martin et al. 
1999) we wished to establish whether Ad5 and/or Ad12 E1B-55K modulated cellular 
DNA replication through its ability to interact with SMARCAL1. To investigate 
whether Ad E1B-55K regulated cellular DNA replication during S-phase we performed 
DNA fibre analyses. The principle of the DNA Fibre analysis is to incorporate 
nucleotide analogues CldU and IdU into newly synthesized DNA for a pre-determined 
time and then detect these two analogues on individual DNA molecules by 
immunofluorescence in order to determine the rate of DNA synthesis. To do this we 
first pulse-labelled both Ad5 and Ad12 E1B-55K U2OS cells (+/- doxycycline) for 20 
minutes each in CldU and IdU, lysed the cells, and then spread the DNA fibres onto 
glass slides where they were fixed in methanol/acetic acid and then denatured in HCl. 
Newly synthesized DNA was then detected with primary antibodies that recognise  
CldU and IdU nucleotide analogues specifically and visualized with the appropriate 
Alexa 488 and 594 secondary antibodies, after which images were acquired using the 
Nikon E600 microscope with an Nikon Plan Apo 60x (1.3 NA) oil lens and Hamamatsu 
digital camera (C4742-95) and by using Velocity acquisition software (Perkin Elmer) 




















Figure 5.4: Principle of the DNA Fibre Assay. Cellular DNA replication was analyzed 
using the DNA Fibre Assay. Cells were pulse-labelled, in turn, with two nucleotide 
analogues CldU (25 µM) and IdU (250 µM) for 20 minutes each. Cells were 
harvested and spread onto glass slides, whereupon they were air dried, fixed in 
methanol-acetic acid and denatured with 2.5 M HCl. DNA fibres were then labelled 
with appropriate primary and secondary antibodies and fibres were visualized using 
high resolution microscope.  
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5.2.5. Ad5 and Ad12 E1B-55K dysregulate DNA replication fork speed. 
Using the protocol outlined above we were able to analyse DNA replication fork speed 
in S-phase in the absence, or presence of Ad5 and Ad12 E1B-55K. Strikingly, analysis 
of the data revealed that CldU-labelled tracks were significantly longer in both Ad5 and 
Ad12 EB-55K induced cells compared to cells that did not express these viral proteins 
[Figure 5.5A and 5.6A]. Indeed, the initial average fork speed in Ad5 E1B-55K 
expressing cells was 2.27kb/min whilst average fork speed in the cells not expressing 
Ad5 E1B-55K was 1.66kb/min [Figure 5.5A]. Similarly, the initial average fork speed 
in Ad12 E1B-55K expressing cells was 1.68kb/min whilst average fork speed in the 
cells not expressing Ad12 E1B-55K was 1.04kb/min [Figure 5.6A]. When the data was 
plotted as a bar graph showing the distribution of CldU fork speeds +/- Ad5 or Ad12 
E1B-55K it was evident that there was a greater proportion of cells expressing Ad E1B 
55K that had increased, initial fork speeds (Figures 5.5B and 5.6B). These data indicate 
that Ad5 and Ad12 E1B-55K expression, initially led to a significant acceleration of 
replication fork speed. However, when we analysed the speed of on-going forks by 
measuring the length of the IdU-labelled tracts it was apparent that IdU fork speeds +/- 
Ad5 and Ad12 E1B-55K cells were very similar and that accelerated fork speed was not 
maintained in on-going forks [Figures 5.5A and 5.6A]. As such the average on-going 
fork speed in Ad5 E1B-55K expressing cells was 1.49kb/min whilst average on-going 
fork speed in the cells not expressing Ad5 E1B-55K was 1.46kb/min [Figure 5.5A]. 
Moreover, the average on-going fork speed in Ad12 E1B-55K expressing cells was 
1.03kb/min whilst average fork speed in the cells not expressing Ad12 E1B-55K was 
0.91kb/min [Figure 5.6A]. Closer inspection of the distribution of IdU fork speeds 
revealed that they were very similar +/- Ad5 or Ad12 E1B-55K [Figure 5.5B and 5.6B]. 
We next measured the distribution of combined fork speeds (CldU + IdU), which very 
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verified that cells expressing Ad5 or Ad12 E1B-55K had increased overall fork speeds 
[Figure 5.5C and 5.6C]. 
 
5.2.6. Ad5 and Ad12 E1B-55K expression increases CldU/IdU fork 
speed ratios. 
Individual CldU and IdU fork speeds were then plotted as a dot plot in order to establish 
the mean CldU and IdU fork speeds +/-Ad5 and Ad12 E1B-55K. These results 
confirmed our expectations that both Ad5 and Ad12 E1B-55K enhanced significantly 
CldU fork speeds, but that IdU fork speeds +/- Ad E1B-55K were not significantly 
different from each other [Figures 5.7 and 5.8]. However, when we plotted CldU/IdU 
ratios for individual DNA fibres it was clear that CldU/IdU ratios were significantly 
higher for cells that expressed Ad E1B-55K, relative to cells that did not express these 
proteins [Figures 5.7 and 5.8]. These data are important, as it has previously been shown 
that cells that display increased CldU/IdU ratios have a tendency to undergo replication 








































Figure 5.5: Effect of Ad5 E1B-55K on cellular DNA replication speed. (A) Representative 
DNA spreads taken from non-induced and Ad5 E1B-55K expressing cells illustrating cellular 
DNA replication fork speeds in CldU and IdU -labelled DNA (B) Bar graph illustrating the 
effect of Ad5 E1B-55K expression, relative to mock (non-induced) cells not expressing Ad5 
E1B-55K, on individual replication fork speeds (kb/min) as judged by the incorporation of 
CldU and IdU into newly synthesized DNA. (C) Distribution of combined CldU and IdU fork 
rates in Ad5 E1B-55K induced cells and mock (non-induced) cells is shown, each panel 
showing the combined CldU + IdU labelling fork rates. Data is taken from three 
independent experiments (Total number of mock (non-induced) cells = 370; Ad5 E1B-55K 
































Figure 5.6: Effect of Ad12 E1B-55K on cellular DNA replication speed. (A) 
Representative DNA spreads taken from non-induced and Ad12 E1B-55K expressing cells 
illustrating cellular DNA replication fork speeds in CldU and IdU -labelled DNA (B) Bar 
graph illustrating the effect of Ad12 E1B-55K expression, relative to mock (non-induced) 
cells not expressing Ad12 E1B-55K, on individual replication fork speeds (kb/min) as 
judged by the incorporation of CldU and IdU into newly synthesized DNA. (C) Distribution 
of combined CldU and IdU fork rates in Ad12 E1B-55K induced cells and mock (non-
induced) cells is shown, each panel showing the combined CldU + IdU labelling fork rates. 
Data is taken from three independent experiments (Total number of mock cells = 347; 
























Figure 5.7: Modulation of cellular DNA replication fork speeds by Ad5 E1B-55K. 
Distribution of fork speeds and CldU/IdU ratios in Ad5 E1B-55K expressing cells relative 
to mock (non-induced) cells is shown as dot plots +/- standard deviation with the red 
bar representing the mean fork speed from three individual experiments. Total 
number of Ad5 mock (non-induced) fibres analyzed was 347 and the total number of 
fibres analyzed from Ad5 E1B-55K expressing cells 368. The data was subjected to an 
ANOVA two-tailed t-test. Ad5 E1B-55K CldU tract length relative to the mock (non-
induced) CldU tract length, P=4.8E-20 (***); Ad5 E1B-55K CldU/IdU ratio relative to the 
mock (non-induced) CldU tract length, P=9.44E-45 (****); ns, not significant. 























Figure 5.8: Modulation of cellular DNA replication fork speeds by Ad12 E1B-55K. 
Distribution of fork speeds and CldU/IdU ratios in Ad12 E1B-55K expressing cells 
relative to mock (non-induced) cells is shown as dot plots +/- standard deviation with 
the red bar representing the mean fork speed from three individual experiments. 
Total number of Ad12 mock (non-induced) fibres analyzed was 370 and the total 
number of fibres analyzed from Ad12 E1B-55K expressing cells was 364. The data was 
subjected to an ANOVA two-tailed t-test. Ad12 E1B-55K CldU tract length relative to 
the mock (non-induced) CldU tract length, P=1.29E-32 (****); Ad12 E1B-55K 
CldU/IdU ratio relative to the mock (non-induced) CldU tract length, P=6.32E-61 
(****); ns, not significant. (Published in J.Virol 2019 by Nazeer et al). 
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5.2.7. Ad5 and Ad12 E1B-55K promote fork stalling during cellular 
DNA replication. 
As the frequency of replication stalling depends on increased fork speed (Petermann, 
Maya-Mendoza et al. 2006, Quinet and Vindigni 2018), we next re-analysed our DNA 
fibre spreads to quantify the number of stalled replication forks in the absence or 
presence of Ad5 and Ad12 E1B-55K expression. To do this we counted the number of 
CldU-only tracts that did not label with IdU. CldU-only labelled tracts are indicative of 
replication stalling [Figures 5.9 and 5.10]. It was clear upon inspection of our slides that 
there was clearly an increased number of stalled replication forks (CldU-only tracts) in 
those cells that expressed Ad5 or Ad12 E1B-55K, relative to cells that did not [Figures 
5.9A and 5.10A]. More detailed analyses revealed that Ad5 and Ad12 E1B-55K 
expression led to an approximately three-fold increase in the number of stalled 
replication forks, relative to cells that did not express these proteins [Figures 5.9B and 
5.10B]. 
 
Overall, these data indicate that expression of Ad5 and Ad12 E1B-55K initially 
enhances cellular DNA replication fork speed which ultimately leads to DNA 
replication fork stalling. Taken together these data indicate that both Ad5 and Ad12 
E1B-55K have the intrinsic ability to modulate cellular DNA replication. In 
consideration of the fact that a main function of SMARCAL1 is to promote replication 
restart after fork collapse during replication stress  (Couch, Bansbach et al. 2013), our 
data suggests that Ad E1B-55K inhibits SMARCAL1 activity in vivo leading to 





























Non-induced Ad5 E1B-55K 
A 
B 
Figure 5.9: Effect of Ad5 E1B-55K expression on replication fork stalling. (A) 
Representative images of dual CldU and IdU-labelled DNA fibres in the absence 
or presence of Ad5 E1B-55K showing an increased number of CldU-only labelled 
fibres relative to mock cells (B). Bar graph illustrating percentage of stalled forks 
in Ad5 E1B-55K induced cells relative to mock cells +/- standard deviation, with 
the error bar representing three experimental repeats. The data was subjected to 
an ANOVA two-tailed t-test. P = 0.009 (**). (Published in J.Virol 2019 by Nazeer 
et al). 

























Non-induced Ad12 E1B-55K 
Figure 5.10: Effect of Ad12 E1B-55K expression on replication fork stalling. (A) 
Representative images of dual CldU and IdU-labelled DNA fibres in the absence 
or presence of Ad12 E1B-55K showing an increased number of CldU-only 
labelled fibres relative to mock cells (B). Bar graph illustrating percentage of 
stalled forks in Ad12 E1B-55K induced cells relative to mock cells +/- standard 
deviation, with the error bar representing three experimental repeats. The data 
was subjected to an ANOVA two-tailed t-test. P = 0.002 (**). (Published in 
J.Virol 2019 by Nazeer et al). 
A 
B 




It is well established that the adenovirus early region protein, E1B-55K often functions 
as a substrate adaptor and serves to recruit cellular proteins involved in the DDR, such 
as p53, MRE11 and BLM, to CRLs, through interaction with E4orf6, for ubiquitin-
mediated proteolysis (Turnell and Grand 2012, Weitzman and Fradet-Turcotte 2018). 
Ad E1B-55K is a multifunctional protein that cooperates with E4 early region proteins, 
including E4orf6, to regulate host cell shut-off of cellular metabolism. In this regard, 
E1B-55K and E4orf6 inhibit cellular mRNA transport into the cytoplasm and inhibit 
cellular mRNA translation, whilst promoting viral mRNA accumulation in the 
cytoplasm (Babich, Feldman et al. 1983, Babiss, Ginsberg et al. 1985, Halbert, Cutt et 
al. 1985). More recently it has been determined that the ability of E1B-55K and E4orf6 
to promote viral mRNA export to the cytoplasm is dependent upon the ubiquitin ligase 
activity of the E1B-55K-E4orf6-CRL complex (Blanchette, Kindsmüller et al. 2008). In 
addition to these properties E1B-55K also promotes adenovirus-mediated 
transformation of human and rodent cells, in cooperation with E1A, E1B-19K and E4 
proteins (Yew, Liu et al. 1994, Nevels, Täuber et al. 1999). In this regard, it is thought 
that E1B-55K contributes to the transformation process through its ability to interact 
with p53 and inhibit its transcriptional activities (Yew and Berk 1992, Boyer, Martin et 
al. 1999).   
 
Given the properties of E1B-55K and E4orf6 in host cell shut-off and cellular 
transformation, we wondered whether E1B-55K functions as a substrate adaptor for 
SMARCAL1 in the Ad-induced targeting of SMARCAL1 for proteasome-mediated 
degradation. Co-immunoprecipitation data presented in this chapter indicated that E1B-
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55K from both Ad5 and Ad12 -transformed human cells possessed the capacity to 
interact with SMARCAL1 suggesting that E1B-55K, consistent with the data presented 
in Chapter 3, does most-likely function as a substrate adaptor for SMARCAL1 (Figures 
5.1 and 5.2; Figures 3.9). As we have indicated previously that SMARCAL1 is 
phosphorylated during the early stages of Ad infection, prior to its degradation, it would 
be extremely interesting to see if E1B-55K binds preferentially to phosphorylated 
SMARCAL1. This would be interesting as E1B-55K has not been shown, as yet, to 
interact with any of its binding partners in a phospho-dependent manner. As we showed 
that E1B-55K bound to SMARCAL1 we next wished to establish whether E1B-55K 
could modulate the cellular function of SMARCAL1, as it does for p53. To do this we 
took advantage of our TET-inducible Ad5 and Ad12 E1B-55K U2OS cell lines 
generated in our laboratory to investigate the individual activities of adenovirus early 
region proteins [Albalawi and Turnell, unpublished data; Figure 5.3].  
 
As described previously SMARCAL1 functions as an annealing helicase in cellular 
DNA replication that is involved in promoting cellular DNA replication restart after fork 
collapse and maintaining replication forks in unperturbed S-phase (Postow, Woo et al. 
2009, Poole and Cortez 2017). SMARCAL1 activity is inhibited in response to 
activation of the DDR, in an ATR-dependent manner, to ensure that cellular replication 
is inhibited in response to DNA damage (Bansbach, Bétous et al. 2009, Couch, 
Bansbach et al. 2013).To investigate whether E1B-55K modulated cellular DNA 
replication, through interaction with SMARCAL1, we performed DNA fibre analyses 
where we observed the effects of E1B-55K expression upon the synthesis of new 
individual, DNA replication strands [(Petermann, Woodcock et al. 2010); Figure 5.4]. 
Our results demonstrated clearly that the expression of either Ad5 or Ad12 E1B-55K, 
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initially promoted accelerated cellular DNA replication [Figures 5.5- 5.8]. Strikingly, 
however, the increased cellular DNA replication rates induced by Ad5 and Ad12 E1B-
55K expression ultimately resulted cellular DNA replication fork stalling [Figures 5.9 
and 5.10]. In this regard, it has been shown previously that replication stress by 
oncogene products can lead, initially, to accelerated DNA replication that is ultimately 
followed by the destabilization of cellular DNA replication and fork collapse (Quinet 
and Vindigni 2018). As SMARCAL1 is recruited to stalled replication forks during 
replication stress, through its interaction of RPA, to promote fork re-start and prevent 
fork collapse (Bansbach, Bétous et al. 2009, Ciccia, Bredemeyer et al. 2009, Postow, 
Woo et al. 2009, Yusufzai, Kong et al. 2009), we hypothesize that E1B-55K expression 
induces replication stress to promote accelerated DNA synthesis, and moreover, inhibits 
SMARCAL1 activity to prevent replication restart after fork collapse. Consistent with 
this idea, the ATR-dependent inactivation of SMARCAL1 during DNA damage leads 
to the inhibition of replication restart and results in stalled fork replication (Couch, 
Bansbach et al. 2013).  
 
Interestingly, the inhibition of MRE11 and p53 also results in cellular DNA replication 
stalling (Bryant, Petermann et al. 2009, Klusmann, Rodewald et al. 2016). Given that 
E1B-55K also interacts with these proteins, it is possible therefore that the effects of 
E1B-55K on cellular DNA replication are dependent upon its abilities to interact with 
SMARCAL1, MRE11 and p53, and potentially other cellular E1B-55K partner proteins. 
To distinguish the relative contribution of SMARCAL1, MRE11 and p53, in the E1B-
55K dependent modulation of cellular DNA replication It would be interesting to make 
multiple E1B-55K mutants that possess selective binding capacity for SMARCAL1, 
MRE11 and p53. In this regard, E1B-55K mutants have been made that purportedly 
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distinguish between p53 and MRE11 binding, although close inspection of the data 
suggests that these mutants do retain at least, some, binding activity for both proteins 
(Carson, Schwartz et al. 2003, Härtl, Zeller et al. 2008). 
 
In conclusion, we speculate that Ad E1B-55K creates a replication stress environment 
in the Ad infected cells by interacting with proteins such as SMARCAL1, MRE11 and 
p53 that results perturbed cellular DNA replication and fork stalling. Given the known 
role of E1B-55K and E4orf6 in host protein shut-off, as described earlier, we speculate 
that Ad E1B-55K and E4orf6 also promote the shut-off of host cell DNA replication and 
promote viral DNA replication through the targeting of SMARCAL1 and other cellular 



































6.1. Regulation of ATR signalling pathways during 
adenovirus infection. 
The work presented in this thesis has helped to determine that SMARCAL1 is targeted 
by adenoviruses for degradation in an E1B-55K/E4orf6 and CRL -dependent manner 
(Figure 3.1and 3.12, Chapter 3) and that E1B-55K expression modulates cellular DNA 
replication (Chapter 5). We also presented data to indicate that SMARCAL1 was 
phosphorylated by ATR and a CDK prior to degradation and that ATR and CDK1 
inhibitors attenuated the Ad-mediated degradation of SMARCAL1 (Figure 3.8, Chapter 
3). In this regard, we were able to show that the recruitment of SMARCAL1 to VRCs 
was to some extent dependent upon ATR and CDK -targeted phosphorylation of 
SMARCAL1, but SMARCAL1 association with the RPA complex was the major 
determining factor in facilitating SMARCAL1 recruitment to VRCs (Figure 4.8, 
Chapter 4). Although we determined that SMARCAL1 was phosphorylated at residues 
S123, S129 and S173 by ATR and CDK kinases during infection (Figure 3.3, Chapter 
3) we were not able to experimentally investigate whether inactivation of these 
phosphorylation sites by mutation affected the Ad-mediated degradation of 
SMARCAL1 (Chapter 4). It will be important in the future to establish, without doubt, 
that phosphorylation at S123, S129 and S173 promote SMARCAL1 degradation.  
 
The primary reason we could not determine whether phosphorylation at these sites was 
required for SMARCAL1 degradation in Ad-infected cells was because we made the 
phospho-inhibitory mutants in GFP-SMARCAL1 cDNA cloned into the retroviral, 
pLEGFP vector, which uses the constitutively active CMV promoter. It is well 
established that the 13S E1A gene transactivates the CMV promoter, such that upon Ad 
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infection GFP-SMARCAL1 levels were elevated and not reduced. To overcome this in 
the future we could try to co-express E1B-55K and E4orf6 plasmids or infect with E1B-
55K and E4orf6 recombinant adenoviruses, in the absence of E1A, into the GFP-
SMARCAL1 cell lines. However, it is also known that in the absence of E1A, E1B-55K 
and E4orf6 mimic many of the E1A like transactivation properties and enhance E1A 
functionality (Dallaire, Schreiner et al. 2015, Dallaire, Schreiner et al. 2016). Indeed, 
E1B-55K and E4orf6 stimulate viral early and late gene expression, in the absence of 
E1A and disrupt E2F-pRB interaction to drive viral and cellular DNA synthesis, such 
that this approach might not be useful either. CRISPR gene editing is a powerful new 
technique that can introduce specific mutations in the genome (Gilani, Shaukat et al. 
2019). It would be interesting to introduce SA phospho-inhibitory mutations into the 
endogenous SMARCAL1 gene loci, to determine whether phosphorylation at these sites 
do promote SMARCAL1 degradation in Ad-infected cells. These studies might also 
determine whether these phosphorylation sites contribute towards regulating the protein 
levels of SMARCAL1 in replicating cells and in cells following replication stress, in the 
absence of Ad infection. Although there are not many published publications attempting 
to investigate the role of specific phosphorylation sites in biological processes it has 
been established that introduction of T25A mutation at the genomic level with CRISPR 
into the proteasome subunit, Rpt3, impairs proteasome activity and reduces the rate of 
cellular proliferation (Guo, Wang et al. 2016). 
 
It is well established that many cellular DDR and replication proteins are recruited to 
VRCs and/or viral DNA during infection, some of which will be pro-viral and some 
anti-viral. The identification of new cellular factors that are recruited to VRCs or viral 
DNA will help establish a molecular profile of those factors that possess pro-viral or 
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anti-viral activity. In this context, Matthew Weitzman’s group has recently utilised 
iPOND (isolation of proteins on nascent DNA), to identify cellular factors that associate 
with, or are excluded from the Ad5 genome during Ad5 DNA replication; the study also 
utilised iPOND to investigate those cellular proteins that associated with replicating 
HSV-1 and VACV DNA (Reyes, Kulej et al. 2017). Several host replication factors and 
DDR factors that are known to be recruited to VRCs, such as the MRN complex, BLM, 
ATR and SMARCAL1 were under-represented on replicating Ad5 DNA, relative to 
host cell DNA, suggesting that these factors all possess ant-viral activities (Reyes, Kulej 
et al. 2017).  Interestingly, they also determined that ATR regulators such as Claspin 
and Timeless were excluded from Ad5 DNA during viral DNA replication, suggesting 
that ATR signalling is generally detrimental to Ad DNA replication. In order to identify 
other anti-viral host cell factors that are recruited to VRCs and potentially function in 
ATR signalling pathways our laboratory is currently using a proteomic approach to 
identify host cell proteins that associate with the RPA complex during infection. In this 
regard, it would also be worthwhile to investigate systematically all proteins known to 
function in the ATR pathway to determine if they are recruited to VRCs and/or degraded 
during Ad infection. If candidate proteins are identified using these approaches we could 
over-express or deplete these proteins and investigate the ability of Ad to replicate its 
DNA and produce new virions.  
 
It is very well established that the adenovirus oncoprotein, E1B-55K interacts with p53 
to inhibit its transcriptional activities (Yew and Berk 1992). It also known to serve as a 
substrate adaptor, for proteins like MRE11, when targeting it for degradation in an E1B-
55K/E4orf6 and  CRL-dependent manner (Stracker, Carson et al. 2002). As we 
determined that E1B-55K interacts with SMARCAL1 (Figure 5.1 and 5.2, Chapter 5), 
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we investigated whether E1B-55K could modulate the function of SMARCAL1 in 
cellular DNA replication. Using the DNA fibre analysis technique, we determined that 
both Ad5 and Ad12 E1B-55K promoted accelerated cellular DNA fork speed that 
ultimately led to DNA fork stalling (Figures 5.5 to 5.10, Chapter 5). It is also known 
however, that depletion of p53 and MRE11 also result in replication fork stalling 
(Bryant, Petermann et al. 2009, Klusmann, Rodewald et al. 2016). Hence, it will be 
interesting to establish in the future whether the ability of E1B-55K to promote 
accelerated replication fork speed that results in fork stalling is due to the combined 
action of E1B-55K on SMARCAL1, p53 and MRE11, or whether these activities are 
separable.  As such, depending on where these proteins bind to E1B-55K, it would be 
of value to identify E1B-55K point mutations that discriminate between SMARCAL1, 
p53 and MRE11 binding so that we can investigate how these E1B-55K mutants affect 
cellular DNA replication and ATR signalling pathways activated in response to DNA 
damage. Moreover, as E1B-55K is known to cooperate with E4orf3 and E4orf6 in the 
inactivation of p53 and the MRN complex during infection and transformation (Yew 
and Berk 1992, Nevels, Täuber et al. 1999, Nevels, Täuber et al. 2001, Soria, Estermann 
et al. 2010), as well as during host-cell shutoff (Babich, Feldman et al. 1983, Babiss, 
Ginsberg et al. 1985, Halbert, Cutt et al. 1985), it will be worthwhile to investigate 
whether E4orf3 and E4orf6 target SMARCAL1, independent of E1B-55K and also 
modulate cellular DNA replication. These studies are currently on-going in our 
laboratory. 
 
It is now established that SMARCAL1 maintains telomere integrity through modulation 
of the ALT pathway (Poole, Zhao et al. 2015, Cox, Maréchal et al. 2016). As such, 
SMARCAL1 associates with ALT telomeres and resolves replication stress, whilst in 
167 
 
the absence of SMARCAL1, DSBs accumulate at ALT telomere DNA, which promotes 
the formation of both chromosome fusions and extrachromosomal telomeric DNA 
(Poole, Zhao et al. 2015, Cox, Maréchal et al. 2016). Interestingly, Ad12 E1B-55K is 
known to extend the life-span of normal human skin fibroblasts in culture, such that 
cells escape cellular mortality-stage 1, senescence (Gallimore, Lecane et al. 1997). 
These cells do eventually enter crisis (mortality-stage 2) but this is not due to telomere-
erosion or the activation of p53 (p21) or p16 pathways. Indeed, telomeric length was 
maintained in Ad12 E1B-55K-expressing fibroblasts in the absence of telomerase 
activation (Gallimore, Lecane et al. 1997), suggestive of the idea that Ad12 E1B-55K 
activates the ALT pathway. It would be very interesting to establish if Ad12 E1B-55K 
modulates SMARCAL1 activity to promote ALT or induces/inhibits DNA damage at 
ALT telomeres or the formation of extrachromosomal telomeric DNA.  
 
Conditionally-replicating adenoviruses are an important therapeutic strategy for a 
number of human cancers (Rein, Breidenbach et al. 2006, Baker, Aguirre-Hernández et 
al. 2018). Interestingly, it has been determined that the killing of pancreatic 
adenocarcinoma cell lines with cytotoxic drugs is enhanced by infection with an E1B-
19K deficient adenovirus (Pantelidou, Cherubini et al. 2016), which promotes the down-
regulation of DDR proteins, MRE11 and Claspin. As such, it was postulated that the 
targeted knockdown, or inhibition of Claspin or MRE11 with selective drugs, could be 
used in combination with oncolytic adenoviruses to enhance cancer cell killing 
(Pantelidou, Cherubini et al. 2016). Given that some oncolytic viruses have deletions in 
the E1B region and that E1B-55K helps to inactivate SMARCAL1 during infection it 
would be worthwhile to use shRNAs/siRNAs against SMARCAL1, or selective drugs 
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for SMARCAL1,that do not exist currently, in combination with E1B-55K-deleted 
adenoviruses to see if cancer cell killing is enhanced in the absence of SMARCAL1.   
 
The work presented in this thesis highlights the complex relationship between 
adenoviruses and host cell DDR pathways. It also re-emphasises the importance of 
studies with adenovirus to identify and dissect the molecular events that regulate host 
cell DDR pathways. Given that genome stability is currently a major, global research 
theme, particularly in relation to cancer research, and that adenoviruses are known to 
target key players in DDR pathways, research into adenovirus biology will continue to 
provide important insight into the fundamental processes that govern genome stability, 
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